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resumo 
 
 
A hiperglicemia é a principal característica da diabetes mellitus (DM), uma das 
causas de morte que mais cresce em Portugal, e cujas complicações a longo 
prazo são mais debilitantes e mais sobrecarregam os sistemas de saúde. No 
entanto, os mecanismos subjacentes à resposta fisiológica de alguns tecidos à 
hiperglicemia não estão completamente esclarecidos. 
 
Este estudo teve como objetivo avaliar de que forma o tempo de exposição à 
hiperglicemia afeta dois tecidos epiteliais, o endotélio e as glândulas salivares, 
que são frequentemente associados a complicações da DM, utilizando um 
modelo animal. Adicionalmente, procurou-se encontrar novos biomarcadores 
para avaliar a suscetibilidade a complicações orais em diabéticos, analisando 
as modificações pós-traducionais (PTMs) da família de proteínas mais 
representativa na saliva humana: proteínas ricas em prolina (PRPs). 
 
A disfunção vascular está na origem de várias complicações da diabetes. 
Neste sentido, observou-se uma progressiva disfunção endotelial com o 
aumento do tempo de exposição à hiperglicemia, que resulta do aumento de 
danos no endotélio e da diminuição da capacidade de mobilização de células 
progenitoras. Simultaneamente, o aumento observado na atividade da via de 
ativação do sistema de complemento mediada por lectinas (MBL), sugere um 
envolvimento do sistema de imunidade inata na patogénese da disfunção 
vascular. 
 
Outra complicação comum da DM é o desenvolvimento de doenças orais, 
nomeadamente as relacionadas com a redução da secreção salivar. Na 
análise às glândulas submandibulares, observou-se uma resposta inicial à 
hiperglicemia com fortes variações na expressão de proteínas, mas a longo 
prazo, estas variações foram atenuadas, sugerindo um mecanismo de 
adaptação à hiperglicemia crónica. Adicionalmente, as proteínas relacionadas 
com a secreção, como as anexinas, apresentaram-se sobre-expressas, 
enquanto as calicreinas e proteínas metabólicas estavam sub-expressas. 
Estas variações sugerem que, apesar de uma diminuição da capacidade de 
regeneração, as células tentam superar a perda de tecido por meio do 
aumento da secreção, embora sem êxito. 
 
O comprometimento funcional das glândulas salivares tem consequências na 
composição e funções da saliva. Analisando as PTMs das PRPs salivares 
humanas, observou-se um aumento da frequência de péptidos com ciclização 
de resíduos N-terminais de glutamina a piroglutamato, o que confere uma 
resistência à atividade proteolítica que, por sua vez, se encontra aumentada 
em diabéticos. Assim, a presença de péptidos com N-piroglutamato poderá ser 
um potencial biomarcador da suscetibilidade a complicações orais em 
diabéticos. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
keywords 
 
Diabetes, hiperglycemia, salivary glands, endothelium, proteomics 
 
 
abstract 
 
Hyperglycemia is the major hallmark of diabetes mellitus, which is one of the 
fastest growing causes of death in Portugal and whose long-term complications 
are more debilitating and burden health-care systems. However, the 
mechanisms underlying the physiological response of some tissues to 
hyperglycemia are not fully understood.  
 
This study aimed to understand how the time of exposure to hyperglycemia 
affects two epithelial tissues, the endothelium and the salivary glands tissue, 
that are often associated with diabetes mellitus complications, using an animal 
model. Complementarily, post translational modifications of the most 
representative family of human salivary proteins, salivary proline-rich proteins 
(PRPs), were evaluated to propose novel biomarkers to assess the 
susceptibility of diabetic patients to oral complications. 
 
Vascular dysfunction is on the genesis of several diabetes complications. In 
this sense, it was observed a progressive endothelial dysfunction over time, 
due to the increase of endothelial damage and diminished capacity for the 
mobilization of progenitor cells. Concomitantly, it was observed an increased 
activity of the MBL pathway of activation of the complement system, suggesting 
an involvement of the innate immune system in the pathogenesis of vascular 
dysfunction. 
 
Another common complication of diabetes is the development of oral diseases, 
namely related to the reduction of saliva secretion. Submandibular glands 
presented an early-phase response with strong variations in protein expression, 
which were attenuated in long-term exposure, suggesting an adaptive 
mechanism to chronic hyperglycemia. Moreover, proteins related to secretion, 
such as annexins, were found up-regulated, while kallikreins and metabolic 
proteins were down-regulated. This suggests that, despite a reduction of the 
regeneration ability, cells may try to overcome the apoptotic loss of tissue, 
though unsuccessfully, through the increase of secretion. 
 
Impairment of salivary gland function has consequences in saliva composition 
and functions. Analysing the PRPs of human salivary proteins, it was observed 
an increase in the frequency of peptides bearing N-terminal cyclization of 
glutamine residues to pyroglutamate, which confers some resistance to the 
increased activity of proteases observed in diabetic patients, making it a 
potential biomarker for susceptibility to oral complications among diabetic 
patients. 
 
 
 
 
 
 
 
Man may be the captain of his fate, but he is also the victim of his blood sugar 
 
Wilfrid Oakley [Trans. Med. Soc. Lond. 78, 16 (1962)]
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1. Introduction 
Hyperglycaemia is the major hallmark of diabetes mellitus (DM). In 
fact, DM is clinically defined as a syndrome of disordered metabolism 
where, due to a deficiency in insulin production and/or its action, patients 
present inappropriate hyperglycemia (Gardner, Shoback et al. 2011). 
Thus, the study of its mechanisms and effects in the organism is essential 
to fully understand the disease and further advance in the search for more 
effective treatments and even a cure. 
2. Diagnosis and classification of diabetes mellitus 
The criteria for the diagnosis and classification of diabetes have 
evolved with the accumulation of new knowledge since, in 1979, a new 
definition was proposed by the (American) National Diabetes Data Group 
Committee, and was generally accepted by the major health organizations 
in America and Europe, including the World Health Organization (WHO). 
An updated report is published annually by the American Diabetes 
Association (ADA), as a supplement to the journal Diabetes Care, 
summarizing the latest clinical practice recommendations (American 
Diabetes Association 2013).  
The classical diagnosis of DM has been based in measuring the 
fasting plasma glucose (FPG) or with an oral glucose tolerance test (OGTT). 
The current WHO diagnostic criteria for DM are FPG ≥7.0 mmol/l 
(126 mg/dl) or 2–h plasma glucose ≥11.1 mmol/l (200 mg/dl) during an 
OGTT (World Health Organization. 2006). However, other tests have been 
used, especially to detect early stages of the disease where glycemia levels 
do not fulfil the requirements for a diagnosis of DM, but are still higher 
than normal. The measurement of glycated hemoglobin (HbA1c) is another 
widely used marker for chronic hyperglycemia, as it reflects the average 
blood glucose levels over the previous 2-3 months. It is not recommended 
as a suitable diagnostic tool by the WHO, due to the lack of a 
standardization of the assay and hence the definition of a threshold (World 
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Health Organization. 2006). Nonetheless, the ADA has included it in the 
latest review for the diagnosis and classification of DM, following the 
publication of a report from an International Expert Committee 
recommending its use with a threshold of ≥6.5%, if using a method 
certified by the (American) National Glycohemoglobin Standardization 
Program (NGSP). As the ADA points out, there are obvious advantages of 
using a chronic marker (HbA1c) instead of a more acute (FPG or OGTT), 
nevertheless, the advantages must be balanced with the higher cost per 
test, its limited availability worldwide and the influence of other 
physiological conditions such as anemia or hemoglobinopathies 
(International Expert Committee 2009). 
As from 2013, DM is classified into 4 major categories: Type 1, Type 
2, Gestational and Other Specific Types (American Diabetes Association 
2013). 
Type 1 diabetes mellitus (T1DM) is the result of the partial or 
complete absence of insulin production originated by the destruction of 
pancreatic beta-cells (Patterson, Dahlquist et al. 2009). Consequently, 
patients rely on insulin therapy to survive. The aetiology of beta-cell 
destruction may be an autoimmune mechanism or an undeterminable 
cause, resulting in “autoimmune T1DM” or “idiopathic T1DM” respectively 
(Deshpande, Harris-Hayes et al. 2008; Jurysta, Nicaise et al. 2013). As a 
result of the lack of insulin, glycemic control is impaired and may result in 
periods of hyperglycemia, as well as hypoglycemia. Due to the dependency 
of insulin therapy to survive, T1DM was formerly known as insulin-
dependent DM. In a similar manner, because of its early onset it could 
also be referred as juvenile-onset DM. 
Type 2 diabetes mellitus (T2DM) is by far the most frequent type of 
diabetes; approximately 90%-95% of the cases reported. It often starts 
with the development of insulin resistance by muscle cells and adipocytes, 
thus preventing the intake of glucose by these cells and keeping them in a 
permanent fasting metabolism. Although initially the pancreas tries to 
overcome this by secreting more insulin, over time the secretion capacity 
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is also affected. Due to the later onset when compared with T1DM, T2DM 
was also known as adult-onset diabetes or noninsulin-dependent 
diabetes, as it usually does not require insulin therapy.  
When hyperglycemia is detected during pregnancy, it is named 
Gestational diabetes mellitus (GDM). This type of diabetes is usually 
diagnosed during prenatal screening tests but its symptoms are very 
similar to T2DM. It occurs in 7% of pregnancies worldwide and usually 
disappears after delivery; however both women and their children have 
increased risk of developing T2DM later in life. Left untreated, it may carry 
risks to both mother and child (IDF guidelines). 
The cases of DM that cannot be included in any of the other 
categories are referred to as other types of DM and may include cases 
ranging from genetic defects to infections, or drug-induced forms. The 
American Diabetes Association has classified them into 8 sub-categories, 
which are further subdivided, according to their aetiology. 
When FPG or OGTT values are still out of the normal range but not 
enough to be diagnosed as DM, individuals are considered to be in a state 
of prediabetes. Individuals presenting FPG <7.0 mmol/l (126 mg/dl) and 
2–h plasma glucose ≥7.8 and <11.1 mmol/l (140 mg/dl and 200 mg/dl) 
are diagnosed with impaired glucose tolerance (IGT), while individuals 
presenting FPG >6.1 and ≤6.9 mmol/l (110 mg/dl and 125 mg/dl) and 2-h 
plasma glucose <7.8 mmol/l (140 mg/dl) are diagnosed with impaired 
fasting glucose (World Health Organization. 2006) 
3. Physiological and molecular mechanisms for regulation of 
glycemia 
3.1. Glucose transporters 
Glucose is a water soluble simple monosaccharide; hence it does not 
cross the lipid bilayer by simple diffusion and needs carrier proteins to 
facilitate the diffusion along the concentration gradient, from the 
bloodstream into the cells. In mammalian cells, glucose is transported by 
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a family of transport facilitators, the GLUT transporters, although these 
may transport sugars and polyols other than glucose. The 13 members of 
this family are structurally divided into 3 classes: Class I (GLUT1-4), Class 
II (GLUT5, 7, 8 and 11) and Class III (GLUT6, 8, 10 and 12 and HMIT) 
(Joost and Thorens 2001).  
Class I contains the most well characterized and widely distributed 
members. GLUT1 is expressed in fetal tissues, erythrocytes and 
endothelial cells, namely from the blood-brain barrier. GLUT2 is expressed 
especially in pancreatic beta-cells, liver and kidney, as well as in the 
basolateral membrane of small intestine cells, and has the lowest affinity 
for glucose ensuring that transporter saturation is not rate limiting and 
rapidly reaches the equilibrium of the intracellular/extracellular glucose 
concentration. GLUT3 is mainly present in brain and nervous tissue but is 
also detected in lower levels in kidney, liver and heart; its distribution in 
tissues with a high glucose demand together with the high affinity 
presented for glucose, suggests it is essential to allow glucose intake in 
those cells even in the case of hypoglycemia. Finally, GLUT4 is the 
primary transporter in adipose tissue, skeletal muscle and heart; the 
expression and translocation of this transporter to the plasma membrane 
is regulated by insulin and it is essential in the rapid removal of blood 
glucose into the body’s glycogen and triacylglycerol storage tissues (Bell, 
Kayano et al. 1990; Gould and Holman 1993; Joost and Thorens 2001; 
Jurysta, Nicaise et al. 2013). 
Classes II and III members are structurally distinct from Class I 
members, some of which are not fully characterized (Joost and Thorens 
2001; Uldry and Thorens 2004). 
3.2. Endocrine regulation of glycemia 
The pancreas is an abdominal organ that comprises both exocrine 
and endocrine cell types, as well as ductal cells. The exocrine function is 
performed by acinar cells that secrete digestive enzymes and bicarbonate 
ions, releasing them through the ducts into the duodenum, and represent 
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the bulk (70%-90%) of the pancreas volume. These secretions play 
important roles in both food digestion and neutralization of the acidic 
chymus released by the stomach. The endocrine function is performed by 
the numerous cell clusters evenly scattered throughout the organ, named 
islets of Langerhans, which secrete directly into the bloodstream and 
represent only 3-5% of pancreatic volume, although they can reach 1 
million islets in a human pancreas (Novak 2008). The islets of Langerhans 
are composed of five main types of cells (Clark, Wells et al. 1988; 
Wieczorek, Pospischil et al. 1998; Andralojc, Mercalli et al. 2009): 
- Alpha cells: secrete glucagon and represent approximately 15-
20% of islet cells; 
- Beta cells: secrete insulin and amylin and cover 70-80% of islet 
cells; 
- Delta cells: secrete somatostatin and are 5% of islet cells; 
- Gamma cells (or PP cells): secrete pancreatic polypeptide (PP) and 
are less than 1% of islet cells; 
- Epsilon cells: secrete ghrelin and the less abundant cells with 
roughly 1 cell/islet. 
 
The regulation of glycemia is performed by the joint action of 
glucagon and insulin (Figure 1). 
When glycemia rises, the pathway of glucose-stimulated insulin 
secretion (CSIS) is activated. Glucose enters beta-cells through the GLUT2 
transporters, this leads to an increase in the ATP/ADP ratio, through the 
stimulation of glycolysis and the Krebs cycle. This increase, in turn, leads 
to the closure of ATP-sensitive K+ channels and subsequent membrane 
depolarization, which promotes the opening of voltage-dependent Ca2+ 
channels. The resulting increase in the levels of cytosolic free Ca2+ is the 
trigger for insulin secretion (Henquin 2000; Henquin, Ravier et al. 2003; 
Bensellam, Laybutt et al. 2012). Glucagon secretion, on the other hand, is 
achieved by intrinsic and paracrine regulation (Walker, Ramracheya et al. 
2011). Like in insulin secretion, the regulation of ion-channels and 
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subsequent membrane depolarization is the key event to promote 
glucagon secretion (Wang, Liang et al. 2012). Insulin itself has been 
shown to inhibit glucagon secretion, together with the simultaneously 
secreted amylin and GABA from beta-cells and somatostatin from delta-
cells, through the Akt-mediated translocation of GABAA receptors and 
subsequent membrane hyperpolarization and closure of Ca2+ channels 
(Aronoff, Berkowitz et al. 2004; Walker, Ramracheya et al. 2011; Wang, 
Liang et al. 2012). When glucose levels are low, beta- and delta-cells 
secretion is inhibited, lowering the levels of insulin, amylin, GABA and 
somatostatin, and the inhibitory effect of these in alpha-cells secretion is 
ceased. The increase in amino acids and free fatty acids, together with 
paracrine and epinephrine stimuli, may lead to the activation of K+ATP and 
Ca2+ channels, triggering the depolarization cascade and the release of 
glucagon (Walker, Ramracheya et al. 2011; Wang, Liang et al. 2012).  
 
Figure 1 - Regulation of insulin and glucagon secretion in the islets of Langerhans. 
In alpha-cells, the entry of glucose through the high affinity GLUT1 transporters activates ATP 
synthesis, increasing the ATP/ADP ratio. This closes the ATP sensitive K+ channels, causing 
membrane depolarisation, which opens Ca2+ channels. The Ca2+ influx promotes exocytosis of 
glucagon vesicles. If there is a high level of insulin stimulation, the K+ channels are open, not 
causing membrane depolarization and Ca2+ entry. Additionally, GABA stimulation of its receptors 
allow the passage of Cl- and causing membrane hyperpolarization, further blocking the 
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Ca2+-stimulated exocytosis. In beta-cells, glucose entry through the low affinity GLUT2 transporters 
has a similar effect on the promotion of Ca2+-stimulated exocytosis of insulin/amylin/GABA 
vesicles. However, if glucagon receptors are stimulated, glycolysis is inhibited and the ATP/ADP 
ratio lowers, inhibiting exocytosis. High levels of circulating fatty acids and certain amino acids 
may also inhibit secretion through the inhibition of the TCA cycle and the reduction of the 
ATP/ADP ratio. Adapted from Wang, Liang et al. (2012) and Walker, Ramracheya et al. (2011) 
3.3. Intracellular response to insulin and glucagon signalling 
Upon release in the bloodstream, insulin major targets are liver, 
adipose tissue and skeletal muscle. These tissues express insulin 
receptors (IRs), type 1 insulin-like growth factor receptors (IGFR) or an 
hybrid form of these, although such receptors have also been found in 
brain, heart, kidney tubules and glomeruli, pulmonary alveoli, pancreatic 
acini, vascular endothelium, monocytes, granulocytes, erythrocytes and 
fibroblasts. This multitude of tissues expressing IRs suggests that the role 
of insulin may be more diverse than the traditional metabolic action it is 
attributed to (Kaplan 1984; Belfiore, Frasca et al. 2009). In the 
traditionally referred to as “insulin main targets”, the binding to IRs 
triggers a signalling cascade that starts with the activation of IR tyrosine 
kinase, which will phosphorylate several substrates, namely IR substrates 
(IRS-1, -2, -3 and -4), generating binding sites for Src homolog 2 (SH2) 
domain proteins, such as regulatory subunits of class 1A 
phosphatidylinositol 3-kinase (PI3K), leading to the activation of the 
Akt/PKB and PKCζ cascades. The Akt/PKB is involved in: the regulation of 
glycogen synthesis, through GSK-3; the regulation of glucose transport, 
through the Rab GTPase activating protein AS160/TBC1D4; the 
regulation of mTOR and protein synthesis, through the Rheb GTPase 
activating complex TSC1/2; the regulation of the expression of 
gluconeogenic and other genes, through Forkhead box (Fox) transcription 
factors; and also apoptosis, through BAD (Siddle 2011).  
In muscle cells and adipocytes, one of the most important features 
of Akt activation is the translocation of GLUT4-containing vesicles to the 
plasma membrane; additionally, the stimulation of glycogen synthesis and 
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lipid synthesis, respectively, further enhances glucose uptake from the 
bloodstream (Figure 2).  
 
Figure 2 – Insulin signalling cascade in muscle cells and adipocytes 
The activation of insulin receptors (IR/IGFR) leads to proliferation stimuli through the ERK1/2 
pathways. Additionally, the activation of insulin-receptor substrate (IRS-1/2) activates protein 
kinase C (PKC), which promotes the translocation of GLUT4 vesicles to the membrane, and Akt, 
which activates the Sterol Regulatory Element-Binding Protein 1 (SREBP-1) transcription factor, 
promoting the transcription of fatty acid synthase (FAS), hexokinase (HK), pyruvate kinase (PK) and 
inhibiting transcription of phosphoenolpyruvate carboxykinase (PEPKC), and the inactivation of 
FoxA1 and FoxA2 transcription factors that promote the transcription of glucose-6-phosphatase, 
PEPCK, carnitine palmitoyltransferase 1 (CPT1) and medium-chain acyl-CoA dehydrogenase 
(MCAD). In muscle cells, Akt also has a pivotal role in the inhibition of GSK3, activating glycogen 
synthase, while in adipocytes, the activation of phosphodiesterase 3 (PDE3), inhibits lypogenolisis 
through the Hormone sensitive Lipase (HSL) by inhibiting the synthesis of cAMP. Adapted from 
Fritsche, Weigert et al. (2008) 
Liver cells express GLUT2 as the main glucose transporter, but the 
activation of the Akt/PKB pathway is important for the inhibition of 
gluconeogenesis and fatty acid oxidation and the stimulation glycolysis 
and glycogen synthesis both directly and through transcriptional 
regulation (Figure 3). Liver, however, also expresses glucagon receptors. 
Glugagon receptors are G-protein coupled and, upon stimulation, induce 
the activation of adenylate cyclase, increasing the levels of cAMP and 
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activating protein kinase A (PKA). PKA activates glycogen phosphorylase 
promoting glycogenolysis. Additionally, PKA inhibits glycogen synthase 
and pyruvate kinase, reducing glycogenesis and glycolysis. Glugagon also 
mediates transcriptional regulation through PKA-activation of the cAMP 
response element-binding protein (CREB), increasing the expression of 
phosphoenolpyruvate carboxykinase (PEPCK) promoting gluconeogenesis 
(Jiang and Zhang 2003). 
 
Figure 3 - Insulin and glucagon signalling cascade in hepatocytes.  
The activation of insulin receptors (IR/IGFR) leads to proliferation stimuli through the ERK1/2 
pathways. Additionally, the activation of insulin-receptor substrate (IRS-1/2) activates the Akt 
pathway, in which the Sterol Regulatory Element-Binding Protein 1 (SREBP-1) transcription factor, 
promotes the transcription of fatty acid synthase (FAS), hexokinase (HK), pyruvate kinase (PK) and 
inhibiting transcription of phosphoenolpyruvate carboxykinase (PEPKC), and the inactivation of 
forkhead box protein (FoxA1 and FoxA2) transcription factors that promote the transcription of 
glucose-6-phosphatase, PEPCK, carnitine palmitoyltransferase 1 (CPT1) and medium-chain acyl-
CoA dehydrogenase (MCAD). The activation of the G-protein coupled glucagon receptors, activates 
adenylate cyclase promoting the activation of protein kinase A (PKA), responsible for the activation 
of glycogen phosphorylase (GlyP) and fructose-1,6 bisphosphatase (FBPase) and inhibition of 
pyruvate kinase (PK). The activation of cAMP response element binding protein (CREB), activates 
the transcription of G6Pase and PEPCK directly and through the activation of FoxO1. Adapted from 
Fritsche, Weigert et al. (2008) 
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4. Pathogenesis of diabetes mellitus 
In T1DM, there is a destruction of beta-cells, resulting in the 
absence of insulin secretion and subsequent impairment of glycemic 
control. The aetiology of diabetes is not fully understood, despite decades 
of research, but some possible factors have been identified and are 
summarized in Table 1. Genetic predisposition may be the result of a 
complex interaction between several genes and the environment (Henquin, 
Anello et al. 2000). 
Table 1 – List of possible etiological factors for T1DM (Adapted from Zimmet, Alberti et al. 
2001) 
Non-genetic Genetic 
Viral infections 
Early infant diet 
Perinatal infections 
Toxins 
Human leucocyte antigen 
(HLA) associated 
Non-HLA associated 
 
In the case of autoimmune diabetes, autoantibodies are currently 
the best biomarkers (Dang, Rockell et al. 2011) and approximately 85-90% 
of individuals present one or more markers of pancreatic islets β-cells 
autoimmune destruction, following the detection of fasting hyperglycemia. 
These markers include anti-insulin autoantibodies (AAI), anti-islets of 
Langerhans (Islet Cell Antibody-ICA), anti-glutamic acid decarboxylase 
(GAD65), anti-zinc transporter 8 (ZnT8) and anti-tyrosine phosphatases 
insulinoma antigen IA-2 and IA-2β (Wilkin, Hoskins et al. 1985; Goldstein, 
Little et al. 2003; Orban, Sosenko et al. 2009; Tsirogianni, Pipi et al. 2009; 
Sorensen, Vaziri-Sani et al. 2012). Conversely, when such autoimmune 
antibodies are not present, as well as any other evidence of an 
autoimmune disorder, we are in presence of an idiopathic T1DM. This 
form of T1DM is strongly inherited and is more frequent in non-Caucasian 
individuals (American Diabetes Association 2013).  
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T2DM, although more prevalent, has a more complex and diverse 
aetiology. The understanding of the disease has suffered significant 
changes over time. It is now recognized an important set of risk factors for 
the development of T2DM and most of them can be prevented by acting 
many years before the onset of the disease (Table 2) (Zimmet, Alberti et al. 
2001).  
Table 2 – Aetiological determinants and risk factors of T2DM (Adapted from Zimmet, Alberti 
et al. 2001) 
Genetic factors 
Genetic markers 
Family history 
Thrifty gene(s) 
Demographic characteristics 
Sex 
Age 
Ethnicity 
Behavioural- and lifestyle-related risk factors 
Obesity 
Physical inactivity 
Diet 
Stress 
Westernization, urbanization, modernization 
Metabolic determinants and intermediate risk categories 
Impaired glucose tolerance 
Insulin resistance 
Pregnancy-related determinants 
 
The evolution of the T2DM is thus a gradual process, unlike the 
abrupt onset of T1DM. Similarly, T2DM patients do not present signs of 
autoimmune destruction of beta-cells. Glucose intolerance in T2DM is 
said to result from a “triumvirate” of interacting factors: impaired insulin 
secretion, muscle insulin resistance and hepatic insulin resistance (Bays, 
Mandarino et al. 2004). Which of the events comes first, and whether it is 
determinant for the progression to overt T2DM, is still a matter of 
extensive discussion. It is recognized that both impaired insulin secretion 
and insulin resistance begin very early, even when there is a normal 
glucose tolerance, and are equally important for the progression to T2DM 
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(Leahy 2005). The need for accurate prognostic tools is thus of paramount 
importance to contain this pandemic. The course to the disease state 
follows a state of prediabetes, where the first signals of glucose 
intolerance, IFG or IGT, are presented. Subjects with this signals have 
increased risk of developing diabetes or cardiovascular diseases and 
should be monitored, especially if other risk factors such as obesity, 
dyslipidemia or hypertension are concomitant, according to the 
recommendations of the ADA (Leahy 2005; American Diabetes Association 
2013). Prediabetes is also characterized by hyperinsulinemia, where beta-
cells respond to the mild hyperglycemia with the secretion of more insulin, 
despite its action being impaired by insulin resistance. At this stage, the 
progression to T2DM could be delayed or even reverted by changes in 
lifestyle, namely, increasing physical activity and through dietary changes, 
consequently controlling some of the risk factors (Nolan, Damm et al. 
2011). When overt hyperglycemia is finally presented, the diagnosis of 
T2DM is established. Reaching this state implies a progressive beta-cells 
dysfunction and consequent impairment of insulin secretion. This 
progressive impairment is the result of numerous factors, such as, lipo- 
and glucotoxicity, age, genetics, insulin resistance, among others 
(DeFronzo 2004). In an initial stage, appropriate diet and metformin, a 
drug that acts in liver inhibiting glucose production and increasing insulin 
sensitivity, usually suffice in the control of hyperglycemia and are the 
standard treatment option. As the disease progresses, other agents for 
hyperglycemia control may be necessary, eventually reaching a stage 
where insulin therapy is required to counteract the complete beta-cell 
failure. However, a shift in treatment strategies towards the prevention 
and alteration of the usual course of the disease, as a way to improve the 
outcome and be more cost effective, has been proposed (Leahy 2005; 
Stumvoll, Goldstein et al. 2005; Nolan, Damm et al. 2011). 
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5. Physiological impact of diabetes mellitus 
In a normal state, when blood glucose levels are high, beta-cells 
secrete insulin. Insulin then signals muscle cells and adipocytes to 
translocate GLUT4 transporters to the membrane, promoting the entry of 
glucose in the cells for posterior glycogenesis. In both these types of cells, 
as well as in hepatocytes, insulin also promotes the glycogen and fatty 
acid synthesis for energy storage (Figure 3). When blood glucose levels 
return to normal, insulin secretion is inhibited and these processes are 
slowed down. If glycemia levels lower below the normal threshold, 
glucagon secretion is increased and triggers the activation of the PKA 
cascade in liver resulting in increased glycogenolysis and gluconeogenesis 
and decreased glycolysis and glycogenesis, thus normalizing glycemia 
levels (Kahn and Saltiel 2005; Ruderman, Myers Jr. et al. 2005).  
In T1DM there is a complete absence of insulin, therefore 
insulin-receptors are not triggered and muscle cells and adipocytes do not 
respond to high blood glucose levels. The lack of insulin signalling also 
promotes glucagon secretion, which induces hepatic glucose production. 
Likewise, in T2DM with the presence of insulin resistance, 
insulin-receptors in muscle cells and adipocytes are not triggered and 
these cells do not increase glucose uptake in response to hyperglycemia; 
additionally, hepatic glucose production is enhanced by glucagon 
(American Diabetes Association 2013). Hence, the overall physiological 
impact of insulin-dysfunctions depends on the integration of the metabolic 
changes observed in each insulin-sensitive cell type. 
The intracellular signalling of insulin was already described in a 
previous section for muscle cells, adipocytes and hepatocytes. If the 
signalling pathway is blocked at its very beginning, all the downstream 
effects are also blocked. Consequently, in liver, there is no 
insulin-mediated transcriptional up-regulation of hexokinase and 
activation of glycogen synthase. The lower hexokinase levels limit the 
uptake of glucose by the hepatocyte, further reducing glycolysis and 
 
Studies of epithelial response to streptozotocin-induced hyperglycemia 
16 
glycogenesis. This effect, coupled to increased glucagon signalling, 
stimulates gluconeogenesis, powered by the ATP production from beta-
oxidation of the increased fatty acids levels. Beta-oxidation increases the 
level of acetyl CoA, which inhibits pyruvate dehydrogenase and activates 
pyruvate carboxylase, further stimulating gluconeogenesis. Moreover, the 
excess of acetyl CoA is responsible for the formation of ketone bodies, 
whose accumulation in the bloodstream lowers the pH to a point where it 
may exceed the blood buffering ability and result in ketoacidosis. The 
increased free fatty acids are the result of impaired glucose uptake in 
adipocytes, as there is no insulin-mediated translocation of 
GLUT4-containing vesicles to the plasma membrane, which results in 
decreased synthesis of glycerol 3-phosphate, hence the impaired 
esterification of lipids and stimulation of lipolysis. In muscle cells, the 
translocation of GLUT4-containing vesicles is also blocked, so there is a 
shift towards glycogenolysis and energy production from beta-oxidation, 
which increases acetyl CoA levels, diverting glycolytic metabolites towards 
alanine and lactate synthesis that have a gluconeogenic effect in the liver 
(Basu and Jensen 2005; Collins, Ahima et al. 2005; Granner and Scott 
2005; Jozsi and Goodyear 2005; Stump and Nair 2005; Fritsche, Weigert 
et al. 2008). 
6. Cellular basis for complications of long-term hyperglycemia 
The immediate complication of hyperglycemia is the development of 
ketoacidosis from the metabolic shift towards energy production from 
lipids, which increases the synthesis of ketone bodies in the liver. 
However, the available therapies allow patients to control hyperglycemia 
either with insulin replacement or insulin-sensitizing agents. Nonetheless, 
in the long-term, the ability to naturally regulate glycemia levels has 
systemic implications, even with a good therapeutic control. 
Diabetic patients are known to have increased risk to develop 
cardiovascular disease (CVD), peripheral arterial disease (PAD), stroke, 
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nephropathy, retinopathy, neuropathy, skin infections and oral problems. 
Interestingly, the majority of such complications are related to the 
cardiovascular system, including both macrovascular and microvascular 
pathologies, with which endothelial dysfunction is closely related.  
A healthy endothelium is responsible for actively decreasing 
vascular tone, maintaining vascular permeability within narrow bounds, 
inhibit platelet adhesion and aggregation, limit the activation of the 
coagulation system and stimulate fibrinolysis. Endothelial dysfunction is 
present when these functions are compromised in a way that turns 
impossible the preservation of organ function (Schram and Stehouwer 
2005; Schmieder 2006). Considering that the endothelium is a specialized 
simple squamous epithelium that lines blood vessels, it is not surprising 
that significant alterations in blood, such as hyperglycemia, may have 
repercussions in endothelial cells. Additionally, some organs have a highly 
adapted endothelium, like the tightly packed blood-brain barrier or the 
fenestrated glomeruli, contributing to a diverse response to stress in 
different organs. These cells express mostly the GLUT1 transporter, so the 
uptake of glucose is not as dependent of insulin as in adipocytes or 
muscle cells, and most of it is meant to be delivered to the underlying 
tissues through GLUT1-mediated translocation, especially in the 
blood-brain barrier where there are no loose interendothelial junctions 
(Bakker, Eringa et al. 2009). However, insulin has to cross the 
endothelium to reach the insulin-sensitive tissues. In liver, the fenestrated 
endothelium allows the passage through interendothelial junctions but, in 
muscle and adipose tissue, insulin crosses the endothelial barrier via an 
insulin-receptor-mediated binding and exchange mechanism. Insulin may 
also regulate vasodilation through the release of endothelin-1 (ET-1) and 
stimulation of endothelial NO synthase (eNOS), both insulin-dependent 
mechanisms. Thus, the exposure of insulin-sensitive tissues may be 
regulated at the endothelial level. In hyperglycaemic patients, endothelial 
dysfunction ranges from structural changes in the endothelial barrier or 
matrix to the impairment of vasodilator response and increased 
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inflammatory activation. The ability to repair endothelial damages and 
regulate angiogenesis is also severely compromised. Antagonic effects are 
observed regarding angiogenesis. The reduction of vascularization 
mechanisms significantly contribute to most of the vascular-related 
complications, however, in retinopathy, is the excessive neovascularization 
that causes the progressive loss of vision. These processes are regulated 
by growth factors such as the vascular endothelial growth factor (VEGF), 
and although some organs present increased expression of VEGF in 
hyperglycemia, a reduction of the expression of VEGF receptors may 
contribute to the impairment of angiogenesis.  Furthermore, there is also 
the absence of insulin-induced stimulation of cell proliferation (Bakker, 
Eringa et al. 2009). 
Another tissue expressing high levels of GLUT1 is the glandular 
epithelium of salivary glands (Jurysta, Nicaise et al. 2013). Interestingly, 
the oral problems observed in diabetic patients are often associated with 
impaired salivary gland secretion. Insulin signalling was shown to be 
present in salivary glands, being responsible for the increase in protein 
synthesis through the transcriptional regulation of Shc/ERK1/2, 
Jak-2/STAT, and Akt pathways (Saad, Carvalho et al. 1996; Chen, 
Sadowski et al. 1997; Rocha, de et al. 2000; Rocha, Hirata et al. 2002; 
Rocha, Carvalho et al. 2003). Acinar cells are responsible by the secretion 
of 85% of saliva proteins, despite a significant contribution of glandular 
duct cells, responsible for secretion of proteins with important biological 
functions such as growth factors, immunoglobulins and kallikreins 
(Vitorino, Lobo et al. 2004; Amado, Vitorino et al. 2005; Esser, Alvarez-
Llamas et al. 2008; Castagnola, Cabras et al. 2011). However, the ductal 
epithelium of salivary glands has been shown to be severely affected by 
long-term hyperglycemia, long before acini start to show morphological 
changes (Anderson, Garrett et al. 1993). So, although not in direct contact 
with hyperglycaemic blood, salivary gland cells suffer the effects of the 
lack of insulin and consequent hyperglycemia. 
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7. Epidemiology of diabetes mellitus 
According to the World Health Statistics 2012, published by the 
WHO, diabetes mellitus (DM) is on the Top 5 worldwide causes of death by 
non-communicable diseases (NCD’s) (World Health Organization. 2012). 
However, the WHO dully acknowledges that hyperglycemia is the cause of 
22% of coronary heart disease and 16% of stroke deaths, and so, DM is 
also tightly related to the major death cause – cardiovascular diseases 
(World Health Organization. 2012). 
This close relation would be sufficient to justify the study of diabetes 
in its several aspects, but the dramatic increase in the incidence of DM in 
developed countries in the last two decades, reinforces the importance of 
its study. The number of patients worldwide is estimated to be around 371 
million by the International Diabetes Federation (IDF), while China, India 
and the USA lead in number of cases with over 179 million, altogether 
(Figure 4). This figure means that around 4.8 million people may have 
died, in 2012, from diabetes related complications (International Diabetes 
Federation 2012a; International Diabetes Federation 2012b). 
 
Figure 4 – World distribution of people with diabetes. 
Adapted from the IDF Diabetes Atlas – Fifth Edition with the IDF estimations for 2012. 
The annual number of deaths attributed to diabetes in Portugal has 
increased more than 50% in the period 1994-2010. A tendency also 
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verified, though not so dramatically, in the 27 countries that form the 
European Union, despite a relatively stable resident population (Figure 5) 
(Pordata 2012).  
 
Figure 5 – Evolution of deaths by certain causes related to the total number of deaths (lines) 
and evolution of the resident population (columns) from 1994 to 2010.  
Data were obtained from PORDATA referring to Portugal (PT) and the European Union (EU27) and 
are presented as an index (1st year with data available = index 100). 
Whilst type 2 diabetes mellitus represents over 90% of the cases , in 
a 2009 study, covering the years 1989-2003, Patterson and colleagues 
predicted that the number of diabetic children (<15 years old) in Europe 
would roughly double in the period 2005-2020, to reach over 160,000 
children (Patterson, Dahlquist et al. 2009). These numbers make type 1 
diabetes mellitus the most common metabolic disease in children (Maahs, 
West et al. 2010; Gan, Albanese-O'Neill et al. 2012). 
For all of these reasons, it is an imperative to conduct studies, such 
as the present one, that contribute to the full comprehension of this 
epidemic disease in its several aspects. 
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8. Aims of the thesis 
So, considering the increased incidence of diabetes over the last 
years, it is proposed to analyse the response to hyperglycemia over time of 
two epithelial tissues strongly affected in diabetic patients: the 
endothelium and salivary glands. Additionally, it is proposed to discover 
potential biomarkers of T1DM in human saliva. 
To accomplish this, specific aims were established and organized in 
4 chapters, as follows: 
Chapter II: 
• Select the appropriate animal model to study these tissues 
• Determine the adequate time points to carry a study of short- 
and long-term hyperglycemia 
Chapter III: 
• Isolate endothelial cells from the aorta 
• Analyse the expression of proteins involved in cell proliferation 
and cell function impairment 
• Evaluate damage and repair capacity of the endothelium 
• Evaluate the activation of the complement system by abnormal 
glycation of endothelial cell proteins 
Chapter IV: 
• Evaluate the changes in protein expression in granule-enriched 
fractions of the submandibular gland exposed to hyperglycemia 
• Correlate protein expression changes with the morphological 
alterations described in literature 
Chapter V: 
• analyse the post-translational modifications of the major family 
of proteins in human saliva – proline-rich proteins 
• correlate the frequency of these modifications in T1DM patients 
with control individuals and cancer patients 
• select potential biomarkers 
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1. Theoretical background 
1.1. Introduction 
The use of animals in scientific research is not exempt of ethical, 
moral and legal issues. Nonetheless, most of our present knowledge 
concerning human physiology, and a plethora of other related disciplines, 
has been achieved through animal experimentation. Biomedical research 
involving animals is still a necessary cost for the advancement of medical 
and biological sciences, among others. One of the guiding principles 
established throughout the years has been to use the “lowest” possible 
animal, making the use rodent models preferred to dogs, cats or primates, 
the exception being when these cannot properly reflect the human 
situation intended to study. Additionally, the less invasive procedures are 
generally preferred, making non-surgical methods favoured over surgical 
methods (Hau 2003). A perfect animal model does not exist. Its usefulness 
does not depend on how well it mimics the human disease, but instead on 
how well it answers the questions driven by the hypothesis in study. 
Hence, selecting the best model is a task that must consider the 
experimental hypothesis and specific aims of the study, but also more 
practical aspects such as the experimental facilities and the project staff 
(Hau 2003). 
The use of animal experimentation to study DM goes back to the 
1880’s and the experiments of von Mering and Minkowsky in dogs.  They 
noticed that by removing the pancreas, animals would present polyuria 
and polydipsia and developed hyperglycemia, being diagnosed with DM.  It 
thus became evident that one of the easiest ways to induce DM, and 
reproduce the effects of hyperglycemia from the absence of insulin, would 
be the total or partial removal of the pancreas (Rees and Alcolado 2005; 
Chatzigeorgiou, Halapas et al. 2009).  
Over the years several non-surgical rodent models were also 
developed to study the effects of DM or hyperglycemia; some are 
spontaneous models and others are induced models. 
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Spontaneous models are the result of the selection for 
hyperglycemia over generations of inbred strains in laboratories. This 
results in strains enriched in many genes and phenotypes, although not 
all may be relevant for the disease. Induced models, on the other hand, 
make use of substances known to have a diabetogenic effect, either by 
direct injection or other way of administration, but given the still diffuse 
knowledge on the aetiology of DM, they may not replicate the exact 
mechanisms responsible for the onset of the disease (Buschard and Thon 
2003; Hau 2003). A brief description of the most common rodent models 
in the study of hyperglycemia and DM, followed by a discussion of pros 
and cons for each, will be presented.  
1.2. The NOD mouse 
The non-obese diabetic (NOD) mouse was developed in Japan by S. 
Makino while selecting for dominant cataract associated with 
microphthalmia (Makino, Kunimoto et al. 1980). He has noticed that some 
animals presented a phenotype where they did not present cataracts but 
exhibited high fasting glucose levels. He then tried to selectively breed this 
phenotype and, at the same time, breed a euglycemic control with the 
animals from the same generation that did not present high fasting 
glucose levels. Surprisingly, at the 20th generation, a female from the 
euglycemic control spontaneously developed T1DM with heavy leucocytic 
infiltrations in pancreas – insulitis – and thus became the “mother” of the 
new NOD strain, while the line selected to high fasting glycemia never 
progressed to overt diabetes and was later named as nonobese 
nondiabetic (NON) (Ikegami and Makino 2005; Mathews and Leiter 2005). 
One of the advantages of the NOD mice model is the relatively high 
frequency of spontaneously developing T1DM. If maintained in a specific 
pathogen-free (SPF) environment, approximately 90% of females and 50-
60% of males, progress into fully overt T1DM. The SPF facilities are 
required because the strain is easily prone to protective 
immunomodulation when stimulated by a wide number of pathogens. The 
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NOD strain develops autoantibodies to insulin, GAD and IA-2, most like in 
human T1DM. Likewise, the usual clinical manifestations of DM are also 
present, such as hyperglycemia, polyuria, polydipsia and glycosuria 
(Chatzigeorgiou, Halapas et al. 2009). Yet, other autoimmune 
manifestations may develop, like leucocytic infiltrations in salivary and 
lacrimal glands or the thyroid gland. The infiltration in salivary glands, 
mostly by T lymphocytes, does not imply the loss of acini in the same 
progression and extension as in the islets of Langerhans and occurs after 
the insulitis. However, the salivary flow rates and protein content is 
severely affected, resulting in xerostomia, which is a common symptom of 
T1DM and Sjögren’s syndrome, although the destruction of the gland 
integrity is not as severe as in the human form of Sjögren’s syndrome 
(Mathews and Leiter 2005). Unlike humans, NOD mice seem resistant to 
ketoacidosis, in a way that they can survive several weeks without insulin 
treatment, even with glycemia >500 mg/dl. If diabetes is left untreated, 
animals will eventually die from dehydration and not from ketoacidosis 
(Rees and Alcolado 2005; Chatzigeorgiou, Halapas et al. 2009). 
1.3. The BB rat 
The diabetes-prone BB rat was discovered in the 1970’s at the Bio 
Breeding Laboratories (Ottawa, Canada) (Nakhooda, Like et al. 1977). 
Scientists noticed some weanling rats died with no apparent cause, other 
than severe cachexia, in an outbred Wistar-derived colony. They began to 
regularly weight all the animals to identify the affected animals and, 
eventually, were able to isolate a sufficient number for further studies. 
They have observed that the bedding of these animals was excessively wet 
and the water intake was 3 times the mean values of normal animals. The 
urine test revealed the presence of sugar and ketone values above normal, 
so fasting plasma glucose was measured to reveal values ranging between 
500-700 mg/dl. The treatment with insulin was initiated and the 
symptoms were markedly reduced. Histological analysis of the pancreas 
showed fibrosis and an absence of beta-cells in the islets. Thus a program 
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was initiated for selective breeding and this new strain was named BB 
after the initials of the laboratory (Chappel and Chappel 1983). Nowadays, 
two main substrains exist, developed at the University of Massachusetts 
Medical School: the diabetes-prone BB (BB-DP) rat and the 
diabetes-resistant BB rat (BB-DR). The major genetic difference between 
these substrains is a recessive mutation in chromosome 4 of the BB-DP 
rat, rendering a phenotype with T-cell lymphopenia in circulating blood. 
As such, the BB-DP rat is immunocompromised and requires a higher 
degree of microbiological quality - specific and opportunistic pathogens 
free (SOPF). On the other hand, the BB-DR may be used as an induced-
model of T1DM as the infection with the Kilham rat virus may trigger 
T1DM in this substrain (Mathews and Leiter 2005; Mordes, Bortell et al. 
2005). 
Like the NOD mouse, the BB rat presents as a model for 
autoimmune diabetes with heavy leucocyte infiltrations in pancreas and 
the presence of autoantibodies to insulin, GAD and IA-2 (Chatzigeorgiou, 
Halapas et al. 2009). However, rather than a NOD-like peri-insulitis, the 
insulitis is more similar to the human phenomenon and starts 2-3 weeks 
before the clinical onset of the disease (Mathews and Leiter 2005; 
Chatzigeorgiou, Halapas et al. 2009). The age of diagnosis is around 12 
weeks, which is analogous to the one observed in humans (juvenile and 
adolescent populations) (Mordes, Bortell et al. 2005). Also, unlike the NOD 
mouse and more like the human T1DM, the BB rat is highly susceptible to 
ketoacidosis, dying within 2 weeks if insulin treatment is not initiated. 
This strain also has the advantage over the NOD mouse of a sex-
independent high incidence of diabetes (80%) (Mathews and Leiter 2005). 
Like the NOD mouse, the BB rat exhibits salivary gland abnormalities, 
namely an enrichment of macrophages and T lymphocytes (Cohen, 
Talarico et al. 1997). 
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1.4. Leptin-signalling deficient rodents 
A common model for mimicking T2DM is the use of obese animals 
with deficiencies in either the leptin gene (ob/ob “obese” mice) or in the 
leptin receptor gene (db/db “diabetic” mice and Zucker fa/fa “diabetic 
fatty” rats). Nowadays, the mice strains are known as Lepob and Leprdb, 
while the rat strain may be referred to as Leprfa, to reflect the discovery of 
the genes involved in such genotypes (Herberg and Leiter 2005). Leptin is 
a hormone expressed in adipose tissue whose secretion is regulated by 
insulin and acts on the hypothalamus regulating appetite and energy 
intake.  
The discovery of the Lepob mutation in chromosome 6 dates back to 
1950, at The Jackson Laboratory (Ingalls, Dickie et al. 1950). The marked 
obesity and hyperphagia were the most immediate characteristics 
observed in homozygous animals. The mutation was then transferred into 
a B6 inbred strain where it developed juvenile onset obesity, 
hyperinsulinemia and insulin resistance. The increased proliferation of 
pancreatic beta-cells, in response to obesity and insulin resistance, led to 
a mild hyperglycemia eventually remitting to a normoglycemic state 
(Herberg and Leiter 2005). 
The Leprdb mutation was discovered a few years later, in 1966 
(Hummel, Dickie et al. 1966). It was identified in chromosome 4 of a BKS 
inbred strain and, unlike the Lepob mutation, the obesity and diabetes 
were permanent, hence the name “diabetic”. In this new strain, there was 
a severe hyperglycemia and necrosis of beta-cells with concomitant 
atrophy of islets (Herberg and Leiter 2005). Within a few months they 
develop ketosis and their lifespan does not go further than 8-10 months 
(Chatzigeorgiou, Halapas et al. 2009). 
The Zucker fatty rat (ZFR) was discovered by Zucker and Zucker 
(1961). It bears a mutation in the leptin receptor gene (fa mutation), in 
chromosome 5, that renders a shortened protein that does not interact 
with leptin. As a result of this deficiency, the animals have hyperphagia 
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and become obese within 4 weeks. Other characteristics are a mild 
hyperglycemia and insulin resistance (Peterson 2005). A substrain of this 
model was generated with selective inbred of ZFR for hyperglycemia. This 
substrain was named Zucker diabetic fatty rat (ZDF) because, unlike the 
ZFR, they develop diabetes as a result of the inability to compensate 
hyperglycemia and insulin resistance with an over-secretion of insulin. In 
fact, the pancreatic beta-cells rapidly succumb to apoptosis from the 
exacerbated stimuli to secrete more insulin (Peterson 2005; 
Chatzigeorgiou, Halapas et al. 2009). 
1.5. The non-obese Goto Kakizaki rat 
The Goto Kakizaki (GK) model was developed by Goto and 
co-workers in Japan in the 1970’s, by selecting animals mildly intolerant 
to glucose, with glycemia levels near the upper limit of the normal range in 
an OGTT, from a Wistar colony. It eventually rendered a strain presenting 
glucose intolerance and impaired insulin secretion (Goto, Kakizaki et al. 
1976; Östenson 2005).  
Unlike the previously described models for T2DM, the GK model is 
not obese. Pancreas islets, however, are less numbered since birth and 
sustain morphological changes, losing the smooth round shape into a 
starfish-like shape, and have an age-progressing lower number of 
beta-cells. Also unlike the leptin-deficiency models, the diabetes exhibited 
by the GK rat is of polygenic nature with a markedly maternal inheritance, 
which puts it closer to what is believed to be the nature of human T2DM 
(Rees and Alcolado 2005). 
Impaired glucose tolerance starts at 2 months and postprandial 
hyperglycemia rises in the first 6 months, progressing as a typical 
impaired insulin secretion/insulin resistance of T2DM. Despite an initial 
stage of general good health, in late stages, the animals develop vascular 
related complications such as retinopathy, neuropathy and nephropathy 
(Östenson 2005; Rees and Alcolado 2005). 
1.6. Genetically engineered rodent models 
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The late developments in science allowed the targeting of specific 
genes to better understand their specific role in DM. The most common 
method is the production of knockout strains where a specific gene has 
been disrupted or deleted. Some of the models already produced bear the 
knockout of the genes for insulin receptor, insulin-receptor substrate 1 
and 2 or glucokinase (Chang, Benecke et al. 1994; Tamemoto, Kadowaki 
et al. 1994; Grupe, Hultgren et al. 1995; Joshi, Lamothe et al. 1996; 
Withers, Gutierrez et al. 1998; Kubota, Tobe et al. 2000). Genetic 
engineering has even allowed the production of tissue-specific knockouts 
by using bacteriophage recombinase enzymes inserted next to a tissue-
specific promoter. However, it is equally possible to add more copies of a 
given gene, and thus study the effects of its over-expression (Rees and 
Alcolado 2005). 
Genetic modification techniques were more evolved in mice than in 
rats until recently; hence the availability of genetically modified mice is far 
superior to rats (Abbott 2004). However, the successful production of a 
genetically modified model is not as straightforward as it may seem in 
theory. Some homozygous deletions may be lethal and prevent embryos 
from further developing, while others may induce changes in the 
expression of non-targeted genes through compensatory mechanisms and 
result in a limited model (Rees and Alcolado 2005). For these reasons the 
cost of producing such models is extremely high. 
1.7. STZ-induced hyperglycemia 
Streptozotocin (2-deoxy-2-([methylnitrosoamino)carbonyl]amino)-D-
glucopyranose) is a glucosamine derivative with antimicrobial properties, 
produced by Streptomyces acromogenes. It is recognized by GLUT2 
transporters and, because the expression of GLUT2 is mainly observed in 
pancreatic beta-cells, liver and kidney (to a lesser extent) (Jurysta, Nicaise 
et al. 2013), the uptake is almost restricted to these cells. Once inside the 
cell, the nitrosourea moiety of STZ acts as a DNA alkylating agent, 
transferring a methyl group from STZ to DNA, especially at the O6 
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position of guanine, resulting in DNA fragmentation. Another mechanism 
thought to be present in STZ-mediated beta-cell toxicity is the 
overstimulation of poly(ADP-ribose) polymerase (PARP) in the attempt to 
repair the damages to the DNA molecule. This overstimulation leads to an 
increased consumption of NAD to a critical point that forces the cell to 
cease its cellular functions and ultimately induces cell necrosis. STZ is 
also capable of alkylating proteins. If along with DNA alkylation, STZ 
induces damages in glycolytic or mitochondrial enzyme, ATP production is 
impaired, as well as the resynthesis of NAD, already over-consumed by 
PARP (Lenzen 2008). 
An interestingly feature of STZ-induced models is that both T1DM 
and T2DM may be mimicked according to the dose injected. A single high 
dose of STZ induces the destruction of all beta-cells. Without beta-cells, 
the organism does not produce insulin and is incapable to regulate 
glycemia, consequently presenting a clinical diagnosis of T1DM. However, 
multiple low doses of STZ do not have such a drastic effect, reducing the 
number of beta-cells but keeping some residual insulin secretion, and, 
when coupled with a high-fat diet, leads to the progressive development of 
insulin resistance, resembling the pathogenesis of T2DM (Mathews and 
Leiter 2005; Srinivasan, Viswanad et al. 2005). 
1.8. Alloxan-induced hyperglycemia 
Alloxan (2,4,5,6-pyrimidinetetrone) is a pyrimidine derivative whose 
molecular structure is also analogue to glucose. Like STZ, alloxan enters 
beta-cells through the GLUT2 transporter, although its mechanism of 
beta-cell toxicity is different. It presents two distinct levels of action, the 
first level is by inhibiting glucokinase, preventing glucose phosphorylation 
upon cellular uptake and its entry in glycolysis and thus blocking the ATP 
signal that triggers insulin secretion; the other level is by generating 
reactive oxygen species (ROS). Alloxan initially reacts with glutathione, or 
other thiols, generating the alloxan radical and dialuric acid, which 
generate the superoxide radical and hydrogen peroxide. The amount of 
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ROS generated eventually surpasses the antioxidant defence capacity of 
the cell, accumulating and damaging the cell components, inducing 
necrosis. It is this mechanism that explains the low toxicity observed in 
liver, which also expresses GLUT2 transporters, but whose antioxidant 
defence pool, namely of catalase, is much more abundant (Lenzen 2008). 
Like in the STZ-induced model, hyperglycemia is achieved with the 
destruction of beta-cells and inability to secrete insulin. 
1.9. Discussion 
Considering the available options, a careful analysis of the pros and 
cons had to be done for each, in order to select the best model for the aims 
proposed. Some of the most important characteristics for each one of the 
models previously described are summarized in Table 3. As previously 
mentioned, both the aims of the study and more practical aspects, like the 
facilities available, should be considered in the selection of an adequate 
model. To carry on the present study, it was aimed to isolate aortic 
endothelial cells, so the animal chosen should have the largest vessels 
possible, not exceeding the animal facilities capacity that only houses 
rodents. Moreover, it was aimed to conduct a proteomic study on the 
response of submandibular glands, but leucocytic infiltrations are 
common in glandular tissue of animal models of DM, so a model that is 
not prone to such feature should be preferred. Additionally, many of the 
analysis are based in immunodetection of specific proteins; therefore the 
availability of antibodies for the species chosen is also an important issue. 
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Table 3 – Summary of the characteristics of each animal model. M: Mus musculus; R: Rattus 
norvegicus; SPF: Specific Pathogens Free; SOPF: Specific and Opportunistic Pathogens Free; 
C: Conventional, Sp: Spontaneous; Ind: Induced; +: High; –: Low; n.a.: not applicable 
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Species M M R R R R M/R M/R M/R 
Type of DM 
mimicked 1 2 2 2 1 2 1/2 1/2 1/2 
Housing 
microbiological 
control 
SPF C C C SOPF C variable C C 
Spontaneous/ 
Induced Sp Sp Sp Sp Sp Sp n.a. Ind Ind 
Insulin: 
secretion 
(long-term) 
/resistance 
/treatment 
–/–/– +/+/– –/+/– –/+/– –/+/+ –/+/– variable –/–/– –/–/– 
Ketoacidosis –    +  variable – – 
Lipidemia – + + + – – variable – – 
Saliva secretion –    –  variable – – 
Salivary glands 
histology 
Leucocytic 
infiltrations   
Increased 
extracellular 
fatty 
droplets 
(Mozaffari, 
Abdelsayed 
et al. 2011) 
Leucocytic 
infiltrations  variable 
Loss of 
ductal cells 
(long-term) 
(Anderson, 
Suleiman et 
al. 1994) 
Increased 
acinar cell 
size 
(Reuterving, 
Hagg et al. 
1987) 
Vascular 
complications 
+    +  variable + + 
Antibody 
availability 
+ + – – – – + (M) – (R) 
+ (M) 
– (R) 
+ (M) 
– (R) 
Price 
EUR 
22a 
EUR 
68b 
EUR 
72b 
EUR 
108b 
USD 
277c 
USD 
126d 
USD 
156(M) 
184(R)d 
EUR 
15a,e 
15b,f 
EUR 
15a,e 
15b,f 
a Taconic Catalog Europe 2013; b Harlan Catalog Spain 2012; c Biomere email 
inquire 2009; d Charles River Catalog USA 2013; e B6 mice; f Wistar rats. 
 
To study the impact of hyperglycemia in the long term, one has to 
exclude the Lepob model because hyperglycemia is usually transient and 
compensated by the increase of islets and insulin secretion. On the other 
hand, one should avoid the presence of other variables that could interfere 
in cellular metabolism and tissue morphology. The use of obese models, 
such as Leprdb mice or ZDF rats, should be avoided as the increase in 
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adipose tissue and hyperlipidemia usually induces morphological changes 
in tissue with the inclusion of lipid droplets and metabolic changes, 
despite being one of the causes of insulin resistance and consequent 
hyperglycemia (Mozaffari, Abdelsayed et al. 2011). For the same reasons, 
the spontaneous T1DM models of NOD mice and BB rats should be 
excluded because the heavy leucocytic infiltrations in salivary glands 
would interfere in the proteomic analysis of those organs. Moreover, these 
models are severely immunocompromised and require special housing 
conditions, not available at the moment of the beginning of the 
experimental protocol and would increase the costs involved (Ikegami and 
Makino 2005; Mordes, Bortell et al. 2005). The economic criteria could 
also be a reason to exclude genetically modified models, however, it should 
not stay above the scientific criteria and it is a fact that studies with 
genetically modified animals are scarcer than with STZ- or alloxan-
induced hyperglycemia, which could limit the impact of the study and 
severely limit the comparison of the data obtained with the literature 
available. Choosing the STZ- or alloxan-induced models gives us the 
advantage of using either mice or rats. The choice of the species brings the 
need to look at other, more practical, criteria. Mouse models are generally 
chosen because they are considered to be easy to handle, faster in 
reproduction and require less space; also the gene manipulation 
technology is highly advanced for mice, making it a widespread model for 
various diseases (Abbott 2004; Iannaccone and Jacob 2009). Another 
advantage is that the availability of antibodies specific for mice proteins is 
far superior. However, rats present some important advantages. For 
starter, its physiology is in many cases more like the human than mice 
(Nature Methods Editorial 2010). But also, its larger size allows the 
potential recover of more material using fewer animals and a larger animal 
was one of the features identified as preferable for this study.  
The choice would now rest on the drug used to induce 
hyperglycemia. Both drugs lack reports of leucocytic infiltrations that 
could interfere in proteomic analysis of salivary glands (Reuterving, Hagg 
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et al. 1987; Anderson, Suleiman et al. 1994). However, STZ has an 
important practical advantage; it is stable in physiological conditions 
(pH 7.4, 37ºC) for up to 1 hour, while alloxan has a half-life of 
approximately 90 seconds in the same conditions (Lenzen 2008). The use 
of any of these drugs, however, has a disadvantage: because the uptake is 
mediated by GLUT2 transporters, both enter hepatocytes and may induce 
liver damage. Nonetheless, several studies have demonstrated that the 
deleterious effects in hepatic function are recoverable within a few weeks 
(Carnovale and Rodriguez Garay 1984; Evelson, Susemihl et al. 2005). As 
this study aims for the long-term effects of hyperglycemia, when the drug 
has obviously cleared the system and its remaining effect is only the 
irreversible destruction of beta-cells, the STZ-induced hyperglycaemic rat 
would be the best model. 
It becomes clear that the STZ-induced hyperglycemia in rat is the 
more advantageous model to conduct the proposed study because it is a 
widely used model, and thus comparable to a wide range of published 
works (over 800 entries in PubMed for “rat streptozotocin”); it presents the 
chronic complications in study, vascular and salivary secretion 
impairments without significant morphological changes in the organs in 
study, other than the ones caused by hyperglycemia; and it is an 
economic and easy to maintain model, not requiring insulin treatment for 
survival over long periods or specific housing conditions. 
Selecting an appropriate model to study the impact of hyperglycemia in 
epithelial-derived tissues 
41 
2. Experimental design 
2.1. Outline 
The study of long term effects in animal models needs to take into 
account that the rat’s lifespan and development is much faster than 
human’s, which is actually a major advantage of using animal models. As 
such, one must draw a parallel correspondence between rat years and 
human years. According to Quinn, a human year is roughly equivalent to 
16.7 rat days in average, although the correspondence is not linear 
throughout the rat lifespan (Quinn 2005). The literature on the effects of 
hyperglycemia has a wide range in the duration of experimental diabetes, 
according to the effect studied or if one is aiming for acute or chronic 
consequences. Renal function has been evaluated with only 8 days of 
STZ-induced hyperglycemia (Carney, Wong et al. 1979), to over 10 weeks 
without insulin therapy or 11 months with insulin therapy (Zatz, Meyer et 
al. 1985); while neuropathy and axonemal transport has been evaluated 
over a 4 weeks period (Marini, Vitadello et al. 1986) and cataract 
formation over a 9 weeks to 5 months period (Fukushi, Merola et al. 
1980). In the case of endothelial and salivary gland effects of 
hyperglycemia, which are the target tissues of this study, a work of 
Bucciarelli and co-workers (2009) has observed a progressive impairment 
of mice arterial and venal endothelial cells over a period of 3 and 7 
months, namely through the increased expression of inflammatory 
proteins mRNA; whereas a work of Anderson and co-workers (1994) has 
shown that the submandibular glands start to show morphological 
changes in ducts after 3 months of uncontrolled hyperglycemia, 
progressing to acini after 6 months (Anderson, Suleiman et al. 1994; 
Bucciarelli, Pollreisz et al. 2009). The present study aims to study the 
effect of hyperglycemia in the endothelium and the submandibular glands. 
To study the endothelium, it was proposed to isolate endothelial cells from 
rat aorta to perform a direct analysis without in vitro proliferation steps, 
and evaluate endothelial damage and repair by flow cytometry analysis of 
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circulating endothelial cells. To study salivary glands, it was proposed to 
conduct a quantitative proteomic analysis of submandibular glands. To 
optimize procedures and evaluate the feasibility of the analysis of 
endothelial cells, a preliminary study was conducted with 13 rats, during 
1 month, before defining the time-points for an experimental animal 
protocol. 
2.2. Material and methods 
2.2.1. Preliminary study 
Eight male Wistar rats were injected with streptozotocin (S0130, 
Sigma-Aldrich) (60 mg/kg) in citrate buffer (pH 4.5), and 5 others were 
injected with citrate buffer alone. Hyperglycemia was observed 3 days 
post-injection of STZ and was retained during 1 month. Upon sacrifice, 
blood was collected from the inferior vena cava into EDTA tubes 
(Vacutainer® Blood Collection Tubes, BD Biosciences, USA) and a portion 
of aorta was collected for endothelial cell isolation. A detailed description 
of the flow cytometry and endothelial cell isolation is provided in 
Chapter III. Glycemia and HbA1c values were also determined as 
described ahead. 
2.2.2. Animals 
Forty 6-week-old male Wistar rats were randomly divided into 
2 groups. Animals were housed at constant temperature (21º-24ºC) with a 
12-hour period of light vs. dark and provided with food and water ad 
libitum. One group (Diabetic) received an intraperitoneal injection of 
streptozotocin (S0130, Sigma-Aldrich) (60 mg/kg) in citrate buffer 
(pH 4.5), while the other group (Control) received an injection with citrate 
buffer alone. After 72 hours, the animals were subjected to glycemic 
control. During the first month, weekly measurements of glycemia and 
weight were performed. Animals were considered hyperglycemic if the 
glycemia levels were consistently above 200 mg/dl. Following the 
experimental design previously established (Figure 8), after two-months 
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half the animals from the control group and half from the diabetic group 
were euthanized. After four-months the remaining animals were 
euthanized.  
Blood was collected with a syringe from the inferior vena cava and 
immediately aliquoted into EDTA, citrate and serum tubes (Vacutainer® 
Blood Collection Tubes, BD Biosciences, USA) and stored on ice for no 
more than 3 hours before further processing. Salivary glands were excised 
and stored on ice in phosphate-buffered saline (pH 7.35) until further 
processing. A portion of aorta with approximately 5 cm was excised for 
endothelial cell isolation and stored on ice in PBS until further processing. 
Tissue samples were collected for microscopic evaluation in 4% 
para-formaldehyde in PBS. 
2.2.3. Glycemic control 
Glycemia was measured using a Glucocard™ G meter (A. Menarini 
Diagnosis, Portugal) with Glucocard™ G sensor test strips. This device 
allows an accurate measurement of glycemia levels up to 600 mg/dl with 
a small drop of capillary blood obtained with a puncture in the tail 
extremity. The tail was briefly disinfected with a cotton ball embedded in 
70% ethanol and once it dried out, a lancing device was triggered 
puncturing the tail. The small drop of blood obtained was loaded on the 
test strip and the reading was registered. No pain manifestation was ever 
observed in the animals. 
2.2.4. Measurement of HbA1c 
Glycated haemoglobin was determined with a Hemoglobin A1C 
chromatographic kit (Biosystems, Spain). Blood collected in EDTA tubes 
(50 µl) was mixed with Reagent 1 (200 µl) and kept at room temperature 
for 15 min. Then 50 µl of the hemolysate was applied on the upper filter of 
the column and allowed to drain, eventually adding 200 µl of Reagent 2 to 
ensure no residues of the hemolysate would remain above the filter. 
Afterwards, 2 ml of Reagent 2 were added and allowed to drain, thus 
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washing HbA1a+b. To elute the HbA1c bound to the resin, 4 ml were 
added to the column and the eluate was collected in a test tube. The 
OD 415nm was measured against distilled water. The total haemoglobin 
OD 415nm was measured from a hemolysate prepared by mixing 6ml of 
Reagent 3 with 25 µl of blood. Glycated haemoglobin was expressed as a 
percentage of total haemoglobin by applying the formula: 
𝑂𝐷𝐻𝑏𝐴1𝑐 × 𝑉𝐻𝑏𝐴1𝑐
𝑂𝐷𝐻𝑏𝑇𝑂𝑇𝐴𝐿 × 𝑉𝐻𝑏𝑇𝑂𝑇𝐴𝐿 = %𝐻𝑏𝐴1𝑐 
Where VHbA1c and VHbTOTAL are 4 ml and 6 ml, respectively. 
2.2.5. Statistical analysis 
All statistical tests were performed using GraphPad Prism v5.00 
(GraphPad Software, Inc., USA). Data were analysed using a two-way 
ANOVA with Bonferroni’s post hoc tests to compare groups. A 
p-value <0.05 was considered significant. 
2.3. Results and Discussion 
The use of STZ-induced hyperglycemia model in the study of DM 
has been widely spread. Given that one of the objectives of the present 
work was to study the effects of DM in the proteome of salivary glands, 
but these glands suffer from leucocyte infiltrations in the case of real DM 
and general spontaneous animal models (Mathews and Leiter 2005), a 
method to induce hyperglycemia, without such alterations, was chosen. 
Moreover, to optimize procedures and decide the appropriate time points 
to use in the main study, a preliminary study was conducted with 13 
animals. 
Hyperglycemia was successfully induced with STZ in 7 animals 
(Figure 6A). Consistently with the effect of prolonged hyperglycemia, the 
% HbA1c was slightly elevated in hyperglycaemic rats (Figure 6B). Flow 
cytometry analysis of circulating endothelial cells (CEC) and endothelial 
progenitor cells (EPC) revealed that with only a month of hyperglycemia 
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there were significant changes in the number of these cells in circulation 
(Figure 6C-D). 
 
Figure 6 – Results of the preliminary study.  
White bars represent control animals, filled bars represent hyperglycemic animals. A - glycemia; 
B - % HbA1c; C - Circulating endothelial cells (CD45-, CD146+, CD133-); D - Endothelial 
progenitor cells (CD45-, CD146+, CD133+). * p<0.05; ** p<0.01; *** p<0.001 
Moreover, the isolation of endothelial cells appeared successful 
when observing the magnetic beads suspension under the microscope 
(Figure 7). 
 
Figure 7 – Suspension of endothelial cells isolated with anti-CD146-coated magnetic beads. 
CD146 positive cells were labelled with Alexa Fluor 488 (green), nuclei were stained with Hoechst. 
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So, considering the results in the preliminary study, vascular 
impairment is already started within 1 month of permanent 
hyperglycemia. However, salivary glands only seem to show morphological 
changes within 3 months of hyperglycemia (Anderson, Suleiman et al. 
1994). Because is likely that morphological changes are preceded by 
protein changes in the cells, it was decided to establish a first time point 
at 2 months of hyperglycemia and a second point at 4 months of 
hyperglycemia, resulting in the experimental protocol schematized in 
Figure 8. 
 
Figure 8 - Experimental design of the animal protocol. 
 
At the time of injection, the animals presented an average weight of 
250.5±10.5 grams. After 72 hours, all but one of the animals treated with 
STZ, presented hyperglycemia. This one was once again injected with a 
new dose of 60 mg/kg of STZ in citrate buffer, but, since it did not present 
hyperglycemia after the two treatments, it was excluded from the 
experiment. The remaining animals were weekly monitored for glycemia 
and weight during the first two-months. After 2-weeks, the treated 
animals presented hyperglycemia with consistent values above the upper 
limit of detection of the equipment used (>600 mg/dl), while untreated 
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animals presented values <100 mg/dl. It was observed that treated 
animals did not gain weight during the following weeks, while untreated 
animals rapidly increased in size and weight (Figure 9). During all the 
experimental period, other effects of hyperglycemia were observed in 
treated animals, namely, polydipsia, polyuria and, reaching the 4-months 
of the trial, loss of sight. None of the animals died during the experimental 
period and none present behavioural changes that could indicate 
suffering. 
 
Figure 9- Evolution of weight and glycemia in the first days post STZ injection.  
Data are presented as mean±SD. 
Half of the animals of each group were euthanized 2-months after 
the injection with STZ or vehicle alone, rendering the first two groups: 
Control 2-months (C2M) and Diabetic 2-months (D2M), with n=10 and 
n=9, respectively. The remaining animals were euthanized after 4-months 
of being injected, rendering the last two groups: Control 4-months (C4M) 
and Diabetic 4-months (D4M), with n=10, each. At the time of sacrifice, 
there were highly significant (p<0.001) differences in weight, glycemia and 
HbA1c between control and treated animals (Figure 10). 
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Figure 10 – Differences in weight, glycemia and % of Hb1Ac at the time of sacrifice.  
White bars: control; filled bars: hyperglycaemic. Data are presented as mean±SD. *** p<0,001 vs. 
control 
The macroscopic observation of the internal organs revealed only a 
higher level of visceral fat in control animals. Because STZ could damage 
the liver (Lenzen 2008), special attention was given to this organ but no 
macroscopic damages were observed either at 2 or 4 months. 
3. Conclusion 
Given the results obtained, it is possible to conclude that the 
STZ-induced hyperglycemia model presents as an economic, yet reliable 
and effective animal model to study the hyperglycemia-derived 
complications in the endothelium and salivary glands present in DM. 
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1. Introduction 
Almost all long-term complications of diabetes mellitus are strongly 
related to damages in blood vessels. Vascular complications may be 
separated into macrovascular, if affecting larger vessels as in the case of 
peripheral/coronary artery disease or stroke, or microvascular 
complications, if affecting capillaries like in retinopathy, neuropathy or 
nephropathy (Fowler 2008). Lining the inner surface of the vascular 
system is a thin single cell layer: the endothelium. Considering that the 
endothelium is in permanent contact with the bloodstream, it is not 
surprising that variations in blood composition will have an effect in 
endothelial cells. Hence it is important to understand the mechanisms 
underlying the endothelial response to hyperglycemia. 
1.1. Embryonic origin and development of the endothelium 
The endothelium is the innermost layer of cells in the circulatory 
system. Depending on the organ, one may consider the vascular 
endothelium, in blood vessels; the endocardium, in the heart cavities; or 
the lymphatic endothelium, in lymphatic vessels. The average human 
adult endothelium weights approximately 1 Kg and may have surface area 
up to 7000 m2 (Aird 2005). 
The endothelium has its embryonic origin in the mesoderm as loose 
aggregations of cells expressing early endothelial markers, which give 
origin to angioblasts in a process not fully understood. The existence of a 
pluripotent intermediate hemangioblast precursor, which could 
differentiate into endothelial and hematopoietic precursors, has been 
postulated but it has been shown that mesoderm cells could differentiate 
directly into angioblasts without the need of an intermediate 
hemangioblast (Pardanaud and Dieterlen-Lievre 1993; Choi, Kennedy et 
al. 1998; Ferguson, Kelley et al. 2005; Patterson 2007). The angioblast 
formation appears to involve members of fibroblast growth factor (FGF) 
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and bone morphogenetic protein (BMP) families, as well as an endoderm-
mesoderm interaction (Vokes and Krieg 2002; Patterson 2007). 
Vasculogenesis, the formation of blood vessels from the in situ 
differentiation of angioblasts into endothelial cells, in contrast to 
angiogenesis that results from the extension or remodelling of existing 
vessels, starts in the para-arotic region of mesoderm and originates the 
dorsal aorta and cardinal veins in a primary vascular network. 
Simultaneously, the endocardium originates from angioblasts that migrate 
from other region of mesoderm (Ferguson, Kelley et al. 2005; Patterson 
2007). Further development of the vascular system occurs mostly by 
angiogenesis until the full development of a mature network (Figure 11).  
 
Figure 11 – Process of blood vessel formation during embryonic development.  
Adapted from Carmeliet and Collen (2000) 
The processes of vessel formation are coordinated by the vascular 
endothelial growth factor (VEGF) and its receptors (VEGFR1 and VEGFR2) 
and neuropilin co-receptors (NP1 and NP2). To be able to respond to 
VEGF, cells need to firstly express its receptors. VEGFR2 is expressed very 
early in embryonic development and it has been reported that BMP 
stimulated VEGFR2 transcription (Eichmann, Corbel et al. 1997; Wu, 
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Moser et al. 2003). VEGF is secreted not only by endothelial cells, but also 
by other cells in endothelial vicinity and its expression is regulated by 
hypoxia-inducible factor 1 (HIF-1) (Carmeliet and Collen 2000). The 
binding of VEGF to its receptors activates intracellular cascades that 
induce cell proliferation and which will be discussed further ahead. 
1.2. The endothelium as a specific type of epithelial tissue 
The classification of the endothelium as an epithelial tissue is not 
consensual. The term endothelium was coined by Wilhelm His, in 1865, to 
distinguish this tissue from the traditional epithelium. His considered 
three major differences between endothelium and “true” epithelium: the 
embryonic origin was different, the endothelium had a clearly recognizable 
structure and the endothelium did not present physiological secretion; 
hence he considered it should be identified by its own name: endothelium 
(Laubichler, Aird et al. 2007).  Indeed, the evolution of scientific knowledge 
since His introduced the term, allowed the discovery of several structural 
and physiological properties, some unique, others common to epithelial 
tissues. For instance, it is now known that endothelial cells have an active 
secretory function of remarkable importance in the development and 
proliferation of blood vessels and in the regulation of vasodilation, 
coagulation and inflammation (Esper, Nordaby et al. 2006). On the other 
hand, endothelial cells have intermediate filaments of vimentin, while 
epithelial cells have filaments of cytokeratin. Moreover, endothelial cells 
possess a unique type of intercellular junctions with vascular endothelial 
(VE)-cadherin, which are not found in other tissues, as well as specific 
receptors involved in cross-talk between endothelial and vascular smooth 
muscle layers (Munoz-Chapuli, Carmona et al. 2005). Despite these 
differences, classic reference books of histology still classify tissues into 
four basic types: epithelial, connective, muscular and nervous. Although 
recognizing the existence of specificities to the mesodermal-derived lining 
tissues, such as the endothelium or the mesothelium, it is considered that 
such differences have a low practical value by both morphological and 
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functional criteria. Hence, the endothelium is considered a simple 
squamous epithelium (Henrikson 1997; Young 2006; Mescher 2009). 
1.3. Endothelial heterogeneity as an organ-dependant 
specialization 
Despite being always a single layer of cells, the vascular 
endothelium has a heterogeneous morphology. Capillary may have a 
continuous non-fenestrated endothelium, with cells densely juxtaposed 
connected by tight-junctions that block any interendothelial transport; a 
continuous fenestrated endothelium, where cells have fenestrae covered 
with a non-membranous diaphragm, which increase permeability but 
retain some filtering properties from the diaphragm; or a discontinuous 
endothelium with large gaps (fenestrae lacking diaphragm), allowing the 
free passage of larger molecules (Figure 12). Arteries have a continuous 
non-fenestrated endothelium, formed by long and narrow cells with 
numerous tight junctions and aligned with the blood flow. Venous 
endothelium is also continuous and non-fenestrated, but cells are not 
aligned, are wider and possess valves (Aird 2003; Aird 2007b; Aird 2007a; 
Stan 2007). 
 
Figure 12 – Schematic representation of the types of capillary endothelium. 
 
The morphology of the endothelium is tightly connected to the 
specific functions it may have in specific organs/tissues. In brain, skin, 
heart muscle and lung, capillary form a tissue-blood barrier to prevent the 
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entry or the leakage of unwanted molecules and cells from blood; hence it 
is of a continuous non-fenestrated type. In the gastrointestinal tract, there 
is a need to rapidly allow the passage of nutrients from the intestinal 
lumen to the bloodstream, so the endothelium has numerous fenestrae 
with diaphragms. Similarly, kidney glomeruli also have continuous 
fenestrated endothelium to facilitate blood filtration (Aird 2007b). Liver 
needs to permanently exchange numerous molecules with blood, namely 
lipid particles, serum proteins, blood toxins and bilirubin; to facilitate this 
exchange, the liver endothelium is discontinuous and has a large number 
of fenestrae without diaphragm. Within the same organ, it is also possible 
to observe heterogeneous endothelium. Pancreas is simultaneously an 
endocrine and an exocrine gland; exocrine pancreas, secretes digestive 
enzymes and electrolytes into ducts and has a continuous endothelium 
with some fenestrae; endocrine pancreas, on the other hand, secretes 
hormones directly into the bloodstream and needs to act rapidly to 
regulate glycemia, consequently, the endothelium is continuous but highly 
fenestrated (Stevens, Rosenberg et al. 2001; Aird 2003; Aird 2007a; 
Lammert 2007). 
1.4. Endothelial dysfunction and repair  
As previously mentioned, the endothelium is more than a simple 
lining tissue or barrier. Several physiological functions were already 
shown to have a strong involvement of the endothelium, making it a 
dynamic organ. The endothelium regulates vasodilator tone in response to 
shear stress, temperature changes, bradykinin and acetylcholine. This is 
achieved with the secretion of molecules, such as, nitric oxide (NO), 
prostacyclin, endothelium-derived hyperpolarizing factors (EDHF), carbon 
monoxide and endothelin, which act on the vascular smooth muscle. 
Moreover, endothelium also regulates coagulation, platelet aggregation, 
adhesion of inflammatory cells and its own repair and regeneration 
(Ozkor, Murrow et al. 2010). Lining the luminal surface of endothelial cells 
is a carbohydrate-rich layer – the glycocalyx – that has critical roles in the 
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regulation of vascular permeability, reduction of blood cell-vessel wall 
interactions, mediation of shear stress sensing, balancing signalling and 
has a general vasculoprotective role (Reitsma, Slaaf et al. 2007). 
Endothelial dysfunction is defined as the loss of any of these proper 
physiological functions (Schram and Stehouwer 2005; Schmieder 2006; 
Avogaro, Albiero et al. 2011). 
The vascular endothelium is permanently subject to chemical and 
physical stress as a consequence of alterations in blood composition and 
the pressure of the blood flow, respectively. As such, the integrity of this 
single-cell layer is kept by its highly effective repair mechanisms. As 
previously mentioned, the growth of endothelial tissue occurs either by 
vasculogenesis – the differentiation of angioblasts into new endothelial 
cells – or by angiogenesis – the proliferation of existent endothelial cells. It 
was thought that vasculogenesis was restricted to the embryonic stage; 
however, the discovery of bone marrow-derived circulating endothelial 
progenitor cells (EPC) has challenged this concept. It has been 
demonstrated the capacity of mobilization of EPC from the bone marrow to 
neoangiogenic sites and participation in the formation of new blood 
vessels (Asahara, Takahashi et al. 1999; Takahashi, Kalka et al. 1999; 
Lyden, Hattori et al. 2001; Costa 2011). Vascular injury may result in 
endothelial cell apoptosis or detachment of endothelial cells from the basal 
lamina, leaving naked areas. Cell detachment may result from mechanical 
injury, alteration of cell adhesion molecules or defective binding to 
anchoring matrix proteins, and cells are released in the blood stream, 
originating a population of circulating endothelial cells (CEC). These cells 
are correlated with severe endothelial damage and their increase is often 
associated to endothelial dysfunction and inflammatory markers (Goon, 
Lip et al. 2006). 
Endothelial proliferation is regulated by VEGF. An increase of serum 
levels of VEGF is correlated to endothelial damage. Upon recognition by 
the VEGF receptors on the surface of endothelial plasma membrane, the 
pro-survival Akt cascade is activated, inducing gene transcription and 
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proliferation. VEGF was also shown to promote the recruitment of EPC 
from bone marrow to injury sites. Thus, the repair of injury may be 
conducted by proliferation of adjacent endothelial cells and/or by the 
recruitment of EPC (Figure 13). Other molecules have a similar role in the 
activation of the Akt cascade and inhibiting apoptosis. It was shown that 
angiopoietin 1, insulin and IGF-1, sphingosine-1-phosphate, HGF, leptin, 
adiponectin and fluid shear stress, also activate PI3K-Akt signalling 
(Shiojima and Walsh 2002). 
 
Figure 13 – Mechanisms of endothelial repair by proliferation of existing endothelial cells 
and recruitment of progenitor cells.  
Upon the detachment of endothelial cells, there is an increase of VEGF secretion and other 
proliferation and mobilization stimuli. These stimuli recruits endothelial progenitor cells (EPC) to 
the injury site. These differentiate into mature endothelial cells to repair the injury. 
Simultaneously, mature endothelial cells with proliferative potential (ECFC) adjacent to the injury 
site, may also proliferate and repair the injury. Adapted from Richardson and Yoder (2011) with 
permission from Elsevier. 
1.5. Endothelium, inflammation and immunity 
The endothelium releases several important physiological and 
pathophysiological inflammatory mediators. The changes that occur in the 
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endothelium, allowing it to participate in the inflammatory response, are 
called endothelial activation (Hunt and Jurd 1998; Hartge, Unger et al. 
2007). When any stimulus induces the release of proinflammatory 
cytokines IL-1beta and TNF-alpha by macrophages, these activate the 
expression of leucocyte adhesion molecules (ELAMs), altering the protein 
composition of the glycocalyx. Activated endothelial cells also secrete 
chemokines and in conjunction with the ELAMs E-selectin, intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1), interact with receptors on the surface of leucocytes and guide 
them to intercellular junctions where they cross into tissue space, 
resulting in inflammation. The endothelial response may be modulated by 
T-cell-derived cytokines; IFN-gamma prolongs the expression of E-selectin, 
whereas IL-4 suppresses it and promotes VCAM-1 expression. Such 
modulation favours the recruitment of T-helper-1 leucocytes by 
IFN-gamma or the T-helper-2 leucocytes by IL-4 (Pober 2002). 
 Proinflammatory cytokines also have an effect in the innate 
immunity system. The endothelial expression of a membrane protein 
named decay-accelerating factor (DAF) is highly responsive to TNF-alpha 
and IFN-gamma cytokines, as well as to growth factors (FGF, VEGF) and 
thrombin. This protein is an important regulator of the complement 
system and, together with the other complement regulators CD46 and 
CD59, is also highly expressed in the presence of C-reactive protein. 
Inflammatory agonists were also shown to induce the synthesis of 
complement proteins in endothelial cells (Augustin 2007). 
The complement system is a set of more than 30 plasma soluble 
proteins, cell receptors and control proteins that act in a cascade-like 
manner to protect against bacteria, viruses, parasites and tumour-cells  
(Rus, Cudrici et al. 2005). It has three independent activation pathways: 
the classical pathway, the alternative pathway and the lectin pathway. 
Each one of these pathways is activated through the recognition of specific 
molecules or complexes. Antigen-antibody complexes are recognized by 
the C1-complex and activate the classical pathway; the spontaneous 
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activation of C3 and certain molecules on the surface of pathogens, such 
as lipopolysaccharides, activate the alternative pathway; some sugars, 
such as mannose, fructosamine or glucose, when in the terminal end of 
glycoproteins on the surface of pathogens, are recognized by the lectins 
ficollin of mannose-binding lectin (MBL) and activate the lectin pathway 
(Fortpied, Vertommen et al. 2010). All of these pathways converge in the 
activation of C3 convertase, which continues a proteolytic cascade 
throughout sever of the complement functions are activated. The 
deposition of C5b peptide on the surface of cells, initiates the formation of 
the membrane attack complex (MAC), opening pores on foreign cells and 
inducing cell lysis; C3a and C5a promote the degranulation of mast cells 
and enhance vascular permeability; C3b acts as an opsonin, enhancing 
phagocytosis (Figure 14) (Janeway, Travers et al. 2001; Rus, Cudrici et al. 
2005). 
 
Figure 14 – Activation pathways for the complement system and respective proteolytic 
cascade. 
Published in Józsi (2011) 
 
Studies of epithelial response to streptozotocin-induced hyperglycemia 
64 
Endothelial cells express G-protein-coupled receptors for C3a and 
C5a proteins, and both activate the expression of IL-1beta and IL-8. C5a 
also induces the release of von Willebrand factor and the expression of 
P-selectin and E-selectin, increasing endothelial adhesiveness for 
neutrophils. C5b-9 induces vesiculation in endothelial cells, which 
become sites for clothing factor Va binding, thus having a procoagulant 
activity in conjunction with endothelial cells (Augustin 2007). 
1.6. Endothelial dysfunction in hyperglycemia 
Poorly controlled glycemia levels mean that blood vessels, in 
particular the endothelium, are in a permanent contact with high 
concentrations of glucose. Thus, it is not surprising that hyperglycemia is 
correlated to endothelial dysfunction (Schram and Stehouwer 2005; 
Bakker, Eringa et al. 2009; Avogaro, Albiero et al. 2011). The mechanisms 
relating both events are not fully disclosed.  
It has been reported a progressive increase of inflammatory markers 
in endothelial cells with the duration of hyperglycemia (Bucciarelli, 
Pollreisz et al. 2009). Insulin signalling is present in endothelial cells and, 
in diabetes, the impairment of this signalling pathways has consequences 
in cell proliferation and vascular tone regulation (Abebe and Mozaffari 
2010). 
The formation of advanced glycation endproducts (AGEs) and 
oxidative stress have also been implied in vascular damage and have been 
extensively studied (Tan, Chow et al. 2002; Basta, Schmidt et al. 2004; 
Potenza, Gagliardi et al. 2009; Alkhalaf, Kleefstra et al. 2012). Despite the 
low reactivity of glucose with amines when compared to other sugars, it is 
possible that such reactions occur (Bunn and Higgins 1981; Negre-
Salvayre, Salvayre et al. 2009). Moreover, ROS may also be generated by 
mitochondrial dysfunction as a consequence of increased free fatty acids 
(Abebe and Mozaffari 2010). 
Due to the presence of glycation events, the complement activation 
by the lectin pathway has been proposed to play an important role in 
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endothelial dysfunction (Hansen, Tarnow et al. 2004; Ostergaard, Hansen 
et al. 2005; Saraheimo, Forsblom et al. 2005; Ostergaard, Thiel et al. 
2007; Ostergaard, Bjerre et al. 2013). MBL recognizes and binds mannose, 
N-acetylglucosamine and fructosamine residues (Fortpied, Vertommen et 
al. 2010), this triggers the complement proteolytic cascade starting on the 
MBL-associated serine protease-1 and -2 (MASP-1/-2). 
Because of the relation of the endothelium, inflammation, the 
complement system and the increased glycation observed in 
hyperglycemia, we proposed the hypothesis that glycation of membrane 
proteins of endothelial cells could generate carbohydrate moieties that 
would be recognized by the mannose-binding lectin and thus activate the 
complement system against the endothelium and promoting an 
inflammatory state. We have tried to analyse endothelial cells isolated 
from the aorta, as well as markers of endothelial damage and repair, 
linking these to the activity of the MBL activity in control and 
hyperglycemic rats. 
2. Methods 
2.1. Aortic endothelial cells isolation 
Aortic endothelial cells were isolated from portions with magnetic 
beads coated with a specific antibody for endothelial cells. First, 
Dynabeads® M-270 Epoxy (14301, Invitrogen, UK) were coated with 
anti-CD146 antibody, according to the manufacturer’s instructions. In 
brief, 300 µl of beads suspension were washed with 0.1 M sodium 
phosphate buffer, pH 7.4, to remove the storage buffer. Afterwards, beads 
were ressuspended in PBS for 2 minutes and 10 µl of anti-Rabbit IgG 
HRP-conjugated (RPN2124, GE Healthcare, UK) were added. After an 
overnight incubation at 37ºC with agitation, the beads were washed twice 
with PBS supplemented with 0.1% (m/v) of BSA (A7906, Sigma, USA) and 
once more with 0.2 M Tris, pH 8.5, supplemented with 0.1% BSA, to block 
the remaining free epoxy groups, and once again with PBS/BSA. Next, the 
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beads were ressuspended in PBS/BSA and 10 µl of Anti-CD146 antibody 
(ab75769, Abcam, UK) were added and incubated overnight at 4ºC with 
agitation. Coated beads were then washed 4 times with PBS/BSA, 
5 minutes at 4ºC with agitation, to block any unspecific binding sites and 
stored at 4ºC in PBS/BSA. 
On the days of animal sacrifices, pieces with approximately 5 cm of 
aorta were collected and kept in PBS, on ice, for no longer than 3 hours 
until the start of the isolation procedure (Figure 15). Cell collection from 
the aortic pieces was performed according to Jaffe, Nachman et al. (1973). 
The aortic piece lumen was washed with PBS using a syringe and needle, 
to remove any traces of blood. One of the extremities was then clamped 
and the blood vessel was filled with a solution of 0.1% type I collagenase 
(17100-017, Gibco, Invitrogen, UK) in PBS was injected through the open 
extremity. The open extremity was also clamped and the blood vessel was 
submersed in PBS at 37ºC for 20 minutes for the collagenase to act, 
releasing the interior layers of cells. The cell suspension was collected in a 
test tube and an approximately equal volume of PBS was injected again in 
the blood vessel to increase cell recovery. The cell suspension was then 
centrifuged at 250x g, 10 minutes at room temperature, the supernatant 
was discarded and the pellet was ressuspended in PBS to wash 
collagenase traces. After another centrifugation, the cell pellet was 
ressuspended in 300 µl of buffer A (PBS supplemented with 2 mM of EDTA 
and 5% (m/v) BSA) for endothelial cells isolation. Endothelial cells 
isolation was performed with the previously prepared anti-CD146-coated 
magnetic beads, adapted from Neurauter, Bonyhadi et al. (2007). Magnetic 
beads were ressuspended in 700 µl of buffer A and added to the cell 
suspension. Following an overnight incubation with agitation, at 4ºC, the 
beads were washed three times with buffer A, 15 minutes at 4ºC with 
agitation. To release the cells from the magnetic beads, 1ml of trypsin-
EDTA solution was added and allowed to incubate for 5 minutes at 37ºC 
with agitation. The supernatant containing the cell suspension was then 
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centrifuged at 300x g for 3 minutes, at room temperature and the pellet 
was ressuspended in 150 µl of PBS.  
 
Figure 15 – Collection of blood from the inferior vena cava (left) and aorta pieces used in 
endothelial cells isolation (right). 
 
2.2. Circulating endothelial cells and endothelial progenitor 
cells labelling 
Blood collected into EDTA tubes was kept on ice and no more than 
3 hours passed between collection and analysis (Figure 15). Red blood 
cells (RBC) were lysed by adding 1 ml of blood to 14 ml of lysis buffer 
freshly prepared from a 10x stock solution (0.15 M NH4Cl, 10 mM KHCO3, 
0.1 mM EDTA, pH 7.3). RBC were allowed to lyse for 3-5 minutes and 
then centrifuged at 300x g for 5 min, at room temperature. The 
supernatant was discarded and the cell pellet was washed, ressuspending 
it in 5 ml of ice-cold phosphate-buffered saline (PBS) and centrifuging 
once more at 300x g, for 5 minutes. The washed cell pellet was then 
ressuspended in 1ml of ice-cold PBS and white blood cells were blocked 
with 100 µg of rat IgG (I4131, Sigma,USA), for 15 minutes, at room 
temperature. Cells were then incubated with 5 µl of the unlabelled 
primary anti-CD133 antibody (ab19898, Abcam, UK), followed by the 
incubation with labelled antibodies: 20 µl of PE-anti-CD146 (FAB3250P, 
R&D Systems, USA), 10 µl of PE/Cy5-anti-CD45 (559135, 
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BD Pharmingen, USA) and 2 µl FITC-anti-rabbit IgG (F9887, 
Sigma-Aldrich, USA). All antibody incubations were conducted at room 
temperature, for 20 minutes. Excess antibody was removed by washing 
once with PBS supplemented with 1% BSA and 0.05% NaN3, and the 
labelled cells were pelleted at 500x g for 5 min and ressuspended in 1 ml 
of PBS/BSA/NaN3. 
2.3. Flow cytometry analysis 
Each sample was analysed in a 3-colour FACScalibur flow cytometer 
(BD Biosciences, USA). Non-labelled samples were firstly analysed to 
establish selection gates and to serve as negative control (Figure 16). 
Samples were analysed for a minimum of 500,000 mononuclear cellular 
events. Cells were initially plotted according to forward- and side-scatter 
profiles and a gate was established to select only mononuclear cell events 
(Figure 18). A second gate was set to exclude CD45 positive cells, but not 
CD45dim, as these may include endothelial progenitor cells. Cells doubly 
positive for CD146 and CD133 were considered endothelial progenitor 
cells (EPC), while cells only positive for CD146 were considered circulating 
endothelial cells (CEC). 
 
Figure 16 – Flow cytometry histograms of labelled (black) and non-labelled (white) samples 
for each of the fluorescence channels. 
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2.4. In vivo labelling with 5-bromo-2’-deoxyuridine 
Two hyperglycemic animals and one control animal from the groups 
of long-term exposure to hyperglycemia (4 months) were injected 
intraperitoneally with a single dose (100 mg/kg) of 
5-bromo-2’-deoxyuridine (BrdU) 72 hours prior to sacrifice. Upon sacrifice, 
pieces of aorta were collected and processed through paraffin embedding 
for light microscopy. Tissue sections were stained with anti-BrdU primary 
antibody (ab1893, Abcam, UK) followed by horseradish-conjugated 
anti-Goat IgG secondary antibody (ab7125, Abcam, UK) and detected with 
Fast Dab Tablets (D0426, Sigma, USA). 
2.5. Western blot 
Approximately 20 µg of serum protein were electrophoresed in a 
12.5% SDS-PAGE, according to Laemmli (1970) and blotted onto a 
nitrocellulose membrane. Non-specific protein binding sites were blocked 
with 5% dry non-fat milk in TBS supplemented with 0.05% Tween-20 
(TBS-T), followed by a 3-hour incubation, at room temperature, with 
mouse anti-VEGF antibody (ab1316, Abcam, UK) diluted 1:1000 in 
blocking solution, three 15-minute washes with TBS-T and a 45-minute 
incubation with horseradish peroxidase-conjugated anti-mouse IgG 
antibody (A9917, Sigma, USA), at room temperature. Immunoreactive 
bands were detected with home-made chemiluminesce substrate on X-ray 
films (Hyperfilm ECL, GE Healthcare, UK) and digital images were 
acquired on a Molecular Imager Gel Doc XR system (Bio-Rad, USA) and 
analysed with QuantityOne software (v4.6.3, Bio-Rad, USA). Results are 
presented as mean±SD for each experimental group of at least three 
independent experiments with n=5. 
2.6. MBL-pathway complement activation 
MBL complex activity was determined as described by Petersen and 
colleagues (2001). Microtiter wells (cat. no. 456537, Maxisorp®, Nunc, 
Germany) were coated with 1 µg of mannan (M7504, Sigma, USA) in 
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100 µl of coating buffer (15 mM Na2CO3, 35 mM NaHCO3, 1.5 mM NaN3, 
pH 9.6). After an overnight incubation at room temperature, the wells were 
blocked for 1 hour with 200 µl of 0.1% (w/v) rat serum albumin (RSA) 
(A6414, Sigma, USA) in TBS (10 mM Tris-HCl, 140 mM NaCl, 1.5 mM 
NaN3, pH 7.4). Wells were incubated overnight, at 4ºC, with 100 µl of rat 
serum diluted 1:50 in MBL-binding buffer (20 mM Tris, 10 mM CaCl2, 1 M 
NaCl, 0,05% Tween-20, 0,1% RSA, pH 7.4), in duplicates. Then, 100 µl of 
a solution of C4 protein (1 ng/µl) (ab98983, Abcam, UK) in barbital buffer 
(4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 3.8 mM NaN3, 
pH 7.5) were added and the plate was incubated for 90 minutes at 37ºC. 
Negative controls were also conducted for each sample with barbital buffer 
without C4 protein. Next, 100 µl of sheep anti-C4 antibody (ab8786, 
Abcam, UK), diluted 1:1000 in washing solution (TBS supplemented with 
0.05% of Tween-20 and 5 mM CaCl2), were added and incubated 90 min 
at room temperature, followed by an 1-hour incubation, at room 
temperature, with 100 µl of Rabbit anti-Sheep IgG H&L (AP) secondary 
antibody (ab6748, Abcam, UK), diluted 1:1000 in washing solution. Then, 
100 µl of substrate solution (1 mg/ml p-nitrophenyl phosphate in 1 M 
dietanolamine, 1 mM MgCl2, 3 mM NaN3, pH 9.6) were added and allowed 
to react at 37ºC with mild shaking for 5 minutes before reading optical 
density at 450nm. The values obtained for the negative controls were 
subtracted to their respective counterparts and the resulting values were 
used to evaluate MBL-complex activity in serum. Between each of the 
incubation steps, excess reagent from the previous incubation was 
washed twice with washing solution. 
2.7. Statistical analysis 
All statistical tests were performed using GraphPad Prism v5.00 
(GraphPad Software, Inc., USA). Data were analysed using a two-way 
ANOVA with Bonferroni’s post hoc tests to compare groups. A 
p value <0.05 was considered significant. 
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3. Results 
3.1. Analysis of aortic endothelial cells 
The use of magnetic beads for the isolation of endothelial cells was 
successful in the preliminary study, as could be observed under the 
microscope (Figure 7). However, the western blot analysis of specific 
endothelial proteins, such as VEGF or eNOS, was not possible (Figure 17). 
Further attempts to enrich the samples in protein content and load more 
protein in the gel were made using acetone precipitation and ultrafiltration 
approaches, but were also unsuccessful. 
 
Figure 17 – Representative western blot of endothelial cell suspension for VEGF.  
Endothelial cell suspensions were loaded in lanes 1-4; a positive control for control (lane 6) and 
hyperglycemic (lane 7) animals made from kidney homogenate in PBS was used. Anti-VEGF 
antibody recognizes a specific and intense band of approximately 24kDa and may recognize dimeric 
forms of VEGF at 43 kDa (arrows). In endothelial cell suspensions, no bands were detected. 
3.2. Evaluation of endothelial damage and repair 
Flow cytometry was successfully applied in the quantification of 
both circulating endothelial cells (CEC) and endothelial progenitor cells 
(EPC) (Figure 18). It was observed a highly significant increase of CEC in 
hyperglycemic animals, which is also progressively accentuated with the 
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duration of hyperglycemia. On the other hand, despite a significant 
reduction of circulating EPC over time, long-term hyperglycemia induced a 
significant reduction of EPC in peripheral blood (Figure 19). 
 
 
 
Figure 18 – Representative flow cytometry dotplots of a non-labelled (panel A) and labelled 
(panel B) sample with the gating strategy.  
Left plot exhibits front- vs side-scatter distribution of the whole sample and the selection gate for 
mononuclear cells; middle plot exhibits the CD45 (FL3 channel) vs. side-scatter distribution of 
mononuclear cells where a selecting gate was established in the lower-left quadrant; right plot 
exhibits the CD133 (FL1 channel) vs. CD146 (FL2 channel) distribution of cells selected in the 
middle plot, where the upper-left quadrant contains CEC and the upper-right quadrant contains 
EPC (dot size was enhanced to allow a better visualization). 
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Figure 19 – Variations in the number of CEC and circulating EPC with short- and long-time 
exposure to hyperglycemia.  
The number of cells was determined by flow cytometry; CEC were defined as mononuclear events 
with a CD45-/CD146+/CD133- phenotype, EPC were defined as mononuclear events with a CD45-
/CD146+/CD133+ phenotype. White columns represent control and black columns represent 
hyperglycemic animals; data are presented as mean±SD of the number of cells per million of 
mononuclear events. * p<0.05, ** p<0.01, *** p<0.001. 
Given that the increase of CEC is a signal of endothelial damage, an 
analysis of circulating VEGF was conducted to determine if the organism 
was responding to endothelial damage by stimulating endothelial cell 
proliferation. It was observable a progressive increase of serum VEGF over 
time. However, hyperglycemia induced a very significant increase of serum 
VEGF levels versus the control after 2 months, which was attenuated at 4 
months, though still significantly higher than controls (Figure 20). 
 
Figure 20 – Variation of the levels of serum VEGF with short- and long-term hyperglycemia. 
On the left is the quantitative data obtained with western blot, white columns represent control 
and black columns represent hyperglycemic animals. On the right is a representative western blot 
and respective nitrocellulose membrane stained with Ponceau S, as a control of the protein loaded. 
Data are presented as mean±SD of the optical density, in arbitrary units, of the immunoreactive 
band at 43kDa. * p<0.05, **p<0.01, ***p<0.001  
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The increase in serum VEGF after just two-months of exposure to 
hyperglycemia suggested that proliferation of endothelial cells could be 
increased. So, it was decided to evaluate if there were qualitative 
differences in endothelial proliferation, after four-months of exposure to 
hyperglycemia, through a BrdU incorporation assay. It was observed a 
higher number of labelled nuclei in endothelial cells from the aorta of 
hyperglycemic animals, suggesting a higher turnover rate (Figure 21). 
 
Figure 21 - BrdU incorporation in aortic endothelium of control (left) and long-term (right) 
hyperglycemic animals.  
Nuclei immunoreactive to anti-BrdU antibody are indicated by the arrows. 
 
3.3. MBL-pathway activity in hyperglycemia 
Considering the role of endothelial cells in the complement system 
and that the activation of the complement cascade may be initiated 
through the recognition of some specific carbohydrate moieties on the cell 
surface, an assay was conducted to determine if the activity of the 
MBL/MASP complex presented differences in a hyperglycemic state. It was 
observed a significant increase of the C4b peptide deposition, originated 
from the specific activation of the complement cascade by the MBL 
pathway, with the serum from hyperglycemic animals, thus suggesting an 
increased activity of the MBL/MASP complex, regardless of the duration of 
hyperglycemia (Figure 22). 
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Figure 22 – Variation of C4b deposition with short- and long-term hyperglycemia.  
White columns represent control and black columns represent hyperglycemic animals; data are 
presented as mean±SD of the optical density at 405nm in a specific MBL-pathway activity assay. 
* p<0.05. 
4. Discussion 
The physiological response to hyperglycemia is not specific of an 
organ or tissue, but rather a multifactorial systemic response. Hence, in 
vitro studies have a strong limitation in the integrated analysis of 
mechanisms modulated by variations in glycemia levels. Such limitation is 
even more evident in the study of vascular endothelium. As blood 
circulates throughout the whole organism, it is an important carrier of 
signalling molecules to and from the various organs. Using endothelial cell 
culture, either with cell lines or primary cultures, limits the 
comprehension of the endothelium response to hyperglycemia because it 
is not possible to mimic, in vitro, the various stimuli carried out by the 
blood stream, and it is usually limited to the study of cellular response in 
high-glucose media or in the presence of cytokines (Chavakis, Bierhaus et 
al. 2004; Schalkwijk and Stehouwer 2005; Son 2007; Packard and Libby 
2008; Maugeri, Rovere-Querini et al. 2009). Moreover, the origin of the 
cells may have influence on their response (Balconi, Pietra et al. 1983). To 
overcome these limitations, indirect forms of analysing the endothelium 
have been used, such as the analysis of circulating endothelial cells. 
However, there is still the perception that a direct analysis of endothelial 
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cells could drastically improve the knowledge about the underlying 
mechanisms of endothelial dysfunction (Onat, Brillon et al. 2011). Thus, it 
is important to carry out direct analyses to endothelial cells obtained from 
in vivo models, in order to keep the integrated systemic perspective.  
This study would have been an important milestone, as proteomic 
studies of the endothelial response to hyperglycemia are, to the best of our 
knowledge, limited to cell culture approaches. However, a critical step in 
the analysis of endothelial cells is the purification of a large enough 
number of cells, suitable for proteomic analysis. Two major strategies have 
been used: fluorescence-activated cell sorting (FACS) and 
immunomagnetic isolation (Scott and Bicknell 1993; Laurens and 
Hinsbergh 2004; van Beijnum, Rousch et al. 2008; Sobczak, Dargatz et al. 
2010). It was chosen the immunomagnetic approach for its simplicity and 
lower requirements of specialized equipment and also because of the 
successful isolation carried out in the preliminary study observed by 
fluorescence microscopy (Chapter II). Unfortunately, it was not possible to 
perform a protein analysis of the isolated cell suspensions because no 
protein was detected by western blot, despite the high levels of protein 
concentration in the samples (Figure 17). The result of the preliminary 
study proved the feasibility of such approach for the isolation of 
endothelial cells with the chosen method; however, the evaluation of the 
success was limited to microscopy and protein concentration. Microscopy 
was only applied for verifying the presence of positive cells to an 
endothelial specific marker (CD146), without any quantification concerns, 
and protein concentration was probably overestimated because the buffers 
used in cell isolation had BSA and cells were released from the magnetic 
beads with trypsin. Moreover, considering an average circumference of 
6 mm, the aorta pieces have an average internal area of 300 mm2, which, 
together with an average cell surface area of 300 µm2, would fit only 103 
cells. So, it is conceivable that despite a successful isolation of endothelial 
cells, the number of recovered cells was not enough to allow a proteomic 
analysis. In the future, the focus should be on the recovery of a higher 
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number of cells by applying a different approach, either by using FACS or 
by isolating cells from a larger cell pool, such as the aorta of a larger 
animal or from a highly vascularized tissue like the lung. 
The application of the number of circulating mature endothelial cells 
(CEC) as a marker of endothelial damage has been proposed by various 
studies, and there is a correlation of diabetes with vascular complications 
and the increase of CEC (Jessani, Lane et al. 2009; Asicioglu, Gogas Yavuz 
et al. 2010; El Amine, Sohawon et al. 2010; Orrico, Pasquinelli et al. 2010; 
Kotb, Gaber et al. 2012; Lanuti, Santilli et al. 2012). Similarly, the 
reduction of endothelial progenitor cells (EPC) has also been linked to 
diabetes and vascular complications through a reduction of endothelial 
repair ability (Lev, Singer et al. 2013; Oh, Oh et al. 2013; Westerweel, 
Teraa et al. 2013; Zhang and Yan 2013). The results presented herein, 
corroborate these linkages. The particular subset of EPC analysed in this 
study, has a special relevance because it expresses both a marker for 
mature endothelial cells (CD146) and a marker of stem cells (CD133), 
which means this subset of cells has already suffered some maturation 
stimuli and reinforces the conclusion that there is an impairment of 
reendothelization from the EPC recruitment mechanism. Interestingly, the 
incorporation of BrdU assay demonstrated that the turnover rate of 
endothelial cells in hyperglycemic animals was increased. Endothelial cells 
have a very slow turnover rate, measured in months or years (Hobson and 
Denekamp 1984; Cines, Pollak et al. 1998; Goon, Lip et al. 2006); the 
incorporation of BrdU in so many cells in just 72 hours, indicates a very 
pronounced turnover rate, which is in accordance with the increased 
stimulus observed by the higher levels of serum VEGF. Nonetheless, the 
increased proliferation should not be sufficient to overcome the damages, 
as the animals presented clear signs of renal function impairment and 
loss of sight. 
The initial hypothesis was that hyperglycemia could result in 
aberrant glycation of endothelial membrane proteins and be recognized by 
MBL as a pathogen, activating the complement cascade to destroy the 
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“invader”. Indeed, the relationship between MBL levels and diabetes have 
been the target of numerous studies (Hansen, Tarnow et al. 2004; Hovind, 
Hansen et al. 2005; Ostergaard, Hansen et al. 2005; Saraheimo, Forsblom 
et al. 2005; Ostergaard, Thiel et al. 2007; Elawa, AoudAllah et al. 2011; 
Ostergaard, Bjerre et al. 2012; Pavlov, La Bonte et al. 2012; Ostergaard, 
Bjerre et al. 2013) but, to the best of our knowledge, no study has 
successfully shown the binding of MBL to the endothelium or identified 
the carbohydrate moieties recognized by MBL on endothelial cell surface. 
It was expected to find such connection with the isolation of endothelial 
cells. Nonetheless, it was shown that hyperglycemic animals present 
increased activity of MBL and its associated proteases, which strongly 
suggests the involvement of this complement pathway in the 
pathophysiology of hyperglycemia complications. 
In conclusion, it was shown a progressive effect of hyperglycemia on 
vascular endothelium. Despite the increase of endothelial damage, there is 
still a physiological response to promote cell proliferation after 4-months 
of chronic hyperglycemia, although it is mainly by angiogenesis. 
Additionally, there is strong evidence of complement involvement in 
endothelial damage. 
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1. Introduction 
Salivary glands are a set of organs possessed by terrestrial animals, 
which secrete saliva into the oral cavity. Saliva is a watery fluid whose 
primary role is the maintenance of oral lubrication. Nonetheless, other 
physiological roles, namely protective and digestive, are performed by 
saliva. Consequently, any dysfunction in salivary secretion leads to 
increased susceptibility to infections, loss of taste and difficulties in eating 
and talking (Holsinger and Bui 2007; Miletich 2010). The decrease in 
salivary secretion, and consequent oral dryness, is called xerostomia and 
is a common complaint among diabetic patients. Moreover, diabetic 
patients also have increased incidence of dental caries, gingivitis, 
periodontitis, delayed healing and oral infections (Löe and Genco 1995; 
SHIP 2003), which reflect a possible impairment of the protective roles of 
salivary secretions. Thus, it is important to understand how 
hyperglycemia affects salivary glands. 
1.1. Histological features of salivary glands 
Salivary glands are branched organs that are composed of a 
parenchymatous region, which is surrounded by a stroma. The 
parenchyma is composed by epithelial tissue that is organized in secretory 
units called “endpieces” connected by an extensive network of duct 
eventually opening into the oral cavity, while the stroma is a layer of 
connective tissue surrounding the gland and dividing it in lobes (Miletich 
2010). 
Secretory endpieces may be classified into three types according to 
the type of cells and their secretions. Mucous endpieces secrete a viscous 
fluid rich in complex carbohydrates attached to mucin proteins, which 
have an essential role in lubrication; secretory cells are usually simple 
columnar cells gathered in tubular shaped acini. Serous endpieces 
secretions are more watery and very rich in proteins, though almost 
absent of glycoproteins; the secretory cells are pyramidal, forming 
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spheroidal acini. Seromucous endpieces have both types of cells, thus 
producing both types of secretions; usually mucous cells are arranged in a 
tubule caped by demilunes of serous cells (Holsinger and Bui 2007; 
Miletich 2010). 
The ductal system is also heterogeneous. Acinar secretions are 
collected into the intercalated ducts, made up from squamous or low 
cuboidal epithelium, which drain into the striated ducts. The striated duct 
cells have basally located membrane invaginations, conferring them a 
striated aspect. The striated ducts empty in excretory ducts, which then 
empty into major ducts with specific names according to the gland. 
Excretory ducts start with simple cuboidal epithelium that becomes 
columnar as the ducts enlarge, eventually becoming stratified columnar or 
squamous epithelium towards the end portion. Although the acini are 
major contributors to salivary secretions, the ducts are not limited to the 
conduction of their secretions into the oral cavity. Some segments of the 
ducts also play a role in electrolyte modification and secretion of some 
proteins. In the intercalated duct, cells secrete bicarbonate ions, 
absorbing chloride ions. Striated ducts are involved in sodium 
reabsorption in exchange with potassium, hence the numerous 
mitochondria located in striations to produce energy for the active 
transport of these ions. They also secrete IgA, lysozyme and other 
proteases, as well as some growth factors. In rodents, however, these 
secretions come from a specialized part of ducts located between 
intercalated and striated ducts, called granular ducts, composed of cells 
with numerous granules (Holsinger and Bui 2007; Miletich 2010). 
In close association with secretory and ductal cells, there is another 
type of cells, myoepithelial cells, which lie between the epithelial cells and 
the basal lamina and have the ability to contract, thus forcing secretion 
(Miletich 2010). 
Salivary glands are also highly vascularized and enervated, which 
allow the rapid transfer of molecules from the bloodstream and the 
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conduction of sympathetic and parasympathetic stimuli for secretory 
regulation, respectively (Holsinger and Bui 2007; Miletich 2010). 
1.2. Anatomy of salivary glands in humans and rodents 
Salivary glands may be classified as major and minor salivary 
glands. Major salivary glands comprise the parotid glands, the 
submandibular glands and the sublingual glands, and are responsible for 
approximately 90% of salivary secretions; whereas minor salivary glands 
comprise numerous uncapsulated small secretory units scattered 
throughout the oral mucosa (Henrikson 1997; Chambers, Artopoulou et 
al. 2007; Holsinger and Bui 2007; Miletich 2010). Despite having the three 
major pairs of salivary gland, humans and rodents have significant 
differences in their relative size and morphology.  
The parotid gland is the largest salivary gland in humans with a 
pyramidal shape and defined lobes, located in the back of the mouth 
between the mandible and the ear, while in rodents is a more diffuse 
organ extending from the submandibular gland to the base of the ear 
(Figure 23) (Henrikson 1997; Treuting and Dintzis 2012). Parotid glands 
are composed of serous acini which empty in the oral cavity through a 
long duct called Stensen’s duct (Miletich 2010). It is responsible by 
roughly two-thirds of the saliva secreted under stimulation, falling to 
about one quarter of unstimulated saliva (Chambers, Artopoulou et al. 
2007; Holsinger and Bui 2007). 
The human submandibular gland is located in the floor of the 
mouth between muscle layers, in the digastric triangle, whereas the 
rodent gland is located in the ventral cervical subcutaneous region, closely 
associated to the sublingual gland, and is the largest rodent salivary gland 
(Figure 23) (Holsinger and Bui 2007; Treuting and Dintzis 2012). It is a 
lobular seromucous gland with a predominance of serous tubular acini 
and only 10% of mucous acini, arranged in demilunes. It connects to the 
oral cavity through the Wharton’s duct, whose opening lies near the base 
of the lingual frenum (Miletich 2010). The submandibular secretions 
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represent over 70% of unstimulated saliva, hence being crucial to the 
maintenance of oral lubrication (Chambers, Artopoulou et al. 2007; 
Holsinger and Bui 2007). 
The sublingual gland is the smallest of the major salivary glands, 
both in humans and rodents. It is located in the anterior part of the 
mouth floor, in humans, and in the ventral cervical subcutaneous region, 
closely associated with the submandibular gland, in rodents (Figure 23) 
(Miletich 2010; Treuting and Dintzis 2012). In humans, it is also a 
seromucous gland where there is predominance of mucous acini, while in 
rodents it has only mucous acini (Treuting and Dintzis 2012). It empties 
in the oral cavity through numerous small ducts, located on the mouth 
floor, and a major sublingual duct that opens into the Wharton’s duct 
(Miletich 2010). The sublingual secretions represent only 5% of saliva 
(Holsinger and Bui 2007). 
 
Figure 23 – Anatomical location of the major salivary glands in humans and rodents. 
 
The minor salivary glands have a disperse location and are 
surrounded by connective tissue but not encapsulated like the major 
salivary glands. These glands represent about 10% of salivary secretions 
regardless of stimulation and may be of different natures: serous, mucous 
or seromucous (Miletich 2010; Treuting and Dintzis 2012). 
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1.3. Salivary glands embryonic origin and development 
The origin of salivary glands is not consensual. It seems established 
that parotid glands originate from the ectodermal layer and minor salivary 
glands derive from the endodermal layer. However, the origin of sublingual 
and submandibular glands is still a matter of debate (Miletich 2010). 
Despite that, it is generally assumed that major salivary glands are 
ectodermal organs. The embryonic development of the mouse 
submandibular gland is usually regarded as a model to salivary gland 
development. It starts with a thickening of the epithelial layer on the 
mouth floor, which progresses into an invagination in the underlying 
mesenchyme, originating a stalk with a terminal bulb. Simultaneously, 
there is an arrangement of mesenchymal cells that condense around the 
epithelial protuberance, originating the stroma. The bulb then starts a 
branching process with multiple furcations in the distal ends resulting in 
a network of epithelial branches with terminal buds. Soon enough, the 
branches and buds start to hollow out and eventually form ducts and 
acini. The branching allows the expansion of the tissue surface area 
within the confinement of the organ (Denny, Ball et al. 1997; Jaskoll and 
Melnick 2006; Miletich 2010) (Figure 24). 
 
Figure 24 – Stages of glandular development. Adapted from Miletich (2010) 
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1.4. Proliferation and regeneration of salivary glands tissue 
Salivary glands size is usually proportional to body size. The 
regulation of the gland’s size is determined by a balance between cell 
proliferation and cell death (Carpenter and Cotroneo 2010). Despite the 
low levels of mitosis observed in adult glands, the regular stimulus of 
mastication through the parasympathetic nerves up-regulates mitosis, 
thus keeping a relatively stable gland size (Schneyer, Humphreys-Beher et 
al. 1993). The regeneration of salivary glands may occur either by 
proliferation from the existing acini and ducts or by an embryonic-like 
pathway through branching from ductal buds. Studies of regeneration 
following ductal ligation-induced atrophy have shown that, not only both 
processes occur, but they also allow the full restoration of tissue function 
(Takahashi and Wakita 1993; Cotroneo, Proctor et al. 2008).  
Salivary glands secrete several growth factors, namely, fibroblast 
growth factor (FGF), epidermal growth factor (EGF), insulin and insulin-
like growth factors 1 and 2 (IGF-1 and -2), transforming growth factors 
(TGF) alpha and beta, nerve growth factor (NGF) and hepatocyte growth 
factor (HGF) (Zelles, Purushotham et al. 1995; Mathison 2010). A 
bioinformatics analysis of the gene expression profile in ligation studies 
with different time-points revealed the activation of MAPK, Wnt and Notch 
pathways. Such pathways are mediated by growth factors and salivary 
glands express several receptors that may activate the proliferation 
pathways. It was shown that the fibroblast growth factor (FGF) receptors 
were up-regulated in regenerating glands, suggesting a possible link to the 
MAPK pathway activation (Carpenter and Cotroneo 2010). Epidermal 
growth factor receptors (EGFR) are also expressed in salivary glands and 
were shown to be involved in morphogenesis, proliferation and 
differentiation (Piludu, Lantini et al. 2003; Dang, Elliott et al. 2008; 
Häärä, Koivisto et al. 2009). Likewise, salivary glands express insulin 
receptors and insulin-like growth factor-1 receptors, which also are 
involved in the activation of these proliferation/differentiation pathways 
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(Chapter I) (Rocha, de et al. 2000; Rocha, Hirata et al. 2002; Rocha, 
Carvalho et al. 2003). The kinin receptor B2 is also abundant in salivary 
glands, stimulating DNA synthesis and cell proliferation, and salivary 
glands express high levels of several tissue kallikreins, namely in ductal 
cells, that release the kinin peptide from kininogen (Garrett, Smith et al. 
1982; Yahiro and Miyoshi 1996; Mahabeer, Naidoo et al. 2000; Dlamini 
and Bhoola 2005). As previously mentioned, parasympathetic stimuli may 
also promote cellular proliferation, as acetylcholine signalling activates 
muscarinic M1 receptors of embryonic epithelium increasing 
morphogenesis and proliferation (Knox, Lombaert et al. 2010). 
Thus, salivary glands are enriched in several mechanism of cell 
proliferation, which not only account for the healing properties of saliva 
but may also play a role in gland regeneration. 
1.5. Salivary secretions and oral health 
Salivary glands are responsible for the daily production of about 800 
to 1500 ml of saliva (Ellis 1991; Aps and Martens 2005; Melvin, Yule et al. 
2005; Moore, Dalley et al. 2010). Saliva is an essential fluid in the 
maintenance of oral health. Among the most abundant proteins secreted 
in saliva we can find immunoglobulins (IgG and IgA), proline-rich proteins, 
mucins, histatins, cystatins, statherin, complement proteins, and also a 
rich pool of growth factors (Zelles, Purushotham et al. 1995; Amado, 
Vitorino et al. 2005; Amado, Ferreira et al. 2012). 
Although the precise functions of some proteins are not yet fully 
disclosed, there is a clear association of these to the maintenance of oral 
health. Mucins and proline-rich proteins are important in the lubrication 
of the oral mucosa, statherin is essential for the protection of teeth 
through the oversaturation of calcium and phosphate salts, histatins and 
lysozyme have an anti-microbial activity, cystatins protect the 
periodontium destruction by some cathepsin proteases and also 
contribute to the mineral balance for teeth protection, and 
immunoglobulins and complement proteins are elements of the immune 
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system (Zelles, Purushotham et al. 1995; Baron, DeCarlo et al. 1999; 
Vitorino, Calheiros-Lobo et al. 2006) 
This unique composition allows a multitude of protective and 
healing properties to saliva.  
1.6. Salivary gland impairment in chronic hyperglycemia 
Poor glycemic control is strongly connected to oral complications, 
namely xerostomia, gingivitis, periodontitis, tooth decay and oral 
candidiasis (Sreebny, Yu et al. 1992; Ryan, Carnu et al. 2003; Lamster, 
Lalla et al. 2008; Yeh, Harris et al. 2012). Xerostomia is a subjective 
feeling of dry mouth, which may be the result of reduced secretion of 
saliva. Considering the already mentioned roles played by saliva in the 
maintenance of oral health, it is conceivable that the impairment of 
salivary gland secretion will increase the risk of all the aforementioned 
complications. Understanding the mechanism that leads to the reduction 
of salivary secretion is thus crucial for delaying the onset of such 
complications and developing therapies. 
Salivary secretion is controlled by stimuli from the sympathetic and 
parasympathetic nerves, with water and electrolyte secretion controlled by 
muscarinic receptors and protein synthesis and secretion controlled by 
the beta-adrenergic receptors (Yeh, Harris et al. 2012).  It has been 
described a decreased response to beta-adrenergic/cholinergic stimulation 
either by decreased receptor expression or loss of neurotransmitter 
responsiveness (Yamamoto, Sims et al. 1996; Yamamoto, Ishibashi et al. 
1997). Also, the salivary composition in both T1DM and T2DM has been 
revealed to suffer dramatic changes in protein and electrolyte 
concentrations (Mata, Marques et al. 2004). Furthermore, morphological 
changes were also reported, namely alterations in secretory granule 
structure and content (Mednieks, Szczepanski et al. 2009) and progressive 
loss of ductal (Anderson, Suleiman et al. 1994) and acinar cells (Cutler, 
Pinney et al. 1979; Anderson, Suleiman et al. 1994). However, the 
molecular mechanisms underlying such events are poorly understood. 
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It is in this framework that the following article is presented as a 
first quantitative proteomic study of the progressive effects of 
hyperglycemia in salivary gland protein expression. 
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with STZ-induced hyperglycemia 
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1QOPNA, Department of Chemistry, University of Aveiro, Aveiro, Portugal 
2CIAFEL, Faculty of Sports, University of Porto, Porto, Portugal 
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Supplementary Table 1 – List of proteins identified in the granule-enriched fractions from rat 
submandibular gland by nLC-MS/MS, in alphabetical order.  
Total (ProtScore) 
A measure of the total amount of evidence for a detected protein. The Total ProtScore is calculated using all of the peptides detected 
for the protein, as described in About the Total ProtScore and the Unused ProtScore. The Total ProtScore does not indicate anything 
about the confidence that a protein has been detected, because some or even all of the spectra contributing to the Total ProtScore may 
be better explained by higher ranked proteins. 
Peptides (95%) 
The number of distinct peptides having at least 95% confidence. Multiple modified and cleaved states of the same underlying peptide 
sequence are considered distinct peptides because they have different molecular formulas. Multiple spectra of the same peptide, due to 
replicate acquisition or different charge states, only count once. 
 
Name Uniprot Accession # 
% 
Cov 
# of peptides 
(95%) 
Total 
protscore 
14-3-3 protein beta/alpha  P35213 34.6 4 4.11 
14-3-3 protein epsilon  P62260 32.9 9 8.88 
14-3-3 protein eta  P68511 22.8 3 2.04 
14-3-3 protein gamma  P61983 28.3 4 4.8 
14-3-3 protein theta  P68255 49.4 6 7.18 
14-3-3 protein zeta/delta  P63102 54.7 7 8.22 
2,4-dienoyl-CoA reductase, mitochondrial  Q64591 22.7 4 7.57 
26S protease regulatory subunit 7  Q63347 17.3 2 4 
26S proteasome non-ATPase regulatory subunit 1  O88761 12.5 3 4.94 
26S proteasome non-ATPase regulatory subunit 2  Q4FZT9 12.7 2 3.44 
2-oxoglutarate dehydrogenase, mitochondrial  Q5XI78 12.3 6 7.81 
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial 
(Fragment)  P11960 11.3 3 3.11 
3-alpha-hydroxysteroid dehydrogenase  P23457 11.8 4 6.12 
3-hydroxyacyl-CoA dehydrogenase type-2  O70351 51.7 9 15.1 
3-hydroxyisobutyrate dehydrogenase, mitochondrial  P29266 41.5 5 6.08 
40S ribosomal protein S10  P63326 48.5 4 6.2 
40S ribosomal protein S11  P62282 44.9 5 4.98 
40S ribosomal protein S12  P63324 34.9 2 2.72 
40S ribosomal protein S14  P13471 45 3 3.32 
40S ribosomal protein S15  P62845 51 5 9.65 
40S ribosomal protein S15a  P62246 33.9 3 4.97 
40S ribosomal protein S16  P62250 44.5 3 5.64 
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40S ribosomal protein S17  P04644 36.3 5 6.71 
40S ribosomal protein S18  P62271 45.4 7 9.14 
40S ribosomal protein S19  P17074 43.5 3 6.1 
40S ribosomal protein S2  P27952 21.8 2 2.4 
40S ribosomal protein S23  P62268 44.8 5 3.71 
40S ribosomal protein S26  P62856 40 3 4.84 
40S ribosomal protein S28  P62859 30.4 3 2.26 
40S ribosomal protein S3  P62909 64.6 6 10.39 
40S ribosomal protein S30  P62864 42.4 3 5.94 
40S ribosomal protein S3a  P49242 38.3 9 11.96 
40S ribosomal protein S4, X isoform  P62703 43 11 18.13 
40S ribosomal protein S5  P24050 35.3 2 3.76 
40S ribosomal protein S6  P62755 34.5 5 8.95 
40S ribosomal protein S7  P62083 37.1 7 11.69 
40S ribosomal protein S8  P62243 53.9 10 16.29 
40S ribosomal protein S9  P29314 48.5 6 10.51 
40S ribosomal protein SA  P38983 71.5 8 16.81 
4-trimethylaminobutyraldehyde dehydrogenase  Q9JLJ3 17.2 3 4.98 
60 kDa heat shock protein, mitochondrial  P63039 35.1 11 19.03 
60S acidic ribosomal protein P0  P19945 28.4 5 10.29 
60S acidic ribosomal protein P1  P19944 36.8 3 3.65 
60S acidic ribosomal protein P2  P02401 71.3 9 8.51 
60S ribosomal protein L10  Q6PDV7 45.8 13 12.13 
60S ribosomal protein L11  P62914 40.5 5 8.62 
60S ribosomal protein L13  P41123 42.7 8 14.49 
60S ribosomal protein L13a  P35427 31.5 3 3.34 
60S ribosomal protein L14  Q63507 31.8 5 4.23 
60S ribosomal protein L15  P61314 55.4 6 12.08 
60S ribosomal protein L17  P24049 34.8 5 7.08 
60S ribosomal protein L18  P12001 18.1 3 2.58 
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60S ribosomal protein L18a  P62718 32.4 4 6.35 
60S ribosomal protein L19  P84100 40.8 3 4.96 
60S ribosomal protein L21  P20280 38.8 5 5.9 
60S ribosomal protein L22  P47198 16.4 2 2 
60S ribosomal protein L23  P62832 25 2 3.73 
60S ribosomal protein L23a  P62752 19.9 2 2.88 
60S ribosomal protein L24  P83732 28.7 3 5.55 
60S ribosomal protein L26  P12749 24.8 3 5.54 
60S ribosomal protein L27  P61354 23.5 2 2.37 
60S ribosomal protein L27a  P18445 34.5 2 4.04 
60S ribosomal protein L29  P25886 46.8 3 4.94 
60S ribosomal protein L3  P21531 29.5 8 15.54 
60S ribosomal protein L30  P62890 35.7 7 4 
60S ribosomal protein L31  P62902 33.6 6 7.87 
60S ribosomal protein L32  P62912 26.7 3 4.55 
60S ribosomal protein L34  P11250 19.7 2 0.72 
60S ribosomal protein L35  P17078 39.8 4 6.59 
60S ribosomal protein L36a  P83883 28.3 4 2.97 
60S ribosomal protein L4  P50878 41.1 12 11.53 
60S ribosomal protein L5  P09895 45.5 8 11.98 
60S ribosomal protein L6  P21533 53.7 15 17.91 
60S ribosomal protein L7  P05426 38.5 3 5.77 
60S ribosomal protein L7a  P62425 33.5 4 6.85 
60S ribosomal protein L8  P62919 32.7 2 3.27 
60S ribosomal protein L9  P17077 16.7 3 5.17 
6-phosphofructokinase, muscle type  P47858 8.7 2 2.92 
6-phosphogluconolactonase  P85971 20.2 2 4 
78 kDa glucose-regulated protein  P06761 63.9 20 35.34 
Acetyl-CoA acetyltransferase, mitochondrial  P17764 39.9 15 19.54 
Aconitate hydratase, mitochondrial  Q9ER34 34.7 15 25.59 
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Actin, aortic smooth muscle  P62738 65.3 39 30.92 
Actin, cytoplasmic 1  P60711 89.9 63 74.6 
Actin, cytoplasmic 2  P63259 88.8 74 53.08 
Actin-related protein 3  Q4V7C7 16.3 3 4.75 
Acyl-CoA-binding protein  P11030 83.9 9 11.89 
Adenine phosphoribosyltransferase  P36972 29.4 4 6.36 
Adenosylhomocysteinase  P10760 22 3 6.42 
Adenylate kinase 2, mitochondrial  P29410 36 3 5.57 
Adenylyl cyclase-associated protein 1  Q08163 11.6 3 4.49 
ADP/ATP translocase 1  Q05962 46 12 18.77 
ADP/ATP translocase 2  Q09073 57.4 17 29.2 
ADP-ribosylation factor 3  P61206 24.9 2 3.53 
ADP-ribosylation factor 4  P61751 12.2 2 2.75 
ADP-ribosylation factor-like protein 1  P61212 29.3 2 4 
Aflatoxin B1 aldehyde reductase member 2  Q8CG45 4.4 2 2 
Alcohol dehydrogenase [NADP+]  P51635 9.5 2 4 
Aldehyde dehydrogenase, mitochondrial  P11884 8.3 6 5.64 
Alpha-actinin-1  Q9Z1P2 26.2 14 15.44 
Alpha-actinin-4  Q9QXQ0 22.8 16 20.37 
Alpha-aminoadipic semialdehyde dehydrogenase  Q64057 19.5 3 4.34 
Alpha-aminoadipic semialdehyde synthase, mitochondrial  A2VCW9 11.8 3 4.51 
Alpha-enolase  P04764 57.1 20 30.59 
Alpha-soluble NSF attachment protein  P54921 13.9 3 4.23 
Aminopeptidase N  P15684 14.7 2 4 
Amyloid beta A4 protein  P08592 7.4 3 3.64 
Annexin A1  P07150 40.2 10 11.01 
Annexin A2  Q07936 33.3 7 13.63 
Annexin A4  P55260 43.9 8 15.68 
Annexin A5  P14668 40.1 9 12.82 
Annexin A6  P48037 47 20 30.66 
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AP-2 complex subunit alpha-2  P18484 7.8 2 2.67 
Arginase-1  P07824 14.9 2 3.2 
Asparagine synthetase [glutamine-hydrolyzing]  P49088 12.8 4 6.54 
Aspartate aminotransferase, mitochondrial  P00507 52.1 10 19.92 
Aspartate--tRNA ligase, cytoplasmic  P15178 15 2 3.64 
ATP synthase subunit alpha, mitochondrial  P15999 72 30 38.1 
ATP synthase subunit b, mitochondrial  P19511 36.3 7 9.89 
ATP synthase subunit beta, mitochondrial  P10719 64.8 37 47.87 
ATP synthase subunit d, mitochondrial  P31399 54 4 8.45 
ATP synthase subunit delta, mitochondrial  P35434 73.2 6 10 
ATP synthase subunit e, mitochondrial  P29419 81.7 9 11.83 
ATP synthase subunit gamma, mitochondrial  P35435 27.1 5 6.85 
ATP synthase subunit O, mitochondrial  Q06647 49.8 9 9.64 
ATP synthase-coupling factor 6, mitochondrial  P21571 75.9 8 13.58 
ATPase inhibitor, mitochondrial  Q03344 38.3 3 2.5 
ATP-binding cassette sub-family F member 1  Q6MG08 8.9 2 3.66 
ATP-citrate synthase  P16638 5.7 2 1.37 
ATP-dependent RNA helicase DDX1  Q641Y8 9.9 3 4.77 
Band 3 anion transport protein  P23562 6.4 2 3.78 
Beta-hexosaminidase subunit beta  Q6AXR4 16.4 2 4.13 
Brain protein 44  P38718 42.5 3 5.35 
Branched-chain-amino-acid aminotransferase, mitochondrial  O35854 27.7 3 6.16 
Calmodulin  P62161 87.3 13 21.74 
Calmodulin-like protein 3  Q5U206 45 4 7 
Calnexin  P35565 20.5 6 10.55 
Calpain small subunit 1  Q64537 17.8 2 2.48 
Calreticulin  P18418 80.1 28 41.78 
Carbonic anhydrase 2  P27139 60.4 9 17.31 
Catenin beta-1  Q9WU82 9 3 5.55 
Cationic trypsin-3  P08426 30.4 2 0.68 
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Chloride intracellular channel protein 1  Q6MG61 9.1 2 2 
Citrate synthase, mitochondrial  Q8VHF5 35.6 8 12.07 
Clathrin heavy chain 1  P11442 12.6 8 13.06 
Clathrin light chain A  P08081 20.2 4 2.79 
Coatomer subunit beta  P23514 11.2 2 4 
Coatomer subunit beta'  O35142 6.3 4 5.25 
Coatomer subunit delta  Q66H80 8.6 3 3.51 
Coatomer subunit gamma  Q4AEF8 18.9 6 6.85 
Collagen alpha-1(I) chain  P02454 54.6 51 21.4 
Collagen alpha-1(III) chain  P13941 36 34 10.55 
Collagen alpha-2(I) chain  P02466 30.7 17 2.25 
Complement component 1 Q subcomponent-binding protein, 
mitochondrial  O35796 41.2 5 8.83 
Core histone macro-H2A.1  Q02874 26.7 8 6.08 
Creatine kinase B-type  P07335 35.7 19 14.74 
Creatine kinase S-type, mitochondrial  P09605 20.8 14 6.68 
Creatine kinase U-type, mitochondrial  P25809 62 34 35.03 
Cullin-associated NEDD8-dissociated protein 1  P97536 7.5 3 6.04 
Cytochrome b-c1 complex subunit 1, mitochondrial  Q68FY0 23.8 8 10.66 
Cytochrome b-c1 complex subunit 2, mitochondrial  P32551 33 10 13.29 
Cytochrome b-c1 complex subunit 6, mitochondrial  Q5M9I5 44.9 8 10.83 
Cytochrome b-c1 complex subunit Rieske, mitochondrial  P20788 36.1 3 4.14 
Cytochrome c oxidase subunit 2  P00406 19.4 4 5.96 
Cytochrome c oxidase subunit 4 isoform 1, mitochondrial  P10888 43.2 6 7.46 
Cytochrome c oxidase subunit 5A, mitochondrial  P11240 45.9 11 11.24 
Cytochrome c oxidase subunit 5B, mitochondrial  P12075 54.3 8 12.13 
Cytochrome c oxidase subunit 6A1, mitochondrial  P10818 72.1 6 8.09 
Cytochrome c oxidase subunit 6C-2  P11951 61.8 4 3.57 
Cytochrome c, somatic  P62898 42.9 4 7.76 
Cytoplasmic aconitate hydratase  Q63270 6.7 2 2.05 
Cytoplasmic dynein 1 heavy chain 1  P38650 8.9 7 15.68 
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Cytosol aminopeptidase  Q68FS4 14.3 3 5.31 
Cytosolic 10-formyltetrahydrofolate dehydrogenase  P28037 10.9 2 2.01 
D-3-phosphoglycerate dehydrogenase  O08651 18.2 3 6 
Decorin  Q01129 8.5 4 2.73 
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial  Q62651 17.7 2 3.81 
Delta-aminolevulinic acid dehydratase  P06214 14.9 6 8 
Destrin  Q7M0E3 53.9 8 14.82 
Dihydrolipoyl dehydrogenase, mitochondrial  Q6P6R2 21.4 6 11.6 
Dihydrolipoyllysine-residue acetyltransferase component of 
pyruvate dehydrogenase complex, mitochondrial  P08461 7.6 3 2.75 
Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial  Q01205 7.3 3 3.59 
Dipeptidyl peptidase 3  O55096 9.6 4 5.24 
DnaJ homolog subfamily C member 3  Q9R0T3 10.1 3 3.77 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
48 kDa subunit  Q641Y0 13.2 3 2.23 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 1  P07153 12.4 4 7.35 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 2  P25235 15.5 2 4 
Dynactin subunit 1  P28023 13.1 2 4.02 
Dynamin-1-like protein  O35303 5.7 2 2.04 
Dynamin-like 120 kDa protein, mitochondrial  Q2TA68 13.4 2 4 
Dynein light chain 2, cytoplasmic  Q78P75 40.5 2 4.03 
EH domain-containing protein 2  Q4V8H8 10.1 2 2 
EH domain-containing protein 3  Q8R491 12.2 2 4 
Electron transfer flavoprotein subunit alpha, mitochondrial  P13803 18.6 6 3.23 
Electron transfer flavoprotein subunit beta  Q68FU3 39.6 4 7.21 
Electron transfer flavoprotein-ubiquinone oxidoreductase, 
mitochondrial  Q6UPE1 9.9 4 3.32 
Elongation factor 1-alpha 1  P62630 54.8 13 24.53 
Elongation factor 1-gamma  Q68FR6 36.4 12 14.48 
Elongation factor 2  P05197 31 17 32.45 
Elongation factor Tu, mitochondrial  P85834 19.5 7 12 
Endoplasmic reticulum resident protein 29  P52555 28.9 2 3.94 
Endoplasmin  Q66HD0 37.9 20 33.49 
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Enoyl-CoA delta isomerase 1, mitochondrial  P23965 15.2 2 2.73 
Enoyl-CoA hydratase, mitochondrial  P14604 31 5 7.61 
Erlin-2  B5DEH2 10.3 2 2.68 
ERO1-like protein alpha  Q8R4A1 10.1 2 3.89 
Ester hydrolase C11orf54 homolog  Q5U2Q3 9.8 2 2.73 
Eukaryotic initiation factor 4A-II  Q5RKI1 19.4 7 6.89 
Eukaryotic translation initiation factor 3 subunit A  Q1JU68 24.5 9 14.65 
Eukaryotic translation initiation factor 3 subunit B  Q4G061 23.7 2 4.08 
Eukaryotic translation initiation factor 3 subunit C  B5DFC8 13.2 2 1.66 
Eukaryotic translation initiation factor 3 subunit E  Q641X8 6.7 2 2.74 
Eukaryotic translation initiation factor 3 subunit J  A0JPM9 22.4 4 6.12 
Eukaryotic translation initiation factor 5A-1  Q3T1J1 58.4 5 9.55 
Ezrin  P31977 26.1 5 9 
F-actin-capping protein subunit alpha-2  Q3T1K5 18.5 2 3.44 
Far upstream element-binding protein 2  Q99PF5 10.4 2 2.56 
Fructose-bisphosphate aldolase A  P05065 50.3 5 10.9 
Gamma-enolase  P07323 20.7 4 4.92 
General vesicular transport factor p115  P41542 8.9 2 1.2 
Glandular kallikrein-10  P36375 85.7 100 90.35 
Glandular kallikrein-12, submandibular/renal  P36376 48.3 26 24.92 
Glandular kallikrein-3, submandibular (Fragment)  P15950 86.7 32 40.67 
Glandular kallikrein-7, submandibular/renal  P36373 85.1 52 57.31 
Glia maturation factor beta  Q63228 35.2 3 6.1 
Glucosamine--fructose-6-phosphate aminotransferase 
[isomerizing] 1  P82808 10.3 3 4 
Glucose-6-phosphate 1-dehydrogenase  P05370 5.8 2 2 
Glucose-6-phosphate isomerase  Q6P6V0 22.9 6 7.85 
Glutamate dehydrogenase 1, mitochondrial  P10860 27.4 8 13.09 
Glutamine synthetase  P09606 23.3 4 6.13 
Glutathione peroxidase 1  P04041 32.8 4 6.74 
Glutathione S-transferase Mu 1  P04905 19.3 3 2.21 
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Glutathione S-transferase Mu 2  P08010 64.7 11 19.6 
Glutathione S-transferase P  P04906 33.8 7 4.15 
Glutathione synthetase  P46413 9.3 2 0.71 
Glyceraldehyde-3-phosphate dehydrogenase  P04797 44.7 8 13.4 
Glycogen phosphorylase, brain form (Fragment)  P53534 22.8 13 17.18 
Golgi integral membrane protein 4  Q5BJK8 9.6 2 3.48 
Golgi phosphoprotein 3  Q9ERE4 15.8 2 3.42 
Golgi reassembly-stacking protein 2  Q9R064 7.9 2 2.64 
GTP-binding protein 1  D2XV59 9.3 2 2.9 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-
1  P54311 10.6 2 3.59 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-
2  P54313 9.4 2 3.61 
Guanine nucleotide-binding protein subunit beta-2-like 1  P63245 39.1 10 10.74 
Heat shock 70 kDa protein 1A/1B  Q07439 36 8 16.83 
Heat shock 70 kDa protein 4  O88600 6.3 3 4.89 
Heat shock cognate 71 kDa protein  P63018 43.8 14 26.71 
Heat shock protein HSP 90-alpha  P82995 26.6 8 12.82 
Heat shock protein HSP 90-beta  P34058 30.4 13 12.4 
Hemoglobin subunit alpha-1/2  P01946 82.4 20 22.91 
Hemoglobin subunit beta-1  P02091 83.7 29 32.17 
Hemoglobin subunit beta-2  P11517 71.4 25 28.04 
Hemopexin  P20059 6.7 3 5.06 
Heterogeneous nuclear ribonucleoprotein A3  Q6URK4 22.2 3 4.76 
Heterogeneous nuclear ribonucleoprotein H2  Q6AY09 9.8 2 2 
Heterogeneous nuclear ribonucleoprotein K  P61980 34.1 7 8.04 
Heterogeneous nuclear ribonucleoprotein M  Q62826 10 2 3.28 
Heterogeneous nuclear ribonucleoprotein Q  Q7TP47 15.2 2 4.05 
Heterogeneous nuclear ribonucleoproteins A2/B1  A7VJC2 43.6 4 6.65 
Hexokinase-1  P05708 9.4 4 7.37 
High mobility group nucleosome-binding domain-containing 
protein 3  Q66H40 31.6 2 1.01 
High mobility group protein B1  P63159 45.6 5 7.11 
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Histone H1.2  P15865 68.5 9 17.53 
Histone H2A type 1  P02262 69.2 14 12.94 
Histone H2A type 2-A  P0CC09 73.1 10 9.76 
Histone H2A.Z  P0C0S7 35.9 2 1.31 
Histone H2B type 1  Q00715 76.8 21 12.95 
Histone H3.3  P84245 78.7 7 8.26 
Histone H4  P62804 64.1 5 9.27 
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial  Q9WVK7 40.1 9 12.89 
Hydroxymethylglutaryl-CoA lyase, mitochondrial  P97519 13.9 2 4 
Hypoxia up-regulated protein 1  Q63617 22.7 13 21.25 
Importin subunit beta-1  P52296 2.9 2 2.82 
Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial  Q99NA5 10.9 4 4.92 
Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial  Q68FX0 14 2 3.83 
Isocitrate dehydrogenase [NADP] cytoplasmic  P41562 13.5 3 3.22 
Isocitrate dehydrogenase [NADP], mitochondrial  P56574 38.9 15 26.9 
Junction plakoglobin  Q6P0K8 11.5 2 4 
Kallikrein-1  P00758 90.8 94 97.53 
Kinesin-1 heavy chain  Q2PQA9 11.9 4 5.54 
LETM1 and EF-hand domain-containing protein 1, mitochondrial  Q5XIN6 10.2 2 4 
Leucine-rich repeat-containing protein 59  Q5RJR8 28.3 5 6.15 
L-lactate dehydrogenase A chain  P04642 47.9 7 13.36 
L-lactate dehydrogenase B chain  P42123 12 3 4.07 
Lon protease homolog, mitochondrial  Q924S5 12.8 2 3.58 
Macrophage migration inhibitory factor  P30904 39.1 2 3.59 
Macrophage-capping protein  Q6AYC4 28.9 6 10.74 
Major vault protein  Q62667 7.4 3 5.62 
Malate dehydrogenase, cytoplasmic  O88989 32 11 16.72 
Malate dehydrogenase, mitochondrial  P04636 41.1 7 8.92 
Malonyl-CoA decarboxylase, mitochondrial  Q920F5 16.9 2 2.89 
Mannose-1-phosphate guanyltransferase alpha  Q5XIC1 20.5 3 4.94 
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Mesencephalic astrocyte-derived neurotrophic factor  P0C5H9 12.3 4 7.57 
Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial  Q5I0C3 12 2 4 
Methylmalonate-semialdehyde dehydrogenase [acylating], 
mitochondrial  Q02253 29.7 7 13.71 
Mitochondrial 2-oxoglutarate/malate carrier protein  P97700 24.8 3 5.66 
Mitochondrial import inner membrane translocase subunit Tim13  P62076 19 2 2 
Mitochondrial import receptor subunit TOM22 homolog  Q75Q41 38 2 4 
Mitochondrial inner membrane protein (Fragment)  Q3KR86 21.2 8 15.73 
Moesin  O35763 22.4 4 6.59 
Multiple coagulation factor deficiency protein 2 homolog  Q8K5B3 35.2 2 4 
Myosin light chain 3  P16409 27 2 2.14 
Myosin light polypeptide 6  Q64119 66.2 6 8 
Myosin regulatory light chain RLC-A  P13832 33.1 4 7.44 
Myosin regulatory light polypeptide 9  Q64122 17.5 2 3.17 
Myosin-10  Q9JLT0 18 7 5.95 
Myosin-11 (Fragments)  Q63862 25.5 14 23.09 
Myosin-4  Q29RW1 12.4 3 2.25 
Myosin-9  Q62812 36.4 54 67.33 
Myosin-Ic  Q63355 11.5 2 4.18 
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1  O08557 19 2 1.38 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 
10, mitochondrial  Q561S0 26.2 5 5.82 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 
9, mitochondrial  Q5BK63 44.6 13 14.56 
NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial  P19234 21.4 4 4.05 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, 
mitochondrial  Q641Y2 35.4 7 11.96 
NADH-cytochrome b5 reductase 1  Q5EB81 19.7 2 4 
NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial  Q66HF1 23.3 8 15.97 
Niban-like protein 1  B4F7E8 13.8 4 6.05 
Non-specific lipid-transfer protein  P11915 4.6 2 1.59 
Nuclease-sensitive element-binding protein 1  P62961 46.6 4 8 
Nucleobindin-2  Q9JI85 51.7 14 23.19 
Nucleolin  P13383 18.1 2 4.24 
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Nucleoside diphosphate kinase B  P19804 34.9 4 7.1 
Nucleosome assembly protein 1-like 4  Q5U2Z3 7.3 2 3.44 
Obg-like ATPase 1  A0JPJ7 17.2 2 4 
Ornithine aminotransferase, mitochondrial  P04182 22.8 5 7.68 
Parathymosin  P04550 65.7 5 5.31 
Peptidyl-prolyl cis-trans isomerase A  P10111 67.1 16 19.11 
Peptidyl-prolyl cis-trans isomerase B  P24368 31.5 3 2.51 
Peroxiredoxin-1  Q63716 25.6 3 5.3 
Peroxiredoxin-2  P35704 30.3 3 5.63 
Peroxiredoxin-5, mitochondrial  Q9R063 41.8 5 9.12 
Phenylalanine--tRNA ligase alpha chain  Q505J8 10.6 4 4.47 
Phosphate carrier protein, mitochondrial  P16036 22.5 4 5.9 
Phosphatidylethanolamine-binding protein 1  P31044 63.1 9 16.84 
Phosphoglycerate kinase 1  P16617 27.3 3 5.41 
Phosphoglycerate mutase 1  P25113 24 5 7.97 
Plasma membrane calcium-transporting ATPase 1  P11505 8.3 2 3.05 
Platelet-activating factor acetylhydrolase IB subunit gamma  O35263 23.3 3 5.21 
Plectin  P30427 14.2 3 6.96 
Polyadenylate-binding protein 1  Q9EPH8 23.9 8 11.17 
Polymerase I and transcript release factor  P85125 17.6 2 4 
Polypyrimidine tract-binding protein 1  Q00438 14.2 3 3.07 
Potassium-transporting ATPase alpha chain 1  P09626 13.8 3 6.13 
Prelamin-A/C  P48679 24.4 3 6.06 
Pro-epidermal growth factor  P07522 12.4 6 8.64 
Profilin-1  P62963 27.9 3 4.49 
Programmed cell death 6-interacting protein  Q9QZA2 11 2 4 
Prohibitin  P67779 37.5 5 8.69 
Prohibitin-2  Q5XIH7 36.5 4 7.01 
Prolactin-inducible protein homolog  O70417 40.4 2 4 
Propionyl-CoA carboxylase alpha chain, mitochondrial  P14882 14.3 3 4.42 
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Propionyl-CoA carboxylase beta chain, mitochondrial  P07633 29 8 11.72 
Prostaglandin E synthase 3  P83868 20 2 0.74 
Prostatic glandular kallikrein-6  P36374 89.7 58 63.77 
Proteasome activator complex subunit 1  Q63797 22.1 3 2.89 
Proteasome subunit alpha type-5  P34064 5 2 3.77 
Proteasome subunit beta type-2  P40307 19.9 2 3.36 
Proteasome subunit beta type-4  P34067 13.3 2 3.62 
Protein disulfide-isomerase  P04785 83.3 42 67.96 
Protein disulfide-isomerase A3  P11598 53.1 25 34.57 
Protein disulfide-isomerase A4  P38659 17.7 5 4.53 
Protein disulfide-isomerase A6  Q63081 35 10 11.43 
Protein DJ-1  O88767 20.6 2 3.06 
Protein ERGIC-53  Q62902 34.2 10 15.84 
Protein phosphatase 1 regulatory subunit 1B  Q6J4I0 49.3 7 12 
Protein S100-A1  P35467 62.8 7 10.56 
Protein S100-A11  Q6B345 52 2 4.18 
Protein S100-A6  P05964 66.3 4 0.94 
Protein transport protein Sec31A  Q9Z2Q1 9 2 4 
Protein-arginine deiminase type-2  P20717 8.4 2 2 
Prothymosin alpha  P06302 43.8 8 11.24 
Purine nucleoside phosphorylase  P85973 37 5 9.73 
Purkinje cell protein 4  P63055 59.7 2 2.62 
Putative 60S ribosomal protein L37a  P61515 37 4 4.27 
Pyruvate carboxylase, mitochondrial  P52873 12.1 3 6.27 
Pyruvate dehydrogenase E1 component subunit alpha, somatic 
form, mitochondrial  P26284 15.6 2 3.1 
Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial  P49432 53.2 11 16.73 
Pyruvate kinase isozymes M1/M2  P11980 23.2 9 10.36 
Rab GDP dissociation inhibitor alpha  P50398 14.3 4 5.4 
Rab GDP dissociation inhibitor beta  P50399 24.7 7 10.83 
Ras-related protein Rab-11A  P62494 10.7 2 1.62 
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Name Uniprot Accession # 
% 
Cov 
# of peptides 
(95%) 
Total 
protscore 
Ras-related protein Rab-1A  Q6NYB7 18.5 2 0.56 
Ras-related protein Rab-1B  P10536 16.9 2 1.39 
Ras-related protein Rab-27A  P23640 24.9 3 3.72 
Ras-related protein Rab-27B  Q99P74 12.8 2 2 
Ras-related protein Rap-1b  Q62636 20.7 3 4 
Retinal dehydrogenase 1  P51647 11 2 1.64 
Rho GDP-dissociation inhibitor 1  Q5XI73 50.5 5 6.83 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  P11507 19.9 3 6.62 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 3  P18596 18.2 7 14.71 
Scaffold attachment factor B1  O88453 10.2 2 3.48 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory 
subunit A beta isoform  Q4QQT4 8.3 2 4 
Serine--tRNA ligase, cytoplasmic  Q6P799 17.2 4 4.97 
Serotransferrin  P12346 13.6 7 12.34 
Short-chain specific acyl-CoA dehydrogenase, mitochondrial  P15651 17.7 2 2.86 
SMR1 protein  P13432 75.3 18 21.5 
SMR2 protein  P18897 55.5 12 18.03 
Sodium/potassium-transporting ATPase subunit alpha-1  P06685 40.6 49 55.54 
Sodium/potassium-transporting ATPase subunit beta-1  P07340 57.2 16 28.16 
Sorting nexin-3  Q5U211 11.1 2 2 
Spectrin alpha chain, brain  P16086 22.2 17 34.82 
Spectrin beta chain, brain 2  Q9QWN8 20.2 6 11.14 
Spliceosome RNA helicase Ddx39b  Q63413 16.4 3 3.19 
Staphylococcal nuclease domain-containing protein 1  Q66X93 33 14 22.61 
STE20-like serine/threonine-protein kinase  O08815 11.7 2 4.02 
Stress-70 protein, mitochondrial  P48721 25 11 17.42 
Submandibular gland secretory Glx-rich protein CB  P08462 96.8 33 48.41 
Submandibular glandular kallikrein-9  P07647 88.4 80 82.53 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial  Q920L2 20.6 9 9.49 
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, 
mitochondrial  P21913 13.5 4 3.88 
Succinate-semialdehyde dehydrogenase, mitochondrial  P51650 7.6 2 4 
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Name Uniprot Accession # 
% 
Cov 
# of peptides 
(95%) 
Total 
protscore 
Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, 
mitochondrial  P13086 33.8 5 9.69 
Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, 
mitochondrial  B2GV06 31.9 7 11.7 
Sulfotransferase 1C1  P50237 50.3 9 11.99 
Superoxide dismutase [Cu-Zn]  P07632 29.2 3 4.3 
Superoxide dismutase [Mn], mitochondrial  P07895 30.2 4 6 
Syntaxin-7  O70257 17.2 2 0.69 
T-complex protein 1 subunit epsilon  Q68FQ0 22.2 5 10 
Thioredoxin  P11232 22.9 2 1.57 
Thioredoxin-like protein 1  Q920J4 13.5 2 3.36 
Thiosulfate sulfurtransferase  P24329 20.2 3 5.35 
Threonine--tRNA ligase, cytoplasmic  Q5XHY5 12.5 2 2.96 
Thymosin beta-4  P62329 77.3 9 13.54 
Tonin  P00759 74.5 59 68.02 
Transaldolase  Q9EQS0 16.9 3 5.75 
Transforming protein RhoA  P61589 35.2 4 7.24 
Transgelin  P31232 15.4 2 1.05 
Transgelin-2  Q5XFX0 57.3 8 8.6 
Transitional endoplasmic reticulum ATPase  P46462 35.5 17 26.96 
Transketolase  P50137 33.7 6 11.51 
Translationally-controlled tumor protein  P63029 48.3 3 5.95 
Translocon-associated protein subunit alpha  Q7TPJ0 16.3 6 3.31 
Translocon-associated protein subunit gamma  Q08013 21.6 4 4 
Transmembrane emp24 domain-containing protein 10  Q63584 41.1 5 6.55 
Transmembrane emp24 domain-containing protein 9  Q5I0E7 16.2 4 4.02 
Trifunctional enzyme subunit alpha, mitochondrial  Q64428 34.2 18 21.93 
Trifunctional enzyme subunit beta, mitochondrial  Q60587 18.3 4 4.4 
Triosephosphate isomerase  P48500 14.9 4 6.3 
Tripeptidyl-peptidase 1  Q9EQV6 5 4 2.99 
Tropomyosin alpha-1 chain  P04692 42.6 9 17.97 
Tropomyosin alpha-3 chain  Q63610 39.5 6 11.16 
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% 
Cov 
# of peptides 
(95%) 
Total 
protscore 
Tropomyosin beta chain  P58775 44.4 8 15.07 
Tubulin alpha-1B chain  Q6P9V9 30.2 20 19.73 
Tubulin alpha-1C chain  Q6AYZ1 31.6 19 18.9 
Tubulin alpha-4A chain  Q5XIF6 37.7 17 22.46 
Tubulin beta-2B chain  Q3KRE8 38 21 29.03 
Tubulin beta-4B chain  Q6P9T8 47 23 34.11 
Tubulin-specific chaperone A  Q6PEC1 21.3 2 2.58 
Tumor protein D54  Q6PCT3 18.6 3 3.01 
Ubiquitin-conjugating enzyme E2 variant 2  Q7M767 13.8 2 3.8 
Ubiquitin-like modifier-activating enzyme 1  Q5U300 22.9 7 11.55 
Ubiquitin-like modifier-activating enzyme 5  Q5M7A4 16.6 3 3.61 
UDP-glucose:glycoprotein glucosyltransferase 1  Q9JLA3 8.1 2 3.91 
UMP-CMP kinase  Q4KM73 14.8 2 2.6 
Vacuolar protein sorting-associated protein 29  B2RZ78 14.8 3 6 
Valine--tRNA ligase  Q04462 12.4 5 8.7 
Vesicle-trafficking protein SEC22b  Q4KM74 13.5 2 3.55 
Vimentin  P31000 23.2 3 5.86 
Vinculin  P85972 4.8 2 2.97 
Voltage-dependent anion-selective channel protein 1  Q9Z2L0 22.6 3 5.04 
V-type proton ATPase subunit B, brain isoform  P62815 15.1 2 3 
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Supplementary table 2 - Classification of the proteins identified by PANTHER Protein Class. This 
table lists the PANTHER Protein Classes enriched in the fractions analyzed, with a p-value below 
0.05 according to the PANTHER database (www.pantherdb.org) 
 Number of gene hits   
PANTHER Protein Class  
Rattus 
norvegicus - 
reference list 
(27758) 
List of 
identified 
proteins (456) 
Expected 
Over-/ Under-
representation in the 
list of identified 
proteins 
P-value 
calcium-binding protein 313 23 5.07 + 6.49E-07 
 intracellular calcium-sensing protein 197 12 3.19 + 2.11E-02 
  calmodulin 197 12 3.19 + 2.11E-02 
chaperone 262 21 4.25 + 7.13E-07 
 Hsp70 family chaperone 22 6 .36 + 3.68E-04 
cytoskeletal protein 974 46 15.79 + 3.16E-08 
 actin family cytoskeletal protein 447 29 7.25 + 9.91E-08 
  actin binding motor protein 60 8 .97 + 1.44E-03 
  tubulin 22 5 .36 + 6.32E-03 
defense/immunity protein 778 1 12.61 - 7.00E-03 
enzyme modulator 
 
     
 G-protein 284 15 4.60 + 1.51E-02 
  small GTPase 210 12 3.40 + 3.77E-02 
isomerase 224 15 3.63 + 1.03E-03 
kinase      
 amino acid kinase 5 3 .08 + 1.49E-02 
 protein kinase 658 1 10.67 - 4.40E-02 
ligase 502 20 8.14 + 4.83E-02 
lyase 178 15 2.89 + 6.42E-05 
 hydratase 20 7 .32 + 9.71E-06 
membrane traffic protein 373 20 6.05 + 8.44E-04 
 vesicle coat protein 44 9 .71 + 1.17E-05 
nucleic acid binding 3434 95 55.67 + 2.41E-05 
 RNA binding protein 1631 85 26.44 + 3.54E-19 
  ribosomal protein 777 60 12.60 + 6.92E-21 
  translation factor 112 10 1.82 + 3.51E-03 
oxidoreductase 862 66 13.97 + 5.75E-23 
 dehydrogenase 305 40 4.94 + 2.61E-21 
 reductase 229 16 3.71 + 2.97E-04 
receptor 1857 4 30.10 - 2.68E-07 
 G-protein coupled receptor 642 0 10.41 - 4.81E-03 
transcription factor 1977 5 32.05 - 3.04E-07 
 zinc finger transcription factor 671 0 10.88 - 2.97E-03 
transfer/carrier protein 470 25 7.62 + 6.41E-05 
transporter      
 cation transporter 217 15 3.52 + 7.09E-04 
  ATP synthase 59 9 .96 + 1.32E-04 
Unclassified 11977 47 194.17 - 3.47E-50 
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The results presented in this chapter were published as a rapid 
communication:  
Vitorino R, Alves R, Barros A, Caseiro A, Ferreira R, Lobo MC, Bastos A, 
Duarte J, Carvalho D, Santos LL, Amado FL. Finding new posttranslational 
modifications in salivary proline-rich proteins. Proteomics. 2010 Oct;10(20):3732-
42. doi: 10.1002/pmic.201000261. 
1. Introduction 
Saliva is a body fluid particularly enriched in several low-molecular 
weight protein species, where peptides up to 20 kDa represent about 40% 
of total secreted proteins (Amado, Vitorino et al. 2005). Salivary 
proline-rich proteins form a protein family that represents approximately 
20-30% of salivary protein content and up to 60% of proteins secreted by 
submandibular and sublingual glands (Levine 2011). Two major 
subgroups are considered in the PRP family: acidic proline-rich proteins 
(aPRP) and basic proline-rich proteins (bPRP).  
aPRPs have a distinctive 30 amino acids N-terminus rich in 
aspartate, glutamate, and containing a few serine phosphate residues, 
giving it acidic properties and are exclusively found in salivary glands 
secretions (Schenkels, Veerman et al. 1995). This N-terminus binds 
strongly to recently cleaned teeth surfaces, inducing a conformational 
change that exposes the C-terminal domain bearing a binding site for 
bacteria (Elangovan, Margolis et al. 2007). For this reason, it is of 
particular relevance in the formation of acquired enamel pellicle (Li, 
Helmerhorst et al. 2004). Acidic PRPs are encoded by two genes PRH1 and 
PRH2, with 3 and 2 alleles, respectively. These are responsible for up to 18 
possible polymorphisms from the possible combinations of the alleles Db, 
Pa, Pif from PRH1 gene with the PRP1 and PRP2 of the PRH2 gene (Levine 
2011). Besides this variability, the proteins may undergo 
post-translational processing either by proteolytic cleavage or amino acid 
modification. The cleavage at Arg123 originates the salivary peptides Db-F, 
Pif-F, PRP-3 and PRP-4, from the N-terminus of Db, Pif, PRP1 and PRP2, 
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respectively, while the C-terminal fragment is known as peptide P-C. The 
Pa allele form is not proteolytically cleaved. Additionally, phosphorylations 
of Ser24, Ser33, Ser38, as well as O-linked addition of glucuronic acid on 
Ser33, were already described (Jonsson, Griffiths et al. 2000; Inzitari, 
Cabras et al. 2005; The UniProt Consortium 2012). 
bPRPs are also found in other glands secretions (Schenkels, 
Veerman et al. 1995). Although not adhering to teeth, they play an 
important role binding bacteria and tannins. Because they bind to several 
oral bacteria, they are important in the protection against dental caries 
(Vitorino, de Morais Guedes et al. 2006). However, caries-free individuals 
do not have increased content of bPRPs in whole saliva. Instead, it 
appears to be less fragmentation (Ayad, Van Wuyckhuyse et al. 2000; 
Vitorino, Lobo et al. 2005). Binding to tannins indicates that bPRPs also 
have a role in astringency. Interestingly, larger bPRPs have higher affinity 
to bind tannins than smaller bPRPs (Charlton, Baxter et al. 1996). This is 
of particular importance as individuals lacking larger forms of bPRPs tend 
to follow a sucrose-rich diet, because sucrose reduces the astringency 
feeling but further increases the risk of developing caries (Ishikawa and 
Noble 1995; Levine 2011). These proteins are encoded by four genes PRB1, 
PRB2, PRB3 and PRB4. Greater allele variations, in addition to alternative 
splice variants, proteolytic cleavage and post-translational modifications, 
is responsible for the large number of bPRPs found (Maeda, Kim et al. 
1985; Levine 2011). Splice variants of the different alleles originates 
several proteins with deletions in certain areas of the primary sequence. 
bPRP1 has deletions of amino acids 93-153 in allele M, 106-319 in clone 
CP5, 106-299 in clone CP-4, 134-255 in allele S; bPRP3 has a deletion of 
amino acids 158-220 in allele S; and bPRP4 has deletions of 113-154 in 
allele M and 113-154 plus 164-184 in allele S (Maeda, Kim et al. 1985; 
The UniProt Consortium 2012>Entries P04280, P02812, Q04118 and 
P10163). Proteolytic cleavage may occur before secretion during granule 
maturation (Messana, Cabras et al. 2008), and originates peptides II-2, IB-
6 and P-H from bPRP1; IB-1, IB-4, IB-7, IB-8c and PE from bPRP2; and 
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protein N1, glycosylated protein A and peptide P-D from bPRP4 (Kauffman, 
Bennick et al. 1991; Vitorino, Barros et al. 2009; The UniProt Consortium 
2012). Like aPRPs, bPRPs may undergo amino acid post-translational 
modifications. Glycosylation is one of the major modifications detected in 
bPRPs, suggesting they have a role in oral lubrication (Hatton, Loomis et 
al. 1985). Moreover, phosphorylation and conversion of N-terminal Gln 
residues to pyroglutamate were also detected (Inzitari, Cabras et al. 2005). 
Thus, it is clear that both acidic and basic proline-rich proteins are 
essential in the maintenance of oral health, but the presence or absence of 
certain PTMs may enhance or reduce such properties. As diabetic patients 
have higher incidence of oral complications, this study proposes to apply 
state of the art mass spectrometry techniques to identify novel PTMs in 
salivary PRPs and compare their frequency against control individuals. 
Because alterations in glycosylation are common biomarkers in cancer, a 
group of head and neck cancer patients was also analysed. 
2. Methods 
2.1. Sample collection 
Unstimulated whole saliva from 20 individuals (aged 23-54) was 
collected at 10:00 a.m. by direct draining into a saliva collection tube, 
after a fasting period of at least 2 hours. The donors were grouped, 
according to their clinical evaluation, in diabetic (T1DM) – 5 individuals 
with type 1 DM; head and neck cancer (HNC) – 10 individuals with head 
and neck cancer not undergoing radiation treatment; and control (C) – 5 
individuals with no evidence of oral pathologies or inflammation. This 
study was approved by the local ethics committee and all participating 
individuals gave their informed consent. 
2.2. Sample preparation 
Salivary peptide isolation was performed as described by Vitorino, 
Barros et al. (2009). Protease activity was blocked with the addition of 
10 µl of PMSF 0.1 M, 1 µl of peptstatin 1 mM and 20 µl of anti-protease 
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cocktail (aprotinin, E-64, EDTA, AEBSF and leupeptin)(P2714, Sigma, 
USA) to 1 ml of whole saliva. Samples were acidified with 0.2% 
trifluoracetic acid (TFA) in a proportion 1:1 and centrifuged at 12,000x g, 
30 min, 4ºC, to remove bacteria, insoluble material and precipitated 
protein. Next, samples were filtered through a sequence of filters with 
cut-offs of 100 kDa, 50 kDa and 10 kDa (Centricom, Millipore, USA). 
Peptide enriched fractions were separated by nano-LC using an 
Ultimate 3000 (Dionex, Thermo Fisher Scientific, USA) onto a 
150 mm x 75 µm Pepmap100 capillary analytical C18 column with a 3 µm 
particle size (Dionex, Thermo Fisher Scientific, USA) at a flow rate of 
300 nl/min. A linear gradient of 5% to 50% of buffer B (85% ACN, 5% 
2-propanol, 0.04% TFA) was run over a period of 35 minutes. Peptides 
eluted from the capillary column were mixed with a continuous flow of 
alpha-CHCA matrix solution (270 nl/min, 2 mg/ml in 70% ACN/0.1% TFA 
and internal standard Glu-Fib at 15 fmol) and were directly deposited onto 
a LC-MALDI plate at 20 second intervals for each spot (100 nl/fraction). 
For every separation run, 156 fractions were collected. 
2.3. Mass spectrometry analysis 
MALDI-TOF/TOF MS analysis was performed using a 
4800 MALDI-TOF/TOF Analyser (Applied Biosystems, USA). A 
signal-to-noise ratio threshold of 50 was applied to select peaks for 
MS/MS analyses. A fragmentation voltage of 2 kV was used throughout 
the automatic runs. Spectra were processed and analysed with the Global 
Protein Server (GPS) Workstation (Applied Biosystems, USA), which uses 
an internal MASCOT software (v.2.1.0.4, Matrix Science, UK) for 
protein/peptide identification based on peptide mass fingerprints and 
MS/MS data. 
An initial search was performed against the SwissProt database 
(March 2009, 428,650 entries) for Homo sapiens. An MS tolerance of 
30 ppm was considered for precursor ions and of 0.3 Da for fragment ions. 
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Protein identifications were considered reliable if the MASCOT score was 
>70.  
For post-translation modifications (PTM) analyses, spectra were 
reprocessed against an internal database including all PRP variants as 
described in literature (Stubbs, Chan et al. 1998) and Uniprot (Apweiler, 
Bairoch et al. 2004). In order to estimate the false positive rate (FDR) and 
considering the repetitive PRP motif, a random decoy database was 
created for all SwissProt and internal database entries, resulting in 12% 
and 5% of FDR, respectively. Unique peptides from FDR search were 
considered for PTM characterization. The PTMs used in the search are 
listed in Table 4. The presence of the PTM was considered reliable when 
the program indicated a significant MASCOT score and the ion score was 
above 20. Each PTM was then validated by the manual analysis of spectra 
through the analysis of a, b and/or y fragmentation ions series. 
Table 4 – List of post-translational modifications searched in the GPS workstation. 
Modification 
Monoisotopic 
mass variation 
(Da) 
Galactosyl (K) 178,05 
Glucosylgalactosyl (K) 340,10 
dHex (S) 146,06 
Hex (N-term) 162,05 
HexNAc (S,N) 203,08 
Phospho (S; T; Y) 79,97 
Pro->pyro-Glu (Pyroglutamic) (P) 13,98 
Gln->pyro-Glu  (N-term-Q) -17,03 
Glucuronyl (S) 17,60 
Sulfo (Sulfation) (S; T; Y) 79,96 
Nmethylmaleimide (K) 111,03 
Oxidation (K, R, P, G, C, H, F, V, L, N) 15,99 
Dioxidation (K, R, P, G, C, H, F, V, L, N) 31,99 
Pro to pyrrolidone -27,99 
Pro to pyro-Glu -30,01 
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2.4. Statistical analysis 
Statistical analysis of frequency tables was performed using 
GraphPad Prism v5.00 (GraphPad Software, Inc., USA). An one-way 
ANOVA analysis followed by the Tukey-Kramer test to all the column pairs 
was used. A p value <0.05 was considered significant. 
3. Results 
A total of 1391 fragments from proline-rich proteins were identified. 
The more represented family was aPRPs with 498 fragments, while bPRP1, 
bPRP2, bPRP3 and bPRP4 had 334, 298, 122 and 139 fragments 
identified, respectively (Figure 25). The mining for 38 different PTMs (Table 
4), allowed the identification of 69 unique peptides with 12 different 
modifications mainly due to glycosylation, phosphorylation and conversion 
of N-terminal Gln to pyroglytamate.  
 
Figure 25 – Distribution of the identified fragments by the several proline-rich proteins. 
 
All PRPs presented at least one phosphorylated Ser residue, with the 
exception of bPRP4, but aPRPs presented the higher number of 
phosphopeptides (Table 5). Apart from the already identified 
phosphorylated residues in Uniprot, a survey for potential 
phosphorylation sites was conducted using NetPhos v2.0 (Blom, 
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Gammeltoft et al. 1999) (Supplementary table 1). So, in addition to the 
already described phosphorylation of Ser8 from bPRP1, we have identified 
the phosphorylation of Ser134 from bPRP2 and Ser8 from bPRP3 (Figure 
26). In aPRPs, despite the high number of phosphorylated peptides 
identified, all contained the same phosphorylated residue: Ser22. 
Table 5 – List of peptides found with post-translational modifications. (*) denotes 
modifications presently indicated in Uniprot and attributed after the publication this study 
(Vitorino, Alves et al. 2010). 
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PGKPQGPPAQGGS       Ser314* HexNAc (S)[13] 7 1 1 5 
GPPPQGGNKPQGPPPPGKPQGPPPQGDKSR Ser71* HexNAc (S)[29] 3 0 1 2 
GPPPPGKPQGPPPQGDKSR     Ser71* HexNAc (S)[18] 7 2 1 4 
GKPQGPPPQGDKSQS     Ser134* dHex (S)[15] 4 1 2 1 
SPQGGNKPQGPPPPPGKPQ     Ser24* Hex (S)[1] 1 0 0 1 
GPPPPGKPQGPPPQGDKS     Lys70 Glucosylgalactosyl (K)[17] 3 0 0 3 
KPQGPPPQGDKSQSPRSPPGK     Lys131 Galacotsyl (K)[11] 3 0 0 3 
GPPPQGGNKPQGPPPPGKPQGPPPQGDKS Lys70 Glucosylgalactosyl (K)[28] 4 0 1 3 
GPPPQGGNKPQGPPPPGKPQGPPAQGGSKS Lys313 Glucosylgalactosyl (K)[29] 4 0 1 3 
QGGNKPQGPPPPPGKPQ     Gln25 Gln->pyro-Glu (N-term Q)[0] 9 2 2 5 
QNLNEDVSQEESPSLIAGNPQGPSPQGGNKPQ Gln1*,Ser8* Gln->pyro-Glu (N-term Q)[0], Phospho (ST)[8] 3 0 1 2 
PQGPPPQGDKSRSPRSPPGKPQ   Ser76* Phospho (ST)[16] 6 3 2 1 
QGPPPQGDKSQSPRSPPGKPQGPPPQ   Ser134* Phospho (ST)[12] 6 3 1 2 
bP
R
P2
 (P
02
81
2)
  
GPPPQGGNKSQGPPPPGKPQ     Asn256* HexNAc (N)[8] 5 0 0 5 
GPPPPGKPQGPPPQGDNKSQ     Asn214* HexNAc (N)[17] 6 1 1 4 
GPPPQGDNKSQSARSPPGKPQ     Asn214* HexNAc (N)[8] 2 0 0 2 
GPPPPGKPQGPPPQGDNKSQ     Ser232* dHex (S)[19] 4 0 2 2 
GPPPQGGNKPQGPPPPGKPQGPPPQGDKS Lys107 Glucosylgalactosyl (K)[28] 2 0 0 2 
QPQGPPRPPQ       Gln397 Gln->pyro-Glu (N-term Q)[0] 4 1 2 1 
QGPPRPPQGGRPS       Gln399 Gln->pyro-Glu (N-term Q)[0] 8 2 2 4 
QAPPAGQPQGPPRPPQ     Gln391 Gln->pyro-Glu (N-term Q)[0] 6 2 3 1 
QGGNQPQGPPPPPGKPQ     Gln62 Gln->pyro-Glu (N-term Q)[0] 6 1 1 4 
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QPQAPPAGQPQGPPRPPQ     Gln389 Gln->pyro-Glu (N-term Q)[0] 2 0 0 2 
QGGNQPQGPPPPPGKPQGPPPQGGNKPQ Gln62 Gln->pyro-Glu (N-term Q)[0] 5 0 4 1 
QQEGNNPQGPPPPAGGNPQQPQAPPAGQPQGPPRPP Gln370 Gln->pyro-Glu (N-term Q)[0] 1 0 0 1 
QEESPSLIAGNPQGAPPQGGNKPQGPPSP Ser36* Phospho (ST) (S)[36] 6 3 1 2 
bP
R
P3
 (Q
04
11
8)
  
KPQGPPPQEGNKPQ       Asn239* Hex (N)[11] 5 1 1 3 
GPPPRPGKPEGPPPQGGNQS     Ser72* dHex (S)[20] 6 2 3 1 
SQGPPPRPGKPEGPPPQGGNQ     Asn71 HexNAc (N)[20] 6 1 1 4 
QPLPPPAGKPQ       Gln277 Gln->pyro-Glu (N-term Q)[0] 6 1 4 1 
QGPPPRPGKPE       Gln47 Gln->pyro-Glu (N-term Q)[0] 3 0 2 1 
QSQGPPPRPGKPE       Gln45 Gln->pyro-Glu (N-term Q)[0] 11 2 4 5 
QGGRPHRPPQGQPP       Gln294 Gln->pyro-Glu (N-term Q)[0] 5 2 2 1 
QGGRPHRPPQGQPPQ     Gln294 Gln->pyro-Glu (N-term Q)[0] 6 2 3 1 
QSQGPPPRPGKPEGSPS     Gln213 Gln->pyro-Glu (N-term Q)[0] 3 0 2 1 
QSQGPPPRPGKPEGQPPQ     Gln66 Gln->pyro-Glu (N-term Q)[0] 6 2 3 1 
QSLNEDVSQEESPSVISGKPEGR   Gln1* Gln->pyro-Glu (N-term Q)[0] 3 0 1 2 
QSLNEDVSQEESPSVISGKPEGR   Gln1*,Ser8* Gln->pyro-Glu (N-term Q)[0], Phospho (ST)[8] 4 0 2 2 
bP
R
P4
 (P
10
16
3)
  
GPPPPPGKPEGRPPQGGNQ     Asn71* HexNAc (N)[18] 8 2 2 4 
QRPPPPP         Gln32 Gln->pyro-Glu (N-term Q)[0] 2 0 0 2 
QPQRPPPPP       Gln30 Gln->pyro-Glu (N-term Q)[0] 6 0 2 4 
QGPPPHPGKPE       Gln74 Gln->pyro-Glu (N-term Q)[0] 6 1 4 1 
QGPPPPPQGGRPP       Gln272 Gln->pyro-Glu (N-term Q)[0] 1 0 0 1 
QSQGPPPHPGKPE       Gln72 Gln->pyro-Glu (N-term Q)[0] 4 0 1 3 
QSHRPPPPPGKPE       Gln177 Gln->pyro-Glu (N-term Q)[0] 2 0 0 2 
QSQGPPPPPGKPEGRPP     Gln51 Gln->pyro-Glu (N-term Q)[0] 3 1 1 1 
QSQGPPPHPGKPERPPP     Gln72 Gln->pyro-Glu (N-term Q)[0] 1 0 0 1 
QSQGPPPHPGKPEGPPPQ     Gln197 Gln->pyro-Glu (N-term Q)[0] 1 0 0 1 
QSQGPPPHPGKPEGPPPQEGNKS   Gln197 Gln->pyro-Glu (N-term Q)[0] 1 0 0 1 
QSQGPPPHPGKPEGPPPQEGNKSR   Gln197 Gln->pyro-Glu (N-term Q)[0] 2 0 0 2 
aP
R
P 
(P
02
81
0)
  
DSEQFIDEER       Ser22* Glucuronyl (S)[2] 5 2 2 1 
DSEQFIDEERQGPPLGGQQSQPS   Ser22* Glucuronyl (S)[2] 6 3 2 1 
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DSEQFIDEERQGPPLGGQQ     Ser22* Glucuronyl (S)[2] 6 3 2 1 
GGDSEQFIDEER       Ser22 Phospho (ST) (S)[4] 16 4 2 10 
DGGDSEQFIDEER       Ser22 Phospho (ST) (S)[5] 12 4 4 4 
GGDSEQFIDEERQ       Ser22 Phospho (ST) (S)[4] 11 4 3 4 
DGGDSEQFIDEERQ       Ser22 Phospho (ST) (S)[5] 8 2 4 2 
VISDGGDSEQFIDEER     Ser22 Phospho (ST) (S)[8] 1 0 0 1 
GGDSEQFIDEERQGPPL     Ser22 Phospho (ST) (S)[4] 7 2 4 1 
VISDGGDSEQFIDEERQ     Ser22 Phospho (ST) (S)[8] 1 0 0 1 
GGDSEQFIDEERQGPPLG     Ser22 Phospho (ST) (S)[4] 4 1 2 1 
GGDSEQFIDEERQGPPLGG     Ser22 Phospho (ST) (S)[4] 17 3 5 9 
GGDSEQFIDEERQGPPLGGQ     Ser22 Phospho (ST) (S)[4] 9 1 4 4 
DVPLVISDGGDSEQFIDEER     Ser22 Phospho (ST) (S)[12] 4 0 2 2 
GGDSEQFIDEERQGPPLGGQQ     Ser22 Phospho (ST) (S)[4] 15 5 4 6 
DGGDSEQFIDEERQGPPLGGQQ   Ser22 Phospho (ST) (S)[5] 9 1 4 4 
GGDSEQFIDEERQGPPLGGQQSQPS   Ser22 Phospho (ST) (S)[4] 7 2 4 1 
VISDGGDSEQFIDEERQGPPLGGQQ   Ser22 Phospho (ST) (S)[8] 3 0 2 1 
DGGDSEQFIDEERQGPPLGGQQSQPS   Ser22 Phospho (ST) (S)[5] 4 1 2 1 
 
 
Figure 26 – Representative MS/MS spectrum of a peptide with m/z 2535.11 from bPRP3. 
Phosphorylation of Ser8 and simultaneous cyclization of N-terminal Gln1 to pyroglutamate may be 
observed in the fragmentation pattern. 
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Along with phosphorylation, a special emphasis was also given to 
glycosylation. It was possible to identify 21 unique peptides containing 
monosaccharide units in bPRPs fragments. Most of the glycosylated 
peptides contained Ser O-glycosylation or Asn N-glycosylation to N-acetyl 
hexosamine (HexNAc). As in phosphorylation, bioinformatics prediction of 
glycosylation sites was also conducted with YinOYang v1.2 (Gupta and 
Brunak 2002) and NetNGlyc v1.0 (Gupta, Jung et al. 2004), revealing 
several potential glycosylation sites: three on bPRP2, eight on bPRP3 and 
eight on bPRP4. It was detected N-HexNAc at Asn214 and Asn256 (Figure 27) 
on bPRP2, Asn71 on bPRP3 and Asn71 on bPRP4; on bPRP1, only O-
HexNAc on Ser71 (Figure 27) and Ser314 was detected (Table 5). The losses 
of terminal sugars fucose or hexose were also identified in some fragments 
by the neutral-loss of 146 Da and 162 Da, respectively, on residues Ser24 
and Ser134 from bPRP1, Ser232 from bPRP2 and Ser232 and Asn239 from 
bPRP3. The PTM mining also allowed the identification of numerous 
bPRPs fragments with cyclisation of N-terminal Gln to pyroglutamate 
(Table 5 and Figure 26). 
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Figure 27 – Representative MS/MS spectra of glycosylated bPRP fragments.  
A: Identification of N-HexNAc at Asn256 in a peptide with m/z 2125.04 from bPRP2. B: Identification 
of O-HexNAc at Ser71 in a peptide with m/z 2097.08 from bPRP1. 
Regarding the frequency of the PTMs in each group, modifications 
were grouped in O-glycosylation, N-glycosylation, Gln->pyroGlu, 
phosphorylation and both O- and N-HexNAc for their apparently high 
occurrence. The distribution of frequencies in each group is graphically 
presented in (Figure 28) as box and whiskers Tukey plots, which allow the 
visualization of outliers. Significant increased frequencies were found for 
N-glycosylation and O-/N-HexNAc in cancer patients, while diabetic 
patients had a very significant increase in the frequency of N-terminal 
cyclised fragments (Figure 28). 
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Figure 28 – Frequency distribution of selected PTMs in control, diabetic (T1DM) and head 
and neck cancer (HNC) patients. 
 
4. Discussion 
There is a direct link between diabetes and oral pathologies, being 
diabetic patients more susceptible to periodontal diseases (Lakschevitz, 
Aboodi et al. 2011). Proline-rich proteins, not only are one of the major 
family of proteins found in saliva, but have been suggested to play 
important roles in oral protection against demineralization and bacteria 
responsible for dental caries (Vitorino, Lobo et al. 2005; Vitorino, 
Calheiros-Lobo et al. 2006; Vitorino, de Morais Guedes et al. 2006). The 
protective role of PRP is directly associated to their ability to adhere to the 
teeth surface and to bind bacterial antigens. These properties depend of 
two main factors: proteolytic cleavage of PRPs and post-translational 
modification of amino acid residues. 
Acidic PRPs strongly interact with calcium in a 
phosphorylation-dependant manner, so it has been proposed that they 
play a role in keeping Ca2+ and PO42- ions supersaturate in saliva, 
preventing hydroxyapatite precipitation (Moreno, Varughese et al. 1979; 
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Moreno and Zahradnik 1979; Bennick, Cannon et al. 1981). Moreover, 
because the N-terminus binds to teeth surface and the C-terminus binds 
to antigens on the surface of bacteria, they have been implied in the 
formation of enamel pellicle (Vitorino, Lobo et al. 2005). In accordance, it 
was observed a high number of aPRPs phosphopeptides. bPRPs 
phosphorylated fragments were identified for the first time on residues 
Ser134 of bPRP2 and Ser8 of bPRP3. Despite that, no significant differences 
were found among groups (Figure 28 and Table 5). 
Regarding the glycosylation of bPRPs, several residues were also 
identified, for the first time, linked to carbohydrate moieties (Table 5). 
Interestingly, it was observed a significant increase of the frequency of O-
/N-HexNAc in cancer patients, which is in agreement with the observed 
accumulation of O-GlcNAcylation in other types of cancer, such as lung 
cancer (Satomaa, Heiskanen et al. 2009). Salivary proteins glycosylation is 
linked to the lubricant properties of saliva, which would seem 
contradictory with the results presented herein, as diabetic patients 
frequently complaint of reduction in oral lubrication. However, 
unstimulated saliva is mainly secreted by submandibular glands, whereas 
bPRPs are mainly secreted by parotid glands, suggesting that lubrication 
is not on the main functions attributed to bPRPs. 
An interesting finding was the significantly higher frequency of 
fragments with N-terminal Gln residues cyclized to pyroglutamate. This 
modification is performed enzymatically by glutaminyl cyclase and has 
been suggested to have a protective role against proteolytic activity 
(Schilling, Wasternack et al. 2008; Rink, Arkema-Meter et al. 2010). 
Diabetic patients were shown to have increased proteolytic activity in 
saliva, namely by matrix-metalloproteases (MMPs), but also by 
kallikrein 1, whose PRPs have long been described as a substrate (Wong, 
Madapallimattam et al. 1983; Caseiro, Ferreira et al. 2012). Moreover, it 
was also described a significant increase of N-terminal 
pyroglutamate-bearing peptides from all PRPs in type 1 diabetes with 
complications (Caseiro, Ferreira et al. 2013). As such, one may conclude 
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that the increased proteolytic activity will increase the relative amount of 
N-terminal pyroglutamate-bearing peptides, by degrading unmodified 
peptides. This will certainly contribute to diminish the protective functions 
of PRP, as their size is intimately linked to their ability to regulate 
astringency and may lead patients to follow a cariogenic diet (Charlton, 
Baxter et al. 1996). 
In conclusion, this study presented the discovery of several modified 
residues in salivary PRPs never described before, as well as an enrichment 
of fragments protected against proteolytic activity in diabetic patients, 
probably as a result of the degradation of unprotected peptides through 
the increased proteolytic activity of saliva. 
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6. Supplementary table 
Supplementary table 1 – Detailed listing of the modified fragments identified with indication 
of prediction sites retrieved from bioinformatics analysis. 
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PGKPQGPPAQGGS       Ser314 HexNAc (S)[13] 
7 5 1 1 
  
YinOYang 
prediction 
hSer8, 
hSer71, 
hSer132, 
hSer193, 
hSer254, 
hSer259, 
hSer314 
1380,68 1380,72 -0,04 -29,41 302 314 34 (98)   
GPPPQGGNKPQGPPPPGKPQGPPPQGDKSR Ser71 HexNAc (S)[29] 
3 2 1 0 
  
3154,6 3154,61 0 -0,92 43 72 39 (99)   
GPPPPGKPQGPPPQGDKSR     Ser71 HexNAc (S)[18] 
7 4 1 2 
  
2097,07 2097,08 -0,01 -3,72 54 72 63 (100)   
GKPQGPPPQGDKSQS     Ser134 dHex (S)[15] 
4 1 2 1 
    
1653,81 1653,86 -0,05 -30,05 120 134 27 (91)     
SPQGGNKPQGPPPPPGKPQ     Ser25 Hex (S)[1] 
1 1 0 0 
    
2027,02 2026,97 0,05 26,02 24 42 43 (98)     
GPPPPGKPQGPPPQGDKS     Lys70 Glucosylgalactosyl (K)[17] 
3 3 0 0 
    
2077,99 2077,94 0,06 26,8 54 71 34 (98)     
KPQGPPPQGDKSQSPRSPPGK Lys131 Galacotsyl (K)[11] 
3 3 0 0 
    
2220,09 2220,07 0,02 7,48 121 141 32 (97)     
GPPPQGGNKPQGPPPPGKPQGPPPQGDKS Lys70 Glucosylgalactosyl (K)[28] 
4 3 1 0 
    
3135,52 3135,59 -0,06 -20,25 43 71 73 (100)     
GPPPQGGNKPQGPPPPGKPQGPPAQGGSKS Lys313 Glucosylgalactosyl (K)[29] 
4 3 1 0 
    
3138,53 3138,56 -0,03 -8,32 287 316 35 (98)     
QGGNKPQGPPPPPGKPQ     Gln25 Gln->pyro-Glu (N-term Q)[0] 
9 5 2 2 
    
1663,86 1663,84 0,01 7,92 26 42 50 (100)     
QNLNEDVSQEESPSLIAGNPQGPSPQGGNKPQ Gln1,Ser8 
Gln->pyro-Glu (N-
term Q)[0], 
Phospho (ST)[8] 3 2 1 0 pSer8 
NetPhos 
prediction 
pSer8, 
pSer73, 
pSer76, 
pSer134, 
pSer137, 
pSer195, 
pSer198, 
pSer254, 
pSer256, 
pSer259, 
pSer318 
3379,51 3379,51 0 0,29 1 32 34 (97) 
PQGPPPQGDKSRSPRSPPGKPQ   Ser76 Phospho (ST)[16] 
6 1 2 3 
  
2375,16 2375,22 -0,06 -24,27 61 82 65 (99)   
QGPPPQGDKSQSPRSPPGKPQGPPPQ   Ser134 Phospho (ST)[12] 
6 2 1 3 
  
2726,3 2726,38 -0,08 -29,19 123 148 43 (99)   
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GPPPQGGNKSQGPPPPGKPQ     Asn256 HexNAc (N)[8] 
5 5 0 0 
Asn152, 
Asn214, 
Asn256 
NetNGlyc 
prediction  
hAsn152, 
hAsn214, 
hAsn256 
2125,07 2125,04 0,03 12,94 249 268 83 (100) 
GPPPPGKPQGPPPQGDNKSQ     Asn214 HexNAc (N)[17] 
6 4 1 1 
2183,07 2183,04 0,03 13,24 198 217 31 (95) 
GPPPQGDNKSQSARSPPGKPQ Asn214 HexNAc (N)[8] 
2 2 0 0 
2333,15 2333,15 0 -1,71 207 227 36 (99) 
GPPPPGKPQGPPPQGDNKSQ     Ser232 dHex (S)[19] 
4 2 2 0     
2126,05 2126,03 0,02 10,58 198 217 34 (95) 
GPPPQGGNKPQGPPPPGKPQGPPPQGDKS Lys107 Glucosylgalactosyl (K)[28] 
2 2 0 0     
3135,52 3135,59 -0,06 -20,25 64 92 73 (100) 
QPQGPPRPPQ       Gln397 Gln->pyro-Glu (N-term Q)[0] 
4 1 2 1 pyro-Gln1   
1084,55 1084,54 0,02 14,52 382 391 45 (100) 
QGPPRPPQGGRPS       Gln399 Gln->pyro-Glu (N-term Q)[0] 
8 4 2 2     
1313,67 1313,66 0,02 11,52 384 396 38 (99) 
QAPPAGQPQGPPRPPQ     Gln391 Gln->pyro-Glu (N-term Q)[0] 
6 1 3 2     
1605,81 1605,8 0,01 5,78 376 391 30 (95) 
QGGNQPQGPPPPPGKPQ     Gln62 Gln->pyro-Glu (N-term Q)[0] 
6 4 1 1     
1663,82 1663,85 -0,04 -21,42 47 63 98 (100) 
QPQAPPAGQPQGPPRPPQ     Gln389 Gln->pyro-Glu (N-term Q)[0] 
2 2 0 0     
1830,92 1830,81 0,11 29 374 391 36 (99) 
QGGNQPQGPPPPPGKPQGPPPQGGNKPQ Gln62 Gln->pyro-Glu (N-term Q)[0] 
5 1 4 0     
2721,35 2721,32 0,03 10,23 47 74 50 (100) 
QQEGNNPQGPPPPAGGNPQQPQAPPAGQPQGPPRPP Gln370 Gln->pyro-Glu (N-term Q)[0] 
1 1 0 0     
3567,71 3567,46 0,25 70,62 355 390 34 (98) 
QEESPSLIAGNPQGAPPQGGNKPQGPPSP Ser36 Phospho (ST) (S)[36] 
6 2 1 3     
2916,35 2916,38 -0,03 -10,75 9 37 36 (100) 
          
bP
R
P3
 Q
04
11
8 
 KPQGPPPQEGNKPQ Asn239 Hex (N)[11] 
5 3 1 1     
1663,83 1663,85 -0,03 -15,48 229 242 38 (100) 
GPPPRPGKPEGPPPQGGNQS     Ser72 dHex (S)[20] 
6 1 3 2     
2097,04 2097,08 -0,04 -21,08 54 73 36 (100) 
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SQGPPPRPGKPEGPPPQGGNQ Asn71 HexNAc (N)[20] 
6 4 1 1 
hAsn50, 
hAsn71, 
hAsn92, 
hAsn113, 
hAsn134, 
hAsn155, 
hAsn176, 
hAsn197 
NetNGlyc 
prediction 
hAsn50, 
hAsn71, 
hAsn92, 
hAsn113, 
hAsn134, 
hAsn155, 
hAsn176, 
hAsn197 2282,12 2282,1 0,01 5,78 52 72 51 (100) 
QPLPPPAGKPQ       Gln277 Gln->pyro-Glu (N-term Q)[0] 
6 1 4 1     
1112,61 1112,6 0,01 6,14 262 272 43 (100) 
QGPPPRPGKPE       Gln47 Gln->pyro-Glu (N-term Q)[0] 
3 1 2 0     
1142,6 1142,58 0,01 10,04 32 42 36 (99) 
QSQGPPPRPGKPE       Gln45 Gln->pyro-Glu (N-term Q)[0] 
11 5 4 2     
1357,69 1357,68 0 1,8 30 42 61 (100) 
QGGRPHRPPQGQPP Gln294 Gln->pyro-Glu (N-term Q)[0] 
5 1 2 2     
1491,76 1491,75 0,01 6,63 279 292 29 (94) 
QGGRPHRPPQGQPPQ     Gln294 Gln->pyro-Glu (N-term Q)[0] 
6 1 3 2     
1619,81 1619,78 0,03 21,55 279 293 57 (100) 
QSQGPPPRPGKPEGSPS     Gln213 Gln->pyro-Glu (N-term Q)[0] 
3 1 2 0     
1685,82 1685,82 0,01 4,05 198 214 49 (100) 
QSQGPPPRPGKPEGQPPQ     Gln66 Gln->pyro-Glu (N-term Q)[0] 
6 1 3 2     
1864,93 1864,92 0,01 5,11 51 68 49 (100) 
QSLNEDVSQEESPSVISGKPEGR   Gln1 Gln->pyro-Glu (N-term Q)[0] 
3 2 1 0     
2455,16 2455,16 0 -0,3 1 23 67 (100) 
QSLNEDVSQEESPSVISGKPEGR   Gln1,Ser8 
Gln->pyro-Glu (N-
term Q)[0], 
Phospho (ST)[8] 
4 2 2 0   
NetPhos 
prediction 
pSer8, 
pSer12, 
pSer14, 
pSer17, 
pSer212, 
pSer214  
2535,12 2535,11 0,01 4,62 1 23 44 (100) 
            
bP
R
P4
 P
10
16
3 
 
GPPPPPGKPEGRPPQGGNQ     Asn71 HexNAc (N)[18] 
8 4 2 2   
NetNGlyc 
prediction 
hAsn50, 
hAsn71, 
hAsn92, 
hAsn134, 
hAsn155, 
hAsn176, 
hAsn197, 
hAsn218 2067,03 2067,02 0 2,03 70 88 52 (100) 
QRPPPPP         Gln32 Gln->pyro-Glu (N-term Q)[0] 
2 2 0 0     
771,41 771,4 0,01 14,8 32 38 52 (100) 
QPQRPPPPP       Gln30 Gln->pyro-Glu (N-term Q)[0] 
6 4 2 0     
996,53 996,55 -0,03 -26,85 30 38 62 (100) 
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QGPPPHPGKPE       Gln74 Gln->pyro-Glu (N-term Q)[0] 
6 1 4 1     
1123,55 1123,54 0,02 14,56 74 84 37 (99) 
QGPPPPPQGGRPP       Gln272 Gln->pyro-Glu (N-term Q)[0] 
1 1 0 0     
1264,64 1264,63 0,01 8,49 272 284 51 (100) 
QSQGPPPHPGKPE       Gln72 Gln->pyro-Glu (N-term Q)[0] 
4 3 1 0     
1338,64 1338,64 0,01 6,11 72 84 73 (100) 
QSHRPPPPPGKPE       Gln177 Gln->pyro-Glu (N-term Q)[0] 
2 2 0 0     
1406,72 1406,71 0,01 3,82 177 189 46 (100) 
QSQGPPPPPGKPEGRPP     Gln51 Gln->pyro-Glu (N-term Q)[0] 
3 1 1 1     
1705,87 1705,84 0,03 16,64 51 67 62 (100) 
QSQGPPPHPGKPERPPP     Gln72 Gln->pyro-Glu (N-term Q)[0] 
1 1 0 0     
1785,9 1785,85 0,05 27,76 72 88 55 (100) 
QSQGPPPHPGKPEGPPPQ     Gln197 Gln->pyro-Glu (N-term Q)[0] 
1 1 0 0     
1814,88 1814,83 0,05 28,25 197 214 36 (99) 
QSQGPPPHPGKPEGPPPQEGNKS   Gln197 Gln->pyro-Glu (N-term Q)[0] 
1 1 0 0     
2330,12 2330,09 0,03 12,24 197 219 29 (96) 
QSQGPPPHPGKPEGPPPQEGNKSR   Gln197 Gln->pyro-Glu (N-term Q)[0] 
2 2 0 0     
2486,22 2486,2 0,02 7,27 197 220 33 (98) 
 
aP
R
P 
P0
28
10
  
DSEQFIDEER       Ser22 Glucuronyl (S)[2] 
5 1 2 2 
pSer8, 
pSer17, 
pSer22  
 NetPhos 
prediction 
pSer8, 
pSer22, 
pSer43 
1443,58 1443,61 -0,03 -20,84 21 30 45 (100) 
DSEQFIDEERQGPPLGGQQSQPS   Ser22 Glucuronyl (S)[2] 
6 1 2 3 
2705,18 2705,10 0,08 29,33 21 43 48 (100) 
DSEQFIDEERQGPPLGGQQ     Ser22 Glucuronyl (S)[2] 
6 1 2 3 
2306,01 2305,97 0,03 14,50 21 39 52 (100) 
GGDSEQFIDEER       Ser22 Phospho (ST) (S)[4] 
16 10 2 4 
1461,54 1461,55 0,00 -2,67 19 30 70 (100) 
DGGDSEQFIDEER       Ser22 Phospho (ST) (S)[5] 
12 4 4 4 
1576,57 1576,57 0,00 2,92 18 30 64 (100) 
GGDSEQFIDEERQ       Ser22 Phospho (ST) (S)[4] 
11 4 3 4 
1589,60 1589,60 0,01 4,40 19 31 50 (100) 
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DGGDSEQFIDEERQ       Ser22 Phospho (ST) (S)[5] 
8 2 4 2 
1704,63 1704,63 0,00 0,70 18 31 63 (100) 
VISDGGDSEQFIDEER     Ser22 Phospho (ST) (S)[8] 
1 1 0 0 
1875,75 1875,74 0,01 5,38 15 30 47 (100) 
GGDSEQFIDEERQGPPL     Ser22 Phospho (ST) (S)[4] 
7 1 4 2 
1953,81 1953,83 -0,01 -7,57 19 35 78 (100) 
VISDGGDSEQFIDEERQ     Ser22 Phospho (ST) (S)[8] 
1 1 0 0 
2003,81 2003,82 -0,01 -3,54 15 31 72 (100) 
GGDSEQFIDEERQGPPLG     Ser22 Phospho (ST) (S)[4] 
4 1 2 1 
2010,83 2010,85 -0,01 -6,32 19 36 78 (100) 
GGDSEQFIDEERQGPPLGG     Ser22 Phospho (ST) (S)[4] 
17 9 5 3 
2067,86 2067,85 0,01 3,82 19 37 80 (100) 
GGDSEQFIDEERQGPPLGGQ     Ser22 Phospho (ST) (S)[4] 
9 4 4 1 
2195,91 2195,88 0,03 13,93 19 38 69 (100) 
DVPLVISDGGDSEQFIDEER     Ser22 Phospho (ST) (S)[12] 
4 2 2 0 
2299,99 2300,01 -0,02 -9,65 11 30 66 (100) 
GGDSEQFIDEERQGPPLGGQQ     Ser22 Phospho (ST) (S)[4] 
15 6 4 5 
2323,97 2323,91 0,06 25,09 19 39 82 (100) 
DGGDSEQFIDEERQGPPLGGQQ   Ser22 Phospho (ST) (S)[5] 
9 4 4 1 
2439,00 2438,99 0,01 2,99 18 39 51 (100) 
GGDSEQFIDEERQGPPLGGQQSQPS   Ser22 Phospho (ST) (S)[4] 
7 1 4 2 
2723,15 2723,07 0,08 28,06 19 43 28 (100) 
VISDGGDSEQFIDEERQGPPLGGQQ   Ser22 Phospho (ST) (S)[8] 
3 1 2 0 
2738,18 2738,19 -0,01 -3,10 15 39 50 (100) 
DGGDSEQFIDEERQGPPLGGQQSQPS   Ser22 Phospho (ST) (S)[5] 
4 1 2 1 
2838,18 2838,10 0,08 27,87 18 43 38 (100) 
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1. General discussion 
Diabetes mellitus is one of the fastest growing causes of death in 
Portugal and the European Union (Pordata 2012). The key symptom of the 
disease is hyperglycemia, which is the basis for the clinical diagnosis of 
DM (World Health Organization. 2006; Gardner, Shoback et al. 2011). The 
regulation of glycemia is orchestrated by the endocrine pancreas, mainly 
through the secretion of glucagon and insulin. In diabetic patients, there 
is a disturbance of glycemic control either by the impairment of insulin 
production and/or the development of resistance to insulin in its key 
targets: adipose and muscle tissues. However, despite the common 
symptoms, the aetiology of DM is diverse and several types have been 
defined.  
A common set of complications is usually present in every type of 
DM, namely neuropathy, nephropathy, retinopathy and a series of 
cardiovascular problems. Most of these complications share a close 
relation to vascular dysfunction. It has been described a relation between 
hyperglycemia and endothelial dysfunction, which justifies an in-depth 
study of the endothelium response to the imbalances present in DM 
(Bakker, Eringa et al. 2009; Bucciarelli, Pollreisz et al. 2009; Abebe and 
Mozaffari 2010; Avogaro, Albiero et al. 2011). However, because of the 
systemic effects observed in DM, the use of cell culture approaches fails to 
adequately reproduce the systemic response that contains numerous 
stimuli from the diverse organs affected by hyperglycemia (Chavakis, 
Bierhaus et al. 2004; Schalkwijk and Stehouwer 2005; Son 2007; Packard 
and Libby 2008; Maugeri, Rovere-Querini et al. 2009). It is thus necessary 
to perform direct analyses of the endothelium to unravel the underlying 
mechanisms of hyperglycemia-associated endothelial dysfunction.  
Another frequent complication of DM is the elevated incidence of 
oral diseases (Sreebny, Yu et al. 1992; Ryan, Carnu et al. 2003; Lamster, 
Lalla et al. 2008; Yeh, Harris et al. 2012). Diabetic patients regularly 
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complain from a sensation of dry-mouth, which is termed xerostomia, and 
is associated with a decrease in the flow rates of salivary secretion 
(Sreebny, Yu et al. 1992; Anderson, Garrett et al. 1993). This suggests 
that hyperglycemia is somehow affecting salivary gland secretion, and it 
has been described a loss of tissue integrity and leucocytic infiltrations in 
the salivary glands of hyperglycemic animal models (Cutler, Pinney et al. 
1979; Anderson, Suleiman et al. 1994). Additionally, diabetic patients 
often suffer from gingivitis, progressing to periodontitis, which affects also 
the connective tissues underneath gingiva and could progress to severe 
loss of connective tissue, alveolar bone and teeth. These complications are 
suggested to be connected to an increased inflammatory response of the 
organism to the bacteria present in the bacterial biofilm overlaying the 
oral cavity as a consequence of impaired wound healing and neutrophil 
chemotaxis, also associated to endothelial dysfunction (Lakschevitz, 
Aboodi et al. 2011). 
The first challenge of every study, such as the present one, is the 
choice of an adequate model to study the effects intended. The choice of 
an animal model allows a tighter control of the variables and provides 
more meaningful results with a smaller sample size. In the field of 
diabetes, there are several animal models in use (Shafrir and Sima 2003; 
Rees and Alcolado 2005). A careful weighting of the pros and cons of 
several models was conducted (Table 3), and it was selected a 
streptozotocin-induced hyperglycemia model, which is also one of the 
more frequent models used. Considering that the direct study of 
endothelial cells would require a rather large number of cells, and in vitro 
proliferation was not a viable choice for the loss of the systemic stimuli, 
given the alternatives of using a mouse or rat model, it was selected the 
rat for its larger size and potential larger number of endothelial cells. 
Having chosen the animal model, an experimental plan had to be 
designed. A preliminary study was conducted with a small number of 
animals to verify the feasibility of endothelial cell isolation and the 
assessment of endothelial damage and repair ability by flow cytometry. 
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The endothelial cell isolation was performed with magnetic beads and was 
successfully confirmed by fluorescence microscopy. With only one month 
of hyperglycemia, it was also observable significant changes in the levels 
of circulating EPC and CEC, confirming the adequateness of the chosen 
model. However, it was also intended to study salivary glands and existing 
literature indicated that morphological changes in salivary glands only 
occurred after 3 months of hyperglycemia (Anderson, Suleiman et al. 
1994). As such, it was chosen to design an experimental plan with time 
points at 2 and 4 months. 
Despite the successful isolation of endothelial cells achieved in the 
preliminary study, the number of isolated cells was probably not enough 
to conduct proteomic studies and it was not possible to analyse the 
proteins involved in cell proliferation and impairment, nor the direct 
binding of MBL from the complement system to endothelial cells. 
Nonetheless, it was possible to observe a highly significant increase of 
CEC, which suggests a strong endothelial damage. Moreover, despite a 
lower number of circulating EPC, there was a stimulus to cell proliferation 
by the increased levels of VEGF and BrdU incorporation in aortic 
endothelial cells. Additionally, an increased specific-activity of the MBL 
pathway of activation of the complement system, still suggests that 
complement activation and endothelial dysfunction are linked, as 
suggested by some other reports (Hansen, Tarnow et al. 2004; Hovind, 
Hansen et al. 2005; Ostergaard, Hansen et al. 2005; Saraheimo, Forsblom 
et al. 2005; Ostergaard, Thiel et al. 2007; Elawa, AoudAllah et al. 2011; 
Ostergaard, Bjerre et al. 2012; Pavlov, La Bonte et al. 2012; Ostergaard, 
Bjerre et al. 2013). 
Regarding the effects on salivary glands, it was observed that there 
is a distinct effect in short- and long-term exposure to hyperglycemia in 
the submandibular. An acute response in the short-term shows more 
pronounced variations of the proteome composition, which is attenuated 
in the long-term, suggesting a mechanism of adaptation to the chronic 
hyperglycemia. Interestingly, it was observed an increase of proteins 
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related to vesicular transport and secretion despite the reported decrease 
in salivary flow-rate. This suggests the lower flow is somehow stimulating 
the gland to increase the secretory activity, although it is not yet possible 
to fully understand why such stimulus fails to produce results. A possible 
link between the decrease of kallikrein expression, increased inflammation 
and reduced proliferation stimuli may be related to this impairment. 
Kallikreins are mostly secreted by duct cells, which are the first to be 
affected by hyperglycemia (Anderson, Suleiman et al. 1994), and are 
responsible by the release of the kinin peptide from kininogen, which may 
have a proliferative effect, as salivary glands express kinin receptors 
(Mahabeer, Naidoo et al. 2000; Dlamini and Bhoola 2005). A decreased 
expression of kallikreins may be responsible for the impairment in salivary 
gland regeneration, which is further enhanced by the lack of the 
proliferative effect of insulin. Moreover, the extremely pronounced increase 
of the apoptosis-trigger protein S100A6 is certainly related to the loss of 
glandular mass and function. 
Because the pathogenesis of periodontal disease is linked to an 
hyper-inflammatory response, impaired neutrophil activity and the 
formation of advanced glycation endproducts (Lakschevitz, Aboodi et al. 
2011), an analysis of post-translational modifications in the major family 
of salivary proteins was also conducted. However, rodents do not normally 
secrete of proline-rich proteins as do humans (Carlson 1993). So, this 
study was conducted using human saliva from 3 test groups: control, 
diabetic and head and neck cancer patients. A higher frequency of N-
glycosylated PRP fragments was observed in cancer patients in accordance 
to the literature (Satomaa, Heiskanen et al. 2009). However, it was 
observed an increased frequency of pyroglutamate-modified fragments in 
diabetic patients, which taken together with posterior reports from our 
group where increased proteolytic activity and pyroglutamate modification 
of bPRP3 and bPRP4 fragments in diabetic patients with vascular 
complications were shown (Caseiro, Ferreira et al. 2012; Caseiro, Ferreira 
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et al. 2013), may suggest it as a potential biomarker for oral 
complications.  
In conclusion, it is reported that different epithelial-derived tissues 
have distinct responses to hyperglycemia. The endothelium presents a 
progressive damage and a shift of the repair mechanisms towards an 
angiogenic process, while salivary glands present an acute and a chronic 
response that suggests an adaptation to chronic hyperglycemia in terms of 
protein expression. Moreover, the analysis of post-translational 
modifications in human proline-rich proteins, suggests that the increase 
of pyroglutamate-modified fragments may be a potential biomarker for 
diabetic susceptibility to oral complications. 
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